



US012115357B2

(12) **United States Patent**  
**Brauker et al.**(10) **Patent No.:** US 12,115,357 B2  
(45) **Date of Patent:** Oct. 15, 2024(54) **INTEGRATED DELIVERY DEVICE FOR  
CONTINUOUS GLUCOSE SENSOR**(71) Applicant: **DexCom, Inc.**, San Diego, CA (US)(72) Inventors: **James H. Brauker**, Addison, MI (US);  
**Mark A. Tapsak**, Orangeville, PA (US);  
**Sean T. Saint**, San Diego, CA (US);  
**Apurv Ullas Kamath**, San Diego, CA (US);  
**Paul V. Neale**, San Diego, CA (US);  
**Peter C. Simpson**, Cardiff, CA (US);  
**Michael Robert Mensinger**, San Diego, CA (US);  
**Dubravka Markovic**, San Diego, CA (US)(73) Assignee: **DEXCOM, INC.**, San Diego, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 47 days.

(21) Appl. No.: **17/696,198**(22) Filed: **Mar. 16, 2022**(65) **Prior Publication Data**

US 2022/0203038 A1 Jun. 30, 2022

**Related U.S. Application Data**

(60) Continuation of application No. 17/556,761, filed on Dec. 20, 2021, which is a continuation of application (Continued)

(51) **Int. Cl.**  
**A61M 5/315** (2006.01)  
**A61B 5/00** (2006.01)  
(Continued)(52) **U.S. Cl.**  
CPC ..... **A61M 5/31525** (2013.01); **A61B 5/0002** (2013.01); **A61B 5/14532** (2013.01);  
(Continued)(58) **Field of Classification Search**CPC ..... A61M 5/1723; G16H 20/17  
See application file for complete search history.(56) **References Cited**

## U.S. PATENT DOCUMENTS

52,641 A 2/1866 Gates  
62,334 A 2/1867 Holmes  
(Continued)

## FOREIGN PATENT DOCUMENTS

CA 2127172 C 7/1998  
EP 0098592 A2 1/1984  
(Continued)

## OTHER PUBLICATIONS


US 7,530,950 B2, 05/2009, Brister et al. (withdrawn)  
(Continued)

Primary Examiner — Laura A Bouchelle

(74) Attorney, Agent, or Firm — Stuart H. Mayer; Kaplan Breyer Schwarz LLP

(57) **ABSTRACT**

Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection (Continued)



between the integrated components provides for full control of the system without required user interaction.

## 20 Claims, 10 Drawing Sheets

### Related U.S. Application Data

No. 15/906,946, filed on Feb. 27, 2018, now Pat. No. 11,246,990, which is a continuation of application No. 14/830,568, filed on Aug. 19, 2015, now Pat. No. 9,937,293, which is a continuation of application No. 13/559,454, filed on Jul. 26, 2012, now Pat. No. 9,155,843, which is a continuation of application No. 13/180,396, filed on Jul. 11, 2011, now Pat. No. 8,460,231, which is a continuation of application No. 12/536,852, filed on Aug. 6, 2009, now Pat. No. 7,976,492, which is a division of application No. 10/789,359, filed on Feb. 26, 2004, now Pat. No. 7,591,801.

### (51) Int. Cl.

<i>A61B 5/145</i>	(2006.01)
<i>A61B 5/1486</i>	(2006.01)
<i>A61M 5/172</i>	(2006.01)
<i>A61M 11/00</i>	(2006.01)
<i>A61M 15/00</i>	(2006.01)
<i>G16H 10/40</i>	(2018.01)
<i>G16H 20/17</i>	(2018.01)
<i>G16H 40/63</i>	(2018.01)

### (52) U.S. Cl.

CPC ..... *A61B 5/14865* (2013.01); *A61B 5/4839* (2013.01); *A61M 5/1723* (2013.01); *A61M 11/00* (2013.01); *A61M 15/0001* (2014.02); *G16H 10/40* (2018.01); *G16H 20/17* (2018.01); *G16H 40/63* (2018.01); *A61B 5/1486* (2013.01); *A61B 2560/0443* (2013.01); *A61M 2005/1726* (2013.01); *A61M 2205/18* (2013.01); *A61M 2205/3303* (2013.01); *A61M 2205/502* (2013.01); *A61M 2205/52* (2013.01); *A61M 2230/201* (2013.01)

### (56)

### References Cited

#### U.S. PATENT DOCUMENTS

65,604 A	6/1867	Reynolds	4,016,866 A	4/1977	Lawton
1,954,643 A	4/1934	Neuhaus	4,024,312 A	5/1977	Korpman
2,719,797 A	10/1955	Rosenblatt et al.	4,040,908 A	8/1977	Clark, Jr.
3,210,578 A	10/1965	Sherer	4,052,754 A	10/1977	Homsy
3,219,533 A	11/1965	Mullins	4,055,175 A	10/1977	Clemens et al.
3,381,371 A	5/1968	Russell	4,073,713 A	2/1978	Newman
3,506,032 A	4/1970	Eveleigh et al.	4,076,656 A	2/1978	White et al.
3,556,950 A	1/1971	Dahms et al.	4,109,505 A	8/1978	Clark et al.
3,610,226 A	10/1971	Albisser	4,119,406 A	10/1978	Clemens
3,775,182 A	11/1973	Patton et al.	4,136,250 A	1/1979	Mueller et al.
3,780,727 A	12/1973	King	4,151,845 A	5/1979	Clemens
3,826,244 A	7/1974	Salcman et al.	4,172,770 A	10/1979	Semersky et al.
3,837,339 A	9/1974	Aisenberg et al.	4,176,659 A	12/1979	Rolfe
3,838,682 A	10/1974	Clark et al.	4,197,840 A	4/1980	Beck et al.
3,874,850 A	4/1975	Sorensen et al.	4,197,852 A	4/1980	Schindler et al.
3,898,984 A	8/1975	Mandel et al.	4,206,755 A	6/1980	Klein
3,910,256 A	10/1975	Clark et al.	4,215,703 A	8/1980	Willson
3,929,971 A	12/1975	Roy	4,240,438 A	12/1980	Updike et al.
3,933,593 A	1/1976	Sternberg	4,240,889 A	12/1980	Yoda et al.
3,943,918 A	3/1976	Lewis	4,245,634 A	1/1981	Albisser et al.
3,957,613 A	5/1976	Macur	4,253,469 A	3/1981	Aslan
3,964,974 A	6/1976	Banauch et al.	4,255,500 A	3/1981	Hooke
3,979,274 A	9/1976	Newman	4,259,540 A	3/1981	Sabia
4,008,717 A	2/1977	Kowarski	4,265,249 A	5/1981	Schindler et al.
			4,319,578 A	3/1982	Enger
			4,327,725 A	5/1982	Cortese et al.
			4,366,040 A	12/1982	Marsoner et al.
			4,369,785 A	1/1983	Rehkopf et al.
			4,374,013 A	2/1983	Enfors
			4,388,166 A	6/1983	Suzuki et al.
			4,403,984 A	9/1983	Ash et al.
			4,415,666 A	11/1983	D'Orazio et al.
			4,431,004 A	2/1984	Bessman et al.
			4,432,366 A	2/1984	Margules
			4,436,094 A	3/1984	Cerami
			4,442,841 A	4/1984	Uehara et al.
			4,454,295 A	6/1984	Wittmann et al.
			4,457,339 A	7/1984	Juan et al.
			4,477,314 A	10/1984	Richter et al.
			4,478,222 A	10/1984	Koning et al.
			4,486,290 A	12/1984	Cahalan et al.
			4,492,575 A	1/1985	Mabille
			4,494,950 A	1/1985	Fischell
			4,506,680 A	3/1985	Stokes
			4,519,973 A	5/1985	Cahalan et al.
			RE31,916 E	6/1985	Oswin et al.
			4,526,569 A	7/1985	Bernardi
			4,534,825 A	8/1985	Koning et al.
			4,535,786 A	8/1985	Kater
			4,538,616 A	9/1985	Rogoff
			4,545,382 A	10/1985	Higgins et al.
			4,554,927 A	11/1985	Fussell
			4,565,665 A	1/1986	Fogt
			4,565,666 A	1/1986	Cahalan et al.
			4,568,444 A	2/1986	Nakamura et al.
			4,571,292 A	2/1986	Liu et al.
			4,573,968 A	3/1986	Parker
			4,577,642 A	3/1986	Stokes
			4,583,976 A	4/1986	Ferguson
			4,592,824 A	6/1986	Smith et al.
			4,600,495 A	7/1986	Fogt
			4,614,514 A	9/1986	Carr et al.
			4,619,793 A	10/1986	Lee
			4,625,730 A	12/1986	Fountain et al.
			4,626,104 A	12/1986	Pointon et al.
			4,632,968 A	12/1986	Yokota et al.
			RE32,361 E	2/1987	Duggan
			4,655,880 A	4/1987	Liu
			4,663,824 A	5/1987	Kenmochi
			4,671,288 A	6/1987	Gough
			4,672,970 A	6/1987	Uchida et al.
			4,680,268 A	7/1987	Clark, Jr.
			4,685,463 A	8/1987	Williams
			4,685,903 A	8/1987	Cable et al.
			4,694,861 A	9/1987	Goodale et al.
			4,702,732 A	10/1987	Powers et al.
			4,703,756 A	11/1987	Gough et al.
			4,705,503 A	11/1987	Dorman et al.
			4,711,245 A	12/1987	Higgins et al.

(56)	References Cited					
U.S. PATENT DOCUMENTS						
4,711,251 A	12/1987	Stokes	4,953,552 A	9/1990	DeMarzo	
4,721,677 A	1/1988	Clark, Jr.	4,957,483 A	9/1990	Gonser et al.	
4,726,381 A	2/1988	Jones	4,963,595 A	10/1990	Ward et al.	
4,731,726 A	3/1988	Allen, III	4,966,579 A	10/1990	Polaschegg	
4,736,748 A	4/1988	Nakamura et al.	4,967,940 A	11/1990	Blette et al.	
4,747,822 A	5/1988	Peabody	4,970,145 A	11/1990	Bennetto et al.	
4,750,496 A	6/1988	Reinhart et al.	4,973,320 A	11/1990	Brenner et al.	
4,753,652 A	6/1988	Langer et al.	4,974,592 A	12/1990	Branco	
4,755,168 A	7/1988	Romanelli et al.	4,974,929 A	12/1990	Curry	
4,757,022 A	7/1988	Shults et al.	4,975,636 A	12/1990	Desautels	
4,759,828 A	7/1988	Young et al.	4,976,687 A	12/1990	Martin	
4,763,648 A	8/1988	Wyatt	4,979,509 A	12/1990	Hakky	
4,763,658 A	8/1988	Jones	4,984,929 A	1/1991	Rock et al.	
4,777,953 A	10/1988	Ash et al.	4,986,671 A	1/1991	Sun et al.	
4,781,798 A	11/1988	Gough	4,988,341 A	1/1991	Columbus et al.	
4,784,157 A	11/1988	Halls et al.	4,989,607 A	2/1991	Keusch et al.	
4,786,394 A	11/1988	Enzer et al.	4,992,794 A	2/1991	Brouwers	
4,787,398 A	11/1988	Garcia et al.	4,994,026 A	2/1991	Fecondini	
4,789,467 A	12/1988	Lindsay et al.	4,994,167 A	2/1991	Shults et al.	
4,791,932 A	12/1988	Margules	4,997,627 A	3/1991	Bergquist et al.	
4,803,243 A	2/1989	Fujimoto et al.	5,002,055 A	3/1991	Merki et al.	
4,805,624 A	2/1989	Yao et al.	5,002,572 A	3/1991	Picha	
4,805,625 A	2/1989	Wyler	5,006,050 A	4/1991	Cooke et al.	
4,807,632 A	2/1989	Liess et al.	5,006,111 A	4/1991	Inokuchi et al.	
4,808,089 A	2/1989	Buchholtz et al.	5,007,929 A	4/1991	Quaid	
4,808,292 A	2/1989	Kessler et al.	5,009,251 A	4/1991	Pike et al.	
4,809,704 A	3/1989	Sogawa et al.	5,019,974 A	5/1991	Beckers	
4,810,243 A	3/1989	Howson	5,026,348 A	6/1991	Venegas	
4,810,470 A	3/1989	Burkhardt et al.	5,030,199 A	7/1991	Barwick et al.	
4,815,471 A	3/1989	Stobie	5,030,333 A	7/1991	Clark, Jr.	
4,820,281 A	4/1989	Lawler, Jr.	5,034,112 A	7/1991	Murase et al.	
4,822,336 A	4/1989	DiTraglia	5,035,711 A	7/1991	Aoki et al.	
4,823,808 A	4/1989	Clegg et al.	5,041,092 A	8/1991	Barwick	
4,828,544 A	5/1989	Lane et al.	5,045,057 A	9/1991	Van Driessche et al.	
4,830,013 A	5/1989	Maxwell	5,046,496 A	9/1991	Betts et al.	
4,831,070 A	5/1989	McInally et al.	5,048,525 A	9/1991	Maxwell	
4,832,005 A	5/1989	Takamiya et al.	5,050,612 A	9/1991	Matsumura	
4,832,034 A	5/1989	Pizziconi et al.	5,055,171 A	10/1991	Peck	
4,834,101 A	5/1989	Collison et al.	5,055,198 A	10/1991	Shettigar	
4,838,281 A	6/1989	Rogers et al.	5,059,654 A	10/1991	Hou et al.	
4,841,974 A	6/1989	Gumbrecht et al.	5,067,491 A	11/1991	Taylor, II et al.	
4,849,458 A	7/1989	Reed et al.	5,068,536 A	11/1991	Rosenthal	
4,852,573 A	8/1989	Kennedy	5,070,169 A	12/1991	Robertson et al.	
4,854,322 A	8/1989	Ash et al.	5,077,476 A	12/1991	Rosenthal	
4,858,615 A	8/1989	Meinema	5,088,981 A	2/1992	Howson et al.	
4,867,741 A	9/1989	Portnoy	5,089,421 A	2/1992	Dieffenbach	
4,871,440 A	10/1989	Nagata et al.	5,096,669 A	3/1992	Lauks et al.	
4,874,363 A	10/1989	Abell	5,097,834 A	3/1992	Skrabal	
4,883,057 A	11/1989	Broderick	5,098,377 A	3/1992	Borsanyi et al.	
4,883,467 A	11/1989	Franetzki et al.	5,101,814 A	4/1992	Palti	
4,889,528 A	12/1989	Nadai et al.	5,108,819 A	4/1992	Heller et al.	
4,889,744 A	12/1989	Quaid	5,109,850 A	5/1992	Blanco et al.	
4,890,620 A	1/1990	Gough	5,112,301 A	5/1992	Fenton, Jr. et al.	
4,890,621 A	1/1990	Hakky	5,116,313 A	5/1992	McGregor	
4,900,305 A	2/1990	Smith et al.	5,127,405 A	7/1992	Alcala et al.	
4,902,294 A	2/1990	Gosserez	5,137,028 A	8/1992	Nishimura	
4,907,857 A	3/1990	Giuliani et al.	5,140,985 A	8/1992	Schroeder et al.	
4,908,208 A	3/1990	Lee et al.	5,145,565 A	9/1992	Kater et al.	
4,909,786 A	3/1990	Gijselhart et al.	5,152,746 A	10/1992	Atkinson et al.	
4,919,114 A	4/1990	Miyazaki	5,153,827 A	* 10/1992	Coutre .....	A61M 5/1723
4,919,141 A	4/1990	Zier et al.				604/67
4,919,649 A	4/1990	Timothy et al.	5,160,418 A	11/1992	Mullen	
4,921,477 A	5/1990	Davis	5,161,532 A	11/1992	Joseph	
4,921,480 A	5/1990	Sealfon	5,165,406 A	11/1992	Wong	
4,925,444 A	5/1990	Orkin et al.	5,165,407 A	11/1992	Wilson et al.	
4,927,407 A	5/1990	Dorman	5,174,291 A	12/1992	Schoonen et al.	
4,927,516 A	5/1990	Yamaguchi et al.	5,176,632 A	1/1993	Bernardi	
4,928,694 A	5/1990	Maxwell	5,176,658 A	1/1993	Ranford	
4,934,369 A	6/1990	Maxwell	5,178,142 A	1/1993	Harjunmaa et al.	
4,934,375 A	6/1990	Cole et al.	5,182,004 A	1/1993	Kohno	
4,944,299 A	7/1990	Silvian	5,188,591 A	2/1993	Dorsey, III	
4,946,439 A	8/1990	Eggers	5,190,041 A	3/1993	Palti	
4,950,246 A	8/1990	Muller	5,195,963 A	3/1993	Yafuso et al.	
4,951,657 A	8/1990	Pfister et al.	5,198,771 A	3/1993	Fidler et al.	
4,951,669 A	8/1990	Maxwell et al.	5,208,147 A	5/1993	Kagenow et al.	
			5,208,313 A	5/1993	Krishnan	
			5,220,917 A	6/1993	Cammilli et al.	
			5,220,920 A	6/1993	Gharib	
			5,224,929 A	7/1993	Remiszewski	

(56)	References Cited					
U.S. PATENT DOCUMENTS						
5,225,063 A	7/1993	Gumbrecht et al.	5,417,206 A	5/1995	Kaneyoshi	
5,232,434 A	8/1993	Inagaki et al.	5,421,328 A	6/1995	Bedingham	
5,235,003 A	8/1993	Ward et al.	5,421,923 A	6/1995	Clarke et al.	
5,243,982 A	9/1993	Mostl et al.	5,423,738 A	6/1995	Robinson et al.	
5,243,983 A	9/1993	Tari et al.	5,423,749 A	6/1995	Merte et al.	
5,249,576 A	10/1993	Goldberger et al.	5,428,123 A	6/1995	Ward et al.	
5,251,126 A	10/1993	Kahn et al.	5,429,485 A	7/1995	Dodge	
5,254,102 A	10/1993	Ogawa	5,429,602 A	7/1995	Hauser	
5,262,305 A	11/1993	Heller et al.	5,429,735 A	7/1995	Johnson et al.	
5,265,594 A	11/1993	Olsson et al.	5,431,160 A	7/1995	Wilkins	
5,266,179 A	11/1993	Nankai et al.	5,431,174 A	7/1995	Knute	
5,269,891 A	12/1993	Colin	5,431,921 A	7/1995	Thombre	
5,271,736 A	12/1993	Picha	5,434,412 A	7/1995	Sodickson et al.	
5,271,815 A	12/1993	Wong	5,437,635 A	8/1995	Fields et al.	
5,279,294 A	1/1994	Anderson et al.	5,438,984 A	8/1995	Schoendorfer	
5,281,319 A	1/1994	Kaneko et al.	5,443,508 A	8/1995	Giampapa	
5,282,848 A	2/1994	Schmitt	5,445,610 A	8/1995	Evert	
5,284,140 A	2/1994	Allen et al.	5,462,051 A	10/1995	Oka et al.	
5,284,570 A	2/1994	Savage et al.	5,462,064 A	10/1995	D'Angelo et al.	
5,285,513 A	2/1994	Kaufman et al.	5,466,356 A	11/1995	Schneider et al.	
5,287,753 A	2/1994	Routh et al.	5,469,846 A	11/1995	Khan	
5,298,022 A	3/1994	Bernardi	5,474,552 A	12/1995	Palti	
5,299,571 A	4/1994	Mastrototaro	5,476,776 A	12/1995	Wilkins	
5,302,093 A	4/1994	Owens et al.	5,482,008 A	1/1996	Stafford et al.	
5,304,468 A	4/1994	Phillips et al.	5,482,446 A	1/1996	Williamson et al.	
5,307,263 A	4/1994	Brown	5,482,473 A	1/1996	Lord et al.	
5,310,469 A	5/1994	Cunningham et al.	5,484,404 A	1/1996	Schulman et al.	
5,311,908 A	5/1994	Barone et al.	5,491,474 A	2/1996	Suni et al.	
5,312,361 A	5/1994	Zadini et al.	5,494,562 A	2/1996	Maley et al.	
5,314,471 A	5/1994	Brauker et al.	5,496,453 A	3/1996	Uenoyama et al.	
5,316,008 A	5/1994	Suga et al.	5,497,772 A	3/1996	Schulman et al.	
5,316,452 A	5/1994	Bogen et al.	5,502,396 A	3/1996	Desarzens et al.	
5,318,511 A	6/1994	Riquier et al.	5,505,828 A	4/1996	Wong et al.	
5,322,063 A	6/1994	Allen et al.	5,507,288 A *	4/1996	Bocker .....	A61B 5/14532
5,324,322 A	6/1994	Grill, Jr. et al.				128/903
5,326,356 A	7/1994	Della Valle et al.	5,508,203 A	4/1996	Fuller et al.	
5,326,449 A	7/1994	Cunningham	5,509,888 A	4/1996	Miller	
5,330,521 A	7/1994	Cohen	5,512,046 A	4/1996	Pusinelli et al.	
5,330,634 A	7/1994	Wong et al.	5,512,055 A	4/1996	Domb et al.	
5,331,555 A	7/1994	Hashimoto et al.	5,512,248 A	4/1996	Van	
5,335,658 A	8/1994	Bedingham	5,513,636 A	5/1996	Palti	
5,337,747 A	8/1994	Neftel	5,514,253 A	5/1996	Davis et al.	
5,342,409 A	8/1994	Mullett	5,515,851 A	5/1996	Goldstein	
5,342,789 A	8/1994	Chick et al.	5,518,601 A	5/1996	Foos et al.	
5,343,869 A	9/1994	Pross et al.	5,527,288 A	6/1996	Gross et al.	
5,344,454 A	9/1994	Clarke et al.	5,531,679 A	7/1996	Schulman et al.	
5,345,932 A	9/1994	Yafuso et al.	5,531,878 A	7/1996	Vadgama et al.	
5,348,788 A	9/1994	White	5,536,249 A	7/1996	Castellano et al.	
5,352,348 A	10/1994	Young et al.	5,538,511 A	7/1996	Van Antwerp	
5,352,351 A	10/1994	White et al.	5,540,828 A	7/1996	Yacynych	
5,354,272 A	10/1994	Swendson et al.	5,545,220 A	8/1996	Andrews et al.	
5,354,449 A	10/1994	Band et al.	5,545,223 A	8/1996	Neuenfeldt et al.	
5,356,375 A	10/1994	Higley	5,549,547 A	8/1996	Cohen et al.	
5,356,378 A	10/1994	Doan	5,549,548 A	8/1996	Larsson	
5,356,786 A	10/1994	Heller et al.	5,549,569 A	8/1996	Lynn et al.	
5,368,028 A	11/1994	Palti	5,549,651 A	8/1996	Lynn	
5,368,224 A	11/1994	Richardson et al.	5,551,850 A	9/1996	Williamson et al.	
5,368,562 A	11/1994	Blomquist et al.	5,553,616 A	9/1996	Ham et al.	
5,372,133 A	12/1994	Hogen Esch	5,554,339 A	9/1996	Cozzette et al.	
5,372,135 A	12/1994	Mendelson et al.	5,561,615 A	10/1996	Kuo et al.	
5,372,709 A	12/1994	Hood	5,562,614 A	10/1996	O'Donnell	
5,376,070 A	12/1994	Purvis et al.	5,562,615 A	10/1996	Nassif	
5,378,229 A	1/1995	Layer et al.	5,564,439 A	10/1996	Picha	
5,380,268 A	1/1995	Wheeler	5,568,806 A	10/1996	Cheney, II et al.	
5,380,491 A	1/1995	Carver, Jr. et al.	5,569,186 A	10/1996	Lord et al.	
5,380,536 A	1/1995	Hubbell et al.	5,569,188 A	10/1996	MacKool	
5,380,665 A	1/1995	Cusack et al.	5,569,219 A	10/1996	Hakki et al.	
5,384,028 A	1/1995	Ito	5,569,462 A	10/1996	Martinson et al.	
5,390,671 A	2/1995	Lord et al.	5,575,293 A	11/1996	Miller et al.	
5,391,250 A	2/1995	Cheney, II et al.	5,575,930 A	11/1996	Tietje-Girault et al.	
5,397,848 A	3/1995	Yang et al.	5,577,499 A	11/1996	Teves	
5,405,510 A	4/1995	Betts et al.	5,582,184 A	12/1996	Erickson et al.	
5,411,052 A	5/1995	Murray	5,582,593 A	12/1996	Hultman	
5,411,647 A	5/1995	Johnson et al.	5,584,813 A	12/1996	Livingston et al.	
5,411,866 A	5/1995	Luong et al.	5,584,876 A	12/1996	Bruchman et al.	

(56)

**References Cited****U.S. PATENT DOCUMENTS**

5,586,553 A	12/1996	Halili et al.	5,820,589 A	10/1998	Torgerson et al.
5,589,133 A	12/1996	Suzuki	5,820,622 A	10/1998	Gross et al.
5,590,651 A	1/1997	Shaffer et al.	5,822,715 A	10/1998	Worthington et al.
5,593,440 A	1/1997	Brauker et al.	5,836,887 A	11/1998	Oka et al.
5,609,572 A	3/1997	Lang	5,836,989 A	11/1998	Shelton
5,611,900 A	3/1997	Worden et al.	5,837,454 A	11/1998	Cozette et al.
5,624,409 A	4/1997	Seale	5,837,728 A	11/1998	Purcell
5,624,537 A	4/1997	Turner et al.	5,840,026 A	11/1998	Uber, III et al.
5,626,563 A	5/1997	Dodge et al.	5,840,148 A	11/1998	Campbell et al.
5,628,619 A	5/1997	Wilson	5,848,991 A	12/1998	Gross et al.
5,628,890 A	5/1997	Carter et al.	5,851,197 A	12/1998	Marano et al.
5,637,083 A	6/1997	Bertrand et al.	5,851,229 A	12/1998	Lentz et al.
5,640,470 A	6/1997	Iyer et al.	5,858,365 A	1/1999	Faller
5,643,195 A	7/1997	Drevet et al.	5,858,747 A	1/1999	Schinistine et al.
5,651,767 A	7/1997	Schulman et al.	5,861,019 A	1/1999	Sun et al.
5,653,756 A	8/1997	Clarke et al.	5,863,400 A	1/1999	Drummond et al.
5,653,863 A	8/1997	Genshaw et al.	5,871,514 A	2/1999	Wiklund et al.
5,658,250 A	8/1997	Blomquist et al.	5,873,862 A	2/1999	Lopez
5,660,163 A	8/1997	Schulman et al.	5,879,713 A	3/1999	Roth et al.
5,660,565 A	8/1997	Williams	5,882,494 A	3/1999	Van Antwerp
5,665,061 A	9/1997	Antwiler	5,895,235 A	4/1999	Droz
5,665,065 A	9/1997	Colman et al.	5,897,525 A	4/1999	Dey et al.
5,667,504 A	9/1997	Baumann et al.	5,897,578 A	4/1999	Wiklund et al.
5,673,694 A	10/1997	Rivers	5,899,855 A	5/1999	Brown
5,674,289 A	10/1997	Fournier et al.	5,904,666 A	5/1999	DeDECKER et al.
5,676,651 A	10/1997	Larson, Jr. et al.	5,904,708 A	5/1999	Goedeke
5,676,820 A	10/1997	Wang et al.	5,911,219 A	6/1999	Aylsworth et al.
5,681,572 A	10/1997	Seare, Jr.	5,913,998 A	6/1999	Butler et al.
5,682,884 A	11/1997	Hill et al.	5,914,026 A	6/1999	Blubaugh, Jr. et al.
5,683,562 A	11/1997	Schaffar et al.	5,917,346 A	6/1999	Gord
5,686,829 A	11/1997	Girault	5,919,215 A	7/1999	Wiklund et al.
5,688,239 A	11/1997	Walker	5,919,216 A	7/1999	Houben et al.
5,688,244 A	11/1997	Lang	5,921,951 A	7/1999	Morris
5,695,623 A	12/1997	Michel et al.	5,925,021 A	7/1999	Castellano et al.
5,696,314 A	12/1997	McCaffrey et al.	5,928,155 A	7/1999	Eggers et al.
5,697,366 A	12/1997	Kimball et al.	5,928,182 A	7/1999	Kraus et al.
5,697,899 A	12/1997	Hillman et al.	5,928,189 A	7/1999	Phillips et al.
5,704,354 A	1/1998	Preidel et al.	5,928,195 A	7/1999	Malamud et al.
5,706,807 A	1/1998	Picha	5,931,814 A	8/1999	Alex et al.
5,711,861 A	1/1998	Ward et al.	5,932,175 A	8/1999	Knute et al.
5,713,888 A	2/1998	Neuenfeldt et al.	5,933,136 A	8/1999	Brown
5,730,654 A	3/1998	Brown	5,935,785 A	8/1999	Reber et al.
5,733,259 A	3/1998	Valcke et al.	5,938,636 A	8/1999	Kramer et al.
5,733,336 A	3/1998	Neuenfeldt et al.	5,944,661 A	8/1999	Swette et al.
5,743,262 A	4/1998	Lepper, Jr. et al.	5,947,911 A	9/1999	Wong et al.
5,749,832 A	5/1998	Vadgama et al.	5,954,643 A	9/1999	Vanantwerp et al.
5,749,907 A	5/1998	Mann	5,954,954 A	9/1999	Houck et al.
5,755,692 A	5/1998	Manicom	5,957,854 A	9/1999	Besson et al.
5,756,632 A	5/1998	Ward et al.	5,957,903 A	9/1999	Mirzaei et al.
5,758,643 A	6/1998	Wong et al.	5,961,451 A	10/1999	Reber et al.
5,763,760 A	6/1998	Gumbrecht et al.	5,963,132 A	10/1999	Yoakum
5,771,890 A	6/1998	Tamada	5,964,745 A	10/1999	Lyles et al.
5,773,286 A	6/1998	Dionne et al.	5,964,993 A	10/1999	Blubaugh, Jr. et al.
5,776,324 A	7/1998	Usala	5,965,125 A	10/1999	Mineau-Hanschke
5,779,665 A	7/1998	Mastrototaro et al.	5,965,380 A	10/1999	Heller et al.
5,781,455 A	7/1998	Hyodo	5,971,922 A	10/1999	Arita et al.
5,782,880 A	7/1998	Lahtinen et al.	5,972,369 A	10/1999	Roorda et al.
5,782,912 A	7/1998	Brauker et al.	5,976,085 A	11/1999	Kimball et al.
5,787,900 A	8/1998	Butler et al.	5,987,352 A	11/1999	Klein et al.
5,791,344 A	8/1998	Schulman et al.	5,995,208 A	11/1999	Sarge et al.
5,791,880 A	8/1998	Wilson	5,995,860 A	11/1999	Sun et al.
5,795,453 A	8/1998	Gilmartin	5,997,501 A	12/1999	Gross et al.
5,795,774 A	8/1998	Matsumoto et al.	5,999,848 A	12/1999	Gord et al.
5,798,065 A	8/1998	Picha	6,001,067 A	12/1999	Shults et al.
5,800,383 A	9/1998	Chandler et al.	6,001,471 A	12/1999	Bries et al.
5,800,420 A	9/1998	Gross et al.	6,002,954 A	12/1999	Van Antwerp et al.
5,800,529 A	9/1998	Brauker et al.	6,007,845 A	12/1999	Domb et al.
5,806,517 A	9/1998	Gerhardt et al.	6,011,984 A	1/2000	Van Antwerp et al.
5,807,274 A	9/1998	Henning et al.	6,014,577 A	1/2000	Henning et al.
5,807,312 A	9/1998	Dzwonkiewicz	6,016,448 A	1/2000	Busacker et al.
5,807,375 A	9/1998	Gross et al.	6,017,435 A	1/2000	Hassard et al.
5,807,406 A	9/1998	Brauker et al.	6,023,629 A	2/2000	Tamada
5,810,770 A	9/1998	Chin et al.	6,024,720 A	2/2000	Chandler et al.
5,811,487 A	9/1998	Schulz, Jr. et al.	6,027,445 A	2/2000	Von Bahr
5,814,599 A	9/1998	Mitragotri et al.	6,027,479 A	2/2000	Alei et al.
			6,032,059 A	2/2000	Henning et al.
			6,032,667 A	3/2000	Heinonen
			6,036,924 A	3/2000	Simons et al.
			6,043,328 A	3/2000	Domschke et al.

(56)	References Cited					
U.S. PATENT DOCUMENTS						
6,045,671 A	4/2000	Wu et al.	6,263,222 B1	7/2001	Diab et al.	
6,048,691 A	4/2000	Maracas	6,264,825 B1	7/2001	Blackburn et al.	
6,049,727 A	4/2000	Crothall	6,270,478 B1	8/2001	Mernoe	
6,059,946 A	5/2000	Yukawa et al.	6,271,332 B1	8/2001	Lohmann et al.	
6,063,637 A	5/2000	Arnold et al.	6,272,364 B1	8/2001	Kurnik	
6,066,088 A	5/2000	Davis	6,272,382 B1	8/2001	Faltys et al.	
6,066,448 A	5/2000	Wohlstadter et al.	6,272,480 B1	8/2001	Tresp et al.	
6,071,391 A	6/2000	Gotoh et al.	6,274,285 B1	8/2001	Gries et al.	
6,077,299 A	6/2000	Adelberg et al.	6,275,717 B1	8/2001	Gross et al.	
6,080,583 A	6/2000	von Bahr	6,280,408 B1	8/2001	Sipin	
6,081,735 A	6/2000	Diab et al.	6,281,015 B1	8/2001	Mooney et al.	
6,081,736 A	6/2000	Colvin et al.	6,284,478 B1	9/2001	Heller et al.	
6,083,523 A	7/2000	Dionne et al.	6,293,925 B1	9/2001	Safabash et al.	
6,083,710 A	7/2000	Heller et al.	6,298,254 B2	10/2001	Tamada	
6,088,608 A	7/2000	Schulman et al.	6,299,578 B1	10/2001	Kurnik et al.	
6,090,087 A	7/2000	Tsukada et al.	6,299,583 B1	10/2001	Eggers et al.	
6,091,975 A	7/2000	Daddona et al.	6,300,002 B1	10/2001	Webb et al.	
6,093,172 A	7/2000	Funderburk et al.	6,302,855 B1	10/2001	Lav et al.	
6,099,511 A	8/2000	Devos et al.	6,309,351 B1	10/2001	Kurnik et al.	
6,103,033 A	8/2000	Say et al.	6,309,384 B1	10/2001	Harrington et al.	
6,103,533 A	8/2000	Hassard et al.	6,309,884 B1	10/2001	Cooper et al.	
6,107,083 A	8/2000	Collins et al.	6,312,388 B1	11/2001	Marcovecchio et al.	
6,115,634 A	9/2000	Donders et al.	6,315,738 B1	11/2001	Nishikawa et al.	
6,117,290 A	9/2000	Say et al.	6,325,978 B1	12/2001	Labuda et al.	
6,120,676 A	9/2000	Heller et al.	6,326,160 B1	12/2001	Dunn et al.	
6,121,009 A	9/2000	Heller et al.	6,329,161 B1	12/2001	Heller et al.	
6,122,536 A	9/2000	Sun et al.	6,329,929 B1	12/2001	Weijand et al.	
6,123,827 A	9/2000	Wong et al.	6,330,464 B1	12/2001	Colvin, Jr. et al.	
6,127,154 A	10/2000	Mosbach et al.	6,343,225 B1	1/2002	Clark, Jr.	
6,128,519 A	10/2000	Say	6,356,776 B1	3/2002	Berner et al.	
6,129,891 A	10/2000	Rolander et al.	6,358,225 B1	3/2002	Butterfield	
6,134,461 A	10/2000	Say et al.	6,365,670 B1	4/2002	Fry	
6,135,978 A	10/2000	Houben et al.	6,366,794 B1	4/2002	Moussy et al.	
6,142,939 A	11/2000	Eppstein et al.	6,368,274 B1	4/2002	Van Antwerp et al.	
6,144,869 A	11/2000	Berner et al.	6,370,941 B2	4/2002	Nakamura et al.	
6,159,186 A	12/2000	Wickham et al.	6,372,244 B1	4/2002	Antanavich et al.	
6,162,201 A	12/2000	Cohen et al.	6,379,301 B1	4/2002	Worthington et al.	
6,162,611 A	12/2000	Heller et al.	6,379,317 B1	4/2002	Kintzig et al.	
6,163,720 A	12/2000	Gyory et al.	6,383,478 B1	5/2002	Prokop et al.	
6,164,921 A	12/2000	Moubayed et al.	6,387,709 B1	5/2002	Mason et al.	
6,165,154 A	12/2000	Gray et al.	6,391,019 B1	5/2002	Ito	
6,167,614 B1	1/2001	Tuttle et al.	6,400,974 B1	6/2002	Lesho	
6,168,568 B1	1/2001	Gavriely	6,402,703 B1	6/2002	Kensey et al.	
6,169,155 B1	1/2001	Alvarez et al.	6,403,944 B1	6/2002	MacKenzie et al.	
6,171,276 B1	1/2001	Lippe et al.	6,406,066 B1	6/2002	Uegane	
6,175,752 B1	1/2001	Say et al.	6,407,195 B2	6/2002	Sherman et al.	
6,180,416 B1	1/2001	Kurnik et al.	6,409,674 B1	6/2002	Brockway et al.	
6,183,437 B1	2/2001	Walker	6,413,393 B1	7/2002	Van Antwerp et al.	
6,187,062 B1	2/2001	Oweis et al.	6,416,651 B1	7/2002	Millar	
6,189,536 B1	2/2001	Martinez et al.	6,424,847 B1	7/2002	Mastrototaro et al.	
6,191,860 B1	2/2001	Klinger et al.	6,430,437 B1	8/2002	Marro	
6,192,891 B1	2/2001	Gravel et al.	6,447,448 B1	9/2002	Ishikawa et al.	
6,201,980 B1	3/2001	Darrow et al.	6,447,542 B1	9/2002	Weadock	
6,201,993 B1	3/2001	Kruse et al.	6,459,917 B1	10/2002	Gowda et al.	
6,206,856 B1	3/2001	Mahurkar	6,461,496 B1	10/2002	Feldman et al.	
6,208,894 B1	3/2001	Schulman et al.	6,464,849 B1	10/2002	Say et al.	
6,212,416 B1	4/2001	Ward et al.	6,466,810 B1	10/2002	Ward et al.	
6,212,424 B1	4/2001	Robinson	6,467,480 B1	10/2002	Meier et al.	
6,213,739 B1	4/2001	Phallen et al.	6,471,689 B1	10/2002	Joseph et al.	
6,214,185 B1	4/2001	Offenbacher et al.	6,474,360 B1	11/2002	Ito	
6,219,574 B1	4/2001	Cormier et al.	6,475,750 B1	11/2002	Han et al.	
6,223,080 B1	4/2001	Thompson	6,477,392 B1	11/2002	Honigs et al.	
6,223,083 B1	4/2001	Rosar	6,477,395 B2	11/2002	Schulman et al.	
6,230,059 B1	5/2001	Duffin	6,481,440 B2	11/2002	Gielen et al.	
6,231,879 B1	5/2001	Li et al.	6,484,045 B1	11/2002	Holker et al.	
6,232,783 B1	5/2001	Merrill	6,484,046 B1	11/2002	Say et al.	
6,233,080 B1	5/2001	Brenner et al.	6,485,449 B2	11/2002	Ito	
6,234,964 B1	5/2001	Iliff	6,488,652 B1	12/2002	Weijand et al.	
6,241,863 B1	6/2001	Monbouquette	6,494,830 B1	12/2002	Wessel	
6,248,067 B1	6/2001	Causey, III et al.	6,494,879 B2	12/2002	Lennox et al.	
6,248,077 B1	6/2001	Elson et al.	6,497,729 B1	12/2002	Moussy et al.	
6,248,093 B1	6/2001	Moberg	6,498,043 B1	12/2002	Schulman et al.	
6,254,586 B1	7/2001	Mann et al.	6,498,941 B1	12/2002	Jackson	
6,256,522 B1	7/2001	Schultz	6,501,976 B1	12/2002	Sohrab	
6,259,937 B1	7/2001	Schulman et al.	6,510,329 B2	1/2003	Wieres et al.	
			6,512,939 B1	1/2003	Heckel	
			6,514,718 B2	1/2003	Colvin et al.	
			6,517,508 B1	2/2003	Heller et al.	
				2/2003	Utterberg et al.	

(56)	References Cited					
U.S. PATENT DOCUMENTS						
6,520,326 B2	2/2003	McIvor et al.	6,679,865 B2	1/2004	Shekalim	
6,520,477 B2	2/2003	Trimmer	6,679,872 B2	1/2004	Turovskiy et al.	
6,520,937 B2	2/2003	Hart et al.	6,683,535 B1	1/2004	Utke	
6,520,997 B1	2/2003	Pekkarinen et al.	6,684,904 B2	2/2004	Ito	
6,526,298 B1	2/2003	Khalil et al.	6,685,668 B1	2/2004	Cho et al.	
6,527,729 B1	3/2003	Turcott	6,687,522 B2	2/2004	Tamada	
6,534,711 B1	3/2003	Pollack	6,689,089 B1	2/2004	Tiedtke et al.	
6,536,433 B1	3/2003	Cewers	6,689,265 B2	2/2004	Heller et al.	
6,537,318 B1	3/2003	Ita et al.	6,694,191 B2	2/2004	Starkweather et al.	
6,541,266 B2	4/2003	Modzelewski et al.	6,695,860 B1	2/2004	Ward et al.	
6,542,765 B1	4/2003	Guy et al.	6,699,188 B2	3/2004	Wessel	
6,544,212 B2	4/2003	Galley et al.	6,699,218 B2	3/2004	Flaherty et al.	
6,545,085 B2	4/2003	Kilgour et al.	6,699,383 B2	3/2004	Lemire et al.	
6,546,268 B1	4/2003	Ishikawa et al.	6,702,249 B2	3/2004	Ito	
6,546,269 B1	4/2003	Kurnik	6,702,857 B2	3/2004	Brauker et al.	
6,549,796 B2	4/2003	Sohrab	6,702,972 B1	3/2004	Markle	
6,551,496 B1	4/2003	Moles et al.	6,711,424 B1	3/2004	Fine et al.	
6,553,241 B2	4/2003	Mannheimer et al.	6,712,796 B2	3/2004	Fentis et al.	
6,553,244 B2	4/2003	Lesho et al.	6,721,587 B2	4/2004	Gough	
6,554,805 B2	4/2003	Hiejima	6,723,086 B2	4/2004	Bassuk et al.	
6,554,822 B1	4/2003	Holschneider et al.	6,723,976 B2	5/2004	Penn et al.	
6,558,320 B1	5/2003	Causey, III et al.	6,736,783 B2	5/2004	Blake et al.	
6,558,321 B1	5/2003	Burd et al.	6,740,072 B2 *	5/2004	Starkweather ..... A61M 5/1723	
6,558,347 B1	5/2003	Jhuboo et al.		604/67		
6,558,351 B1	5/2003	Steil et al.	6,740,075 B2	5/2004	Lebel et al.	
6,558,955 B1	5/2003	Kristal et al.	6,741,877 B1	5/2004	Shults et al.	
6,561,978 B1	5/2003	Conn et al.	6,742,635 B2	6/2004	Hirshberg	
6,562,001 B2	5/2003	Lebel et al.	6,743,635 B2	6/2004	Neel et al.	
6,565,509 B1	5/2003	Say et al.	6,749,587 B2	6/2004	Flaherty	
6,565,535 B2	5/2003	Zaias et al.	6,750,055 B1	6/2004	Connelly et al.	
6,565,807 B1	5/2003	Patterson et al.	6,770,030 B1	8/2004	Schaupp et al.	
6,569,195 B2	5/2003	Yang et al.	6,770,067 B2	8/2004	Lorenzen et al.	
6,569,521 B1	5/2003	Sheridan et al.	6,773,565 B2	8/2004	Kunimoto et al.	
6,571,128 B2	5/2003	Lebel et al.	6,780,297 B2	8/2004	Matsumoto et al.	
6,572,545 B2	6/2003	Knobbe et al.	6,793,632 B2	9/2004	Sohrab	
6,572,579 B1	6/2003	Raghavan et al.	6,801,041 B2	10/2004	Karinika et al.	
6,574,490 B2	6/2003	Abbinsk et al.	6,802,957 B2	10/2004	Jung et al.	
6,575,905 B2	6/2003	Knobbe et al.	6,804,002 B2	10/2004	Fine et al.	
6,577,899 B2	6/2003	Lebel et al.	6,805,693 B2	10/2004	Gray et al.	
6,579,257 B1	6/2003	Elgas et al.	6,809,653 B1	10/2004	Mann et al.	
6,579,498 B1	6/2003	Eglise	6,810,290 B2	10/2004	Lebel et al.	
6,579,690 B1	6/2003	Bonnecaze et al.	6,811,548 B2	11/2004	Jeffrey	
6,585,644 B2	7/2003	Lebel et al.	6,813,519 B2	11/2004	Lebel et al.	
6,585,675 B1	7/2003	O'Mahony et al.	6,832,200 B2	12/2004	Greeven et al.	
6,585,763 B1	7/2003	Keilman et al.	6,850,790 B2	2/2005	Berner et al.	
6,587,705 B1	7/2003	Kim et al.	6,858,020 B2	2/2005	Rusnak	
6,589,229 B1	7/2003	Connelly et al.	6,862,465 B2	3/2005	Shults et al.	
6,591,125 B1	7/2003	Buse et al.	6,869,413 B2	3/2005	Langley et al.	
6,594,514 B2	7/2003	Berner et al.	6,875,195 B2	4/2005	Choi	
6,595,756 B2	7/2003	Gray et al.	6,887,228 B2	5/2005	McKay	
6,595,919 B2	7/2003	Berner et al.	6,892,085 B2	5/2005	McIvor et al.	
6,602,221 B1	8/2003	Saravia et al.	6,893,552 B1	5/2005	Wang et al.	
6,605,072 B2	8/2003	Stryuys et al.	6,895,263 B2	5/2005	Shin et al.	
6,607,509 B2	8/2003	Bobroff et al.	6,895,265 B2	5/2005	Silver	
6,609,071 B2	8/2003	Shapiro et al.	6,902,544 B2	6/2005	Ludin et al.	
6,612,984 B1	9/2003	Kerr, II	6,925,393 B1	8/2005	Kalatz et al.	
6,613,379 B2	9/2003	Ward et al.	6,926,691 B2	8/2005	Miethke	
6,615,061 B1	9/2003	Khalil et al.	6,931,327 B2	8/2005	Goode, Jr. et al.	
6,615,078 B1	9/2003	Burson et al.	6,932,584 B2	8/2005	Gray et al.	
6,618,603 B2	9/2003	Varalli et al.	6,936,006 B2	8/2005	Sabra	
6,618,934 B1	9/2003	Feldman et al.	6,936,029 B2	8/2005	Mann et al.	
6,620,138 B1	9/2003	Marigli et al.	6,945,965 B2	9/2005	Whiting	
6,633,772 B2	10/2003	Ford et al.	6,948,492 B2	9/2005	Wermeling et al.	
6,635,014 B2	10/2003	Starkweather et al.	6,952,604 B2	10/2005	Denuzzio et al.	
6,641,533 B2	11/2003	Causey, III et al.	6,954,662 B2	10/2005	Freger et al.	
6,642,015 B2	11/2003	Vachon et al.	6,960,192 B1	11/2005	Flaherty et al.	
6,645,181 B1	11/2003	Lavi et al.	6,965,791 B1	11/2005	Hitchcock et al.	
6,648,821 B2	11/2003	Lebel et al.	6,966,325 B2	11/2005	Erickson	
6,653,091 B1	11/2003	Dunn et al.	6,975,893 B2	12/2005	Say et al.	
6,654,625 B1	11/2003	Say et al.	6,979,315 B2	12/2005	Rogers et al.	
6,656,114 B1	12/2003	Poulsen et al.	6,989,891 B2	1/2006	Braig et al.	
6,656,157 B1	12/2003	Duchon et al.	6,997,921 B2	2/2006	Gray et al.	
6,663,615 B1	12/2003	Madou et al.	6,998,247 B2	2/2006	Monfre et al.	
6,673,022 B1	1/2004	Bobo et al.	7,008,979 B2	3/2006	Schottman et al.	
6,673,596 B1	1/2004	Sayler et al.	7,011,630 B2	3/2006	Desai et al.	
			7,016,713 B2	3/2006	Gardner et al.	
			7,022,072 B2	4/2006	Fox et al.	
			7,022,219 B2	4/2006	Mansouri et al.	
			7,025,727 B2	4/2006	Brockway et al.	

(56)	References Cited					
U.S. PATENT DOCUMENTS						
7,025,743 B2	4/2006	Mann et al.	7,402,153 B2	7/2008	Steil et al.	
7,027,848 B2	4/2006	Robinson et al.	7,417,164 B2	8/2008	Suri	
7,029,444 B2	4/2006	Shin et al.	7,426,408 B2	9/2008	Denuzzio et al.	
7,033,322 B2	4/2006	Silver	7,433,727 B2	10/2008	Ward et al.	
7,044,911 B2	5/2006	Drinan et al.	7,519,408 B2	4/2009	Rasdal et al.	
7,048,727 B1	5/2006	Moss	7,519,478 B2	4/2009	Bartkowiak et al.	
7,058,437 B2	6/2006	Buse et al.	7,523,004 B2	4/2009	Bartkowiak et al.	
7,060,059 B2	6/2006	Keith et al.	7,534,230 B2	5/2009	Follman et al.	
7,061,593 B2	6/2006	Braig et al.	7,569,030 B2	8/2009	Lebel et al.	
7,063,086 B2	6/2006	Shahbazpour et al.	7,583,990 B2	9/2009	Goode, Jr. et al.	
7,066,884 B2	6/2006	Custer et al.	7,591,801 B2	9/2009	Brauker et al.	
7,070,577 B1	7/2006	Haller et al.	7,599,726 B2	10/2009	Goode, Jr. et al.	
7,074,307 B2	7/2006	Simpson et al.	7,604,593 B2	10/2009	Parris et al.	
7,081,195 B2	7/2006	Simpson et al.	7,615,007 B2	11/2009	Shults et al.	
7,097,775 B2	8/2006	Greenberg et al.	7,618,368 B2	11/2009	Brown	
7,098,803 B2	8/2006	Mann et al.	7,618,369 B2	11/2009	Hayter et al.	
7,100,628 B1	9/2006	Izenson et al.	7,624,028 B1	11/2009	Brown	
7,108,778 B2	9/2006	Simpson et al.	7,640,032 B2	12/2009	Jones	
7,120,483 B2	10/2006	Russell et al.	7,640,048 B2	12/2009	Dubbles et al.	
7,131,967 B2	11/2006	Gray et al.	7,647,237 B2	1/2010	Malave et al.	
7,134,999 B2	11/2006	Brauker et al.	7,654,955 B2	2/2010	Polidori et al.	
7,136,689 B2	11/2006	Shults et al.	7,657,297 B2	2/2010	Simpson et al.	
7,146,202 B2	12/2006	Ward et al.	7,670,288 B2	3/2010	Sher	
7,150,741 B2	12/2006	Erickson et al.	7,695,434 B2	4/2010	Malecha	
7,162,290 B1	1/2007	Levin	7,727,147 B1	6/2010	Osorio et al.	
7,166,074 B2	1/2007	Reghabi et al.	7,731,659 B2	6/2010	Malecha	
7,168,597 B1	1/2007	Jones et al.	7,761,126 B2	7/2010	Gardner et al.	
7,169,289 B2	1/2007	Schuelein et al.	7,766,830 B2	8/2010	Fox et al.	
7,183,102 B2	2/2007	Monfre et al.	7,857,760 B2	12/2010	Bristet et al.	
7,184,810 B2	2/2007	Caduff et al.	7,901,394 B2	3/2011	Ireland et al.	
7,207,968 B1	4/2007	Harcinske	7,905,833 B2	3/2011	Brister et al.	
7,211,074 B2	5/2007	Sansoucy	7,927,274 B2	4/2011	Rasdal et al.	
7,221,970 B2	5/2007	Parker	7,946,985 B2	5/2011	Mastrototaro et al.	
7,223,253 B2	5/2007	Hogendijk	7,976,492 B2	7/2011	Brauker et al.	
7,225,535 B2	6/2007	Feldman et al.	8,000,901 B2	8/2011	Brauker et al.	
7,228,162 B2	6/2007	Ward et al.	8,005,524 B2	8/2011	Brauker et al.	
7,229,288 B2	6/2007	Stuart et al.	8,005,525 B2	8/2011	Goode, Jr. et al.	
7,238,165 B2	7/2007	Vincent et al.	8,010,174 B2	8/2011	Goode, Jr. et al.	
7,247,138 B2	7/2007	Reghabi et al.	8,920,401 B2	12/2014	Brauker et al.	
7,254,450 B2	8/2007	Christopherson et al.	8,926,585 B2	1/2015	Brauker et al.	
7,255,690 B2	8/2007	Gray et al.	9,050,413 B2	6/2015	Brauker et al.	
7,258,681 B2	8/2007	Houde	9,155,843 B2	10/2015	Brauker et al.	
7,261,690 B2	8/2007	Teller et al.	9,451,908 B2	9/2016	Kamath et al.	
7,266,400 B2	9/2007	Fine et al.	9,452,258 B2	9/2016	Dubbles et al.	
7,267,665 B2	9/2007	Steil et al.	9,452,259 B2	9/2016	Dubbles et al.	
7,276,029 B2	10/2007	Goode, Jr. et al.	9,457,146 B2	10/2016	Dubbles et al.	
7,278,983 B2	10/2007	Ireland et al.	9,463,277 B2	10/2016	Dubbles et al.	
7,279,174 B2	10/2007	Pacetti et al.	9,572,935 B2	2/2017	Dubbles et al.	
7,282,029 B1	10/2007	Poulsen et al.	9,572,936 B2	2/2017	Dubbles et al.	
7,288,085 B2	10/2007	Olsen	9,586,004 B2	3/2017	Dubbles et al.	
7,291,114 B2	11/2007	Mault	9,597,453 B2	3/2017	Dubbles et al.	
7,295,867 B2	11/2007	Berner et al.	9,827,372 B2	11/2017	Dubbles et al.	
7,299,082 B2	11/2007	Feldman et al.	9,937,293 B2	4/2018	Brauker et al.	
7,311,690 B2	12/2007	Burnett	10,278,580 B2	5/2019	Brister et al.	
7,313,425 B2	12/2007	Finarov et al.	10,653,835 B2	5/2020	Dubbles et al.	
7,314,452 B2	1/2008	Madonia	10,966,609 B2	4/2021	Brister et al.	
7,315,767 B2	1/2008	Caduff et al.	11,744,943 B2	9/2023	Dubbles et al.	
7,316,662 B2	1/2008	Delnevo et al.	2001/0007950 A1	7/2001	North et al.	
7,317,939 B2	1/2008	Fine et al.	2001/0016682 A1	8/2001	Berner et al.	
7,318,814 B2	1/2008	Levine et al.	2001/0021817 A1	9/2001	Brugger et al.	
7,327,273 B2	2/2008	Hung et al.	2001/0039053 A1	11/2001	Liseo et al.	
7,329,234 B2	2/2008	Sansoucy	2001/0041830 A1	11/2001	Varalli et al.	
7,334,594 B2	2/2008	Ludin	2001/0044588 A1	11/2001	Mault	
7,335,179 B2	2/2008	Burnett	2001/0051768 A1	12/2001	Schulman et al.	
7,335,195 B2	2/2008	Mehler	2002/0009810 A1	1/2002	O'Connor et al.	
7,338,464 B2	3/2008	Blischak et al.	2002/0016535 A1	2/2002	Martin et al.	
7,344,500 B2	3/2008	Talbot et al.	2002/0016719 A1*	2/2002	Nemeth ..... A61B 5/0022	705/2
7,354,420 B2	4/2008	Steil et al.				
7,357,793 B2	4/2008	Pacetti				
7,359,723 B2	4/2008	Jones	2002/0018843 A1	2/2002	Van Antwerp et al.	
7,361,155 B2	4/2008	Sage, Jr. et al.	2002/0019022 A1	2/2002	Dunn et al.	
7,364,562 B2	4/2008	Braig et al.	2002/0019330 A1	2/2002	Murray et al.	
7,367,942 B2	5/2008	Grage et al.	2002/0022883 A1	2/2002	Burg	
7,396,353 B2	7/2008	Lorenzen et al.	2002/0023852 A1	2/2002	McIvor et al.	
7,399,277 B2	7/2008	Saidara et al.	2002/0026110 A1	2/2002	Parris et al.	

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2002/0026111 A1	2/2002	Ackerman	2004/0006263 A1	1/2004	Anderson et al.	
2002/0042090 A1	4/2002	Heller et al.	2004/0010207 A1	1/2004	Flaherty et al.	
2002/0042561 A1	4/2002	Schulman et al.	2004/0011671 A1	1/2004	Shults et al.	
2002/0043471 A1	4/2002	Ikeda et al.	2004/0015063 A1	1/2004	Denuzzio et al.	
2002/0045808 A1	4/2002	Ford et al.	2004/0015134 A1	1/2004	Lavi et al.	
2002/0060692 A1	5/2002	Broemmelsiek	2004/0023253 A1	2/2004	Kunwar et al.	
2002/0065453 A1	5/2002	Lesho et al.	2004/0023317 A1	2/2004	Motamed et al.	
2002/0068860 A1	6/2002	Clark	2004/0024327 A1	2/2004	Brodnick	
2002/0071776 A1	6/2002	Bandis et al.	2004/0030285 A1	2/2004	Lavi et al.	
2002/0084196 A1	7/2002	Liamos et al.	2004/0030294 A1	2/2004	Mahurkar	
2002/0099282 A1	7/2002	Knobbe et al.	2004/0039298 A1	2/2004	Abreu	
2002/0099997 A1	7/2002	Piret	2004/0039406 A1	2/2004	Jessen	
2002/0111547 A1	8/2002	Knobbe et al.	2004/0040840 A1	3/2004	Mao et al.	
2002/0119711 A1	8/2002	Vanantwerp et al.	2004/0044272 A1	3/2004	Moerman et al.	
2002/0123048 A1	9/2002	Gau	2004/0045879 A1	3/2004	Shults et al.	
2002/0133224 A1	9/2002	Bajgar et al.	2004/0052689 A1	3/2004	Yao	
2002/0151796 A1	10/2002	Kouluk	2004/0054352 A1	3/2004	Adams et al.	
2002/0155615 A1	10/2002	Novikov et al.	2004/0068230 A1	4/2004	Estes et al.	
2002/0161288 A1	10/2002	Shin et al.	2004/0074785 A1	4/2004	Holker et al.	
2002/0182241 A1	12/2002	Borenstein et al.	2004/0078219 A1	4/2004	Kaylor et al.	
2002/0188185 A1	12/2002	Sohrab	2004/0106857 A1	6/2004	Gough	
2002/0193679 A1	12/2002	Malave et al.	2004/0122297 A1	6/2004	Stahmann et al.	
2002/0193885 A1	12/2002	Legeay et al.	2004/0122353 A1	6/2004	Shahmirian et al.	
2002/0198513 A1	12/2002	Lebel et al.	2004/0138543 A1	7/2004	Russell et al.	
2003/0004432 A1	1/2003	Assenheimer	2004/0143173 A1	7/2004	Reghabi et al.	
2003/0006669 A1	1/2003	Pei et al.	2004/0146909 A1	7/2004	Duong et al.	
2003/0021729 A1	1/2003	Moller et al.	2004/0152187 A1	8/2004	Haight et al.	
2003/0023171 A1	1/2003	Sato et al.	2004/0152622 A1	8/2004	Keith et al.	
2003/0023317 A1	1/2003	Brauker et al.	2004/0162678 A1	8/2004	Hetzell et al.	
2003/0028089 A1	2/2003	Galley et al.	2004/0167801 A1	8/2004	Say et al.	
2003/0031699 A1	2/2003	Van Antwerp	2004/0173472 A1	9/2004	Jung et al.	
2003/0032874 A1	2/2003	Rhodes et al.	2004/0176672 A1	9/2004	Silver et al.	
2003/0050546 A1	3/2003	Desai et al.	2004/0180391 A1	9/2004	Gratzl et al.	
2003/0054428 A1	3/2003	Monfre et al.	2004/0186362 A1	9/2004	Brauker et al.	
2003/0060692 A1	3/2003	L. Ruchti et al.	2004/0186365 A1	9/2004	Jin et al.	
2003/0060753 A1	3/2003	Starkweather et al.	2004/0193025 A1	9/2004	Steil et al.	
2003/0060765 A1	3/2003	Campbell et al.	2004/0199059 A1	10/2004	Brauker et al.	
2003/0070548 A1	4/2003	Clausen	2004/0204687 A1	10/2004	Mogensen et al.	
2003/0072741 A1	4/2003	Berglund et al.	2004/0219664 A1	11/2004	Heller et al.	
2003/0076082 A1	4/2003	Morgan et al.	2004/0220517 A1	11/2004	Starkweather et al.	
2003/0078481 A1	4/2003	McIvor et al.	2004/0224001 A1	11/2004	Pacetti et al.	
2003/0078560 A1	4/2003	Miller et al.	2004/0248282 A1	12/2004	Sobha M et al.	
2003/0088238 A1	5/2003	Poulsen et al.	2004/0253365 A1	12/2004	Warren et al.	
2003/0091433 A1	5/2003	Tam et al.	2004/0254433 A1	12/2004	Bandis et al.	
2003/0097082 A1	5/2003	Purdy et al.	2005/0003399 A1	1/2005	Blackburn et al.	
2003/0099682 A1	5/2003	Moussy et al.	2005/0010265 A1	1/2005	Baru et al.	
2003/0100040 A1	5/2003	Bonnecaze et al.	2005/0026689 A1	2/2005	Marks	
2003/0100821 A1	5/2003	Heller et al.	2005/0027180 A1	2/2005	Goode, Jr. et al.	
2003/0114836 A1	6/2003	Estes et al.	2005/0027181 A1	2/2005	Goode, Jr. et al.	
2003/0117296 A1	6/2003	Seely	2005/0027182 A1	2/2005	Siddiqui et al.	
2003/0119208 A1	6/2003	Yoon et al.	2005/0027462 A1	2/2005	Goode, Jr. et al.	
2003/0120152 A1	6/2003	Omiya	2005/0027463 A1	2/2005	Goode, Jr. et al.	
2003/0125612 A1	7/2003	Fox et al.	2005/0031689 A1	2/2005	Shults et al.	
2003/0125613 A1	7/2003	Enegren et al.	2005/0033132 A1	2/2005	Shults et al.	
2003/0130616 A1	7/2003	Steil et al.	2005/0038332 A1	2/2005	Saidara et al.	
2003/0132227 A1	7/2003	Geisler et al.	2005/0043598 A1	2/2005	Goode, Jr. et al.	
2003/0134347 A1	7/2003	Heller et al.	2005/0049472 A1	3/2005	Manda et al.	
2003/0143746 A1	7/2003	Sage	2005/0051427 A1	3/2005	Brauker et al.	
2003/0153821 A1	8/2003	Berner et al.	2005/0051440 A1	3/2005	Simpson et al.	
2003/0176183 A1	9/2003	Drucker et al.	2005/0054909 A1	3/2005	Petisce et al.	
2003/0187338 A1	10/2003	Say et al.	2005/0056552 A1	3/2005	Simpson et al.	
2003/0188427 A1	10/2003	Say et al.	2005/0065464 A1	3/2005	Talbot et al.	
2003/0199744 A1	10/2003	Buse et al.	2005/0077584 A1	4/2005	Uhland et al.	
2003/0199745 A1	10/2003	Burson et al.	2005/0090607 A1	4/2005	Tapsak et al.	
2003/0208113 A1	11/2003	Mault et al.	2005/0096519 A1	5/2005	Denuzzio et al.	
2003/0211050 A1	11/2003	Majeti et al.	2005/0101847 A1	5/2005	Routt et al.	
2003/0211625 A1	11/2003	Cohan et al.	2005/0107677 A1	5/2005	Ward et al.	
2003/0212317 A1	11/2003	Kovatchev et al.	2005/0112169 A1	5/2005	Brauker et al.	
2003/0212346 A1	11/2003	Yuzhakov et al.	2005/0113653 A1	5/2005	Fox et al.	
2003/0212347 A1	11/2003	Sohrab	2005/0113744 A1	5/2005	Donoghue et al.	
2003/0212379 A1	11/2003	Bylund et al.	2005/0115832 A1	6/2005	Simpson et al.	
2003/0225324 A1	12/2003	Anderson et al.	2005/0118344 A1	6/2005	Pacetti	
2003/0225437 A1	12/2003	Ferguson	2005/0119720 A1	6/2005	Gale et al.	
2003/0231550 A1	12/2003	MacFarlane	2005/0121322 A1	6/2005	Say et al.	
2003/0235817 A1	12/2003	Bartkowiak et al.	2005/0124873 A1	6/2005	Shults et al.	
			2005/0131305 A1	6/2005	Danielson et al.	
			2005/0139489 A1	6/2005	Davies et al.	
			2005/0143635 A1	6/2005	Kamat et al.	
			2005/0143675 A1	6/2005	Neel et al.	

# US 12,115,357 B2

Page 10

---

(56)	References Cited			
U.S. PATENT DOCUMENTS				
2005/0154271 A1	7/2005 Rasdal et al.	2007/0066956 A1	3/2007 Finkel	
2005/0176136 A1	8/2005 Burd et al.	2007/0085995 A1	4/2007 Pesach et al.	
2005/0177036 A1	8/2005 Shults et al.	2007/0100222 A1	5/2007 Mastrototaro et al.	
2005/0177398 A1	8/2005 Watanabe et al.	2007/0106135 A1	5/2007 Sloan et al.	
2005/0181012 A1	8/2005 Saint et al.	2007/0112298 A1	5/2007 Mueller, Jr. et al.	
2005/0182451 A1	8/2005 Griffin et al.	2007/0116600 A1	5/2007 Kochar et al.	
2005/0183954 A1	8/2005 Hitchcock et al.	2007/0129619 A1	6/2007 Ward et al.	
2005/0187720 A1	8/2005 Goode, Jr. et al.	2007/0129621 A1	6/2007 Kellogg et al.	
2005/0192557 A1	9/2005 Brauker et al.	2007/0135698 A1	6/2007 Shah et al.	
2005/0197553 A1	9/2005 Cooper	2007/0135699 A1	6/2007 Ward et al.	
2005/0197554 A1	9/2005 Polcha	2007/0151869 A1	7/2007 Heller et al.	
2005/0203360 A1	9/2005 Brauker et al.	2007/0173706 A1	7/2007 Neinast et al.	
2005/0211571 A1	9/2005 Schulein et al.	2007/0173710 A1	7/2007 Petisce et al.	
2005/0215871 A1	9/2005 Feldman et al.	2007/0173761 A1	7/2007 Kanderian, Jr. et al.	
2005/0215872 A1	9/2005 Berner et al.	2007/0179434 A1	8/2007 Weinert et al.	
2005/0239154 A1	10/2005 Feldman et al.	2007/0197889 A1	8/2007 Brister et al.	
2005/0242479 A1	11/2005 Petisce et al.	2007/0200254 A1	8/2007 Curry	
2005/0245795 A1	11/2005 Goode, Jr. et al.	2007/0200267 A1	8/2007 Tsai	
2005/0245799 A1	11/2005 Brauker et al.	2007/0203407 A1	8/2007 Hoss et al.	
2005/0245904 A1	11/2005 Estes et al.	2007/0203410 A1	8/2007 Say et al.	
2005/0251083 A1	11/2005 Carr-Brendel et al.	2007/0203966 A1	8/2007 Brauker et al.	
2005/0261563 A1	11/2005 Zhou et al.	2007/0206193 A1	9/2007 Pesach	
2005/0288596 A1	12/2005 Eigler et al.	2007/0208244 A1	9/2007 Brauker et al.	
2006/0001550 A1	1/2006 Mann et al.	2007/0208245 A1	9/2007 Brauker et al.	
2006/0015020 A1	1/2006 Neale et al.	2007/0208246 A1	9/2007 Brauker et al.	
2006/0015024 A1	1/2006 Brister et al.	2007/0213610 A1	9/2007 Say et al.	
2006/0016700 A1	1/2006 Brister et al.	2007/0218097 A1	9/2007 Heller et al.	
2006/0019327 A1	1/2006 Brister et al.	2007/0219441 A1	9/2007 Carlin et al.	
2006/0020186 A1	1/2006 Brister et al.	2007/0225579 A1	9/2007 Lucassen et al.	
2006/0020187 A1	1/2006 Brister et al.	2007/0225675 A1	9/2007 Robinson et al.	
2006/0020188 A1	1/2006 Kamath et al.	2007/0227907 A1	10/2007 Shah et al.	
2006/0020189 A1	1/2006 Brister et al.	2007/0233013 A1	10/2007 Schoenberg	
2006/0020190 A1	1/2006 Kamath et al.	2007/0235331 A1	10/2007 Simpson et al.	
2006/0020191 A1	1/2006 Brister et al.	2007/0240497 A1	10/2007 Robinson et al.	
2006/0020192 A1	1/2006 Brister et al.	2007/0244381 A1	10/2007 Robinson et al.	
2006/0036139 A1	2/2006 Brister et al.	2007/0244382 A1	10/2007 Robinson et al.	
2006/0036140 A1	2/2006 Brister et al.	2007/0249916 A1	10/2007 Pesach et al.	
2006/0036141 A1	2/2006 Kamath et al.	2007/0255126 A1	11/2007 Moberg et al.	
2006/0036142 A1	2/2006 Brister et al.	2007/0275193 A1	11/2007 Desimone et al.	
2006/0036143 A1	2/2006 Brister et al.	2007/0293742 A1	12/2007 Simonsen et al.	
2006/0036144 A1	2/2006 Brister et al.	2007/0299409 A1	12/2007 Whitbourne et al.	
2006/0036145 A1	2/2006 Brister et al.	2008/0021666 A1	1/2008 Goode, Jr. et al.	
2006/0040402 A1	2/2006 Brauker et al.	2008/0021668 A1	1/2008 Son	
2006/0047095 A1	3/2006 Pacetti	2008/0027301 A1	1/2008 Ward et al.	
2006/0052745 A1	3/2006 Van Antwerp et al.	2008/0029390 A1	2/2008 Roche et al.	
2006/0067908 A1	3/2006 Ding	2008/0029391 A1	2/2008 Mao et al.	
2006/0078908 A1	4/2006 Pitner et al.	2008/0033254 A1	2/2008 Kamath et al.	
2006/0079740 A1	4/2006 Silver et al.	2008/0034972 A1	2/2008 Gough et al.	
2006/0079809 A1	4/2006 Goldberger et al.	2008/0045824 A1	2/2008 Tapsak et al.	
2006/0094946 A1	5/2006 Kellogg et al.	2008/0071157 A1	3/2008 McGarraugh et al.	
2006/0100588 A1	5/2006 Brunnberg et al.	2008/0071158 A1	3/2008 McGarraugh et al.	
2006/0134165 A1	6/2006 Pacetti	2008/0072663 A1	3/2008 Keenan et al.	
2006/0171980 A1	8/2006 Helmus et al.	2008/0086040 A1	4/2008 Heller et al.	
2006/0173406 A1	8/2006 Hayes et al.	2008/0086041 A1	4/2008 Heller et al.	
2006/0177379 A1	8/2006 Asgari	2008/0086042 A1	4/2008 Brister et al.	
2006/0183871 A1	8/2006 Ward et al.	2008/0086043 A1	4/2008 Heller et al.	
2006/0183984 A1	8/2006 Dobbles et al.	2008/0086044 A1	4/2008 Brister et al.	
2006/0183985 A1	8/2006 Brister et al.	2008/0086273 A1	4/2008 Shults et al.	
2006/0189863 A1	8/2006 Peyser et al.	2008/0091094 A1	4/2008 Heller et al.	
2006/0195029 A1	8/2006 Shults et al.	2008/0091095 A1	4/2008 Heller et al.	
2006/0222566 A1	10/2006 Brauker et al.	2008/0097289 A1	4/2008 Steil et al.	
2006/0224141 A1	10/2006 Rush et al.	2008/0108942 A1	5/2008 Brister et al.	
2006/0253085 A1	11/2006 Geismar et al.	2008/0119703 A1	5/2008 Brister et al.	
2006/0258929 A1	11/2006 Goode, Jr. et al.	2008/0119704 A1	5/2008 Brister et al.	
2006/0263839 A1	11/2006 Ward et al.	2008/0119706 A1	5/2008 Brister et al.	
2006/0269586 A1	11/2006 Pacetti	2008/0125751 A1	5/2008 Fjeld et al.	
2006/0275857 A1	12/2006 Kjaer et al.	2008/0139910 A1	6/2008 Mastrototaro et al.	
2006/0281985 A1	12/2006 Ward et al.	2008/0154101 A1	6/2008 Jain et al.	
2007/0007133 A1	1/2007 Mang et al.	2008/0183061 A1	7/2008 Goode et al.	
2007/0016381 A1	1/2007 Kamath et al.	2008/0183399 A1	7/2008 Goode et al.	
2007/0027385 A1	2/2007 Brister et al.	2008/0187655 A1	8/2008 Markle et al.	
2007/0032706 A1	2/2007 Kamath et al.	2008/0188722 A1	8/2008 Markle et al.	
2007/0038044 A1	2/2007 Dobbles et al.	2008/0188725 A1	8/2008 Markle et al.	
2007/0049873 A1	3/2007 Hansen et al.	2008/0189051 A1	8/2008 Goode et al.	
2007/0066873 A1	3/2007 Kamath et al.	2008/0193936 A1	8/2008 Squirrell	
		2008/0194837 A1	8/2008 Kim et al.	
		2008/0194935 A1	8/2008 Brister et al.	
		2008/0194936 A1	8/2008 Goode et al.	

# US 12,115,357 B2

Page 11

---

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2008/0194937 A1	8/2008	Goode et al.	2009/0299162 A1	12/2009	Brauker et al.	
2008/0195967 A1	8/2008	Goode et al.	2009/0299276 A1	12/2009	Brauker et al.	
2008/0197024 A1	8/2008	Simpson et al.	2010/0010324 A1	1/2010	Brauker et al.	
2008/0200788 A1	8/2008	Brister et al.	2010/0010331 A1	1/2010	Brauker et al.	
2008/0200789 A1	8/2008	Brister et al.	2010/0010332 A1	1/2010	Brauker et al.	
2008/0200791 A1	8/2008	Simpson et al.	2010/0016687 A1	1/2010	Brauker et al.	
2008/0208025 A1	8/2008	Shults et al.	2010/0022855 A1	1/2010	Brauker et al.	
2008/0210557 A1	9/2008	Heller et al.	2010/0030053 A1	2/2010	Goode, Jr. et al.	
2008/0214915 A1	9/2008	Brister et al.	2010/0030484 A1	2/2010	Brauker et al.	
2008/0262469 A1	10/2008	Brister et al.	2010/0030485 A1	2/2010	Brauker et al.	
2008/0269723 A1	10/2008	Mastrototaro et al.	2010/0036215 A1	2/2010	Goode, Jr. et al.	
2008/0287764 A1	11/2008	Rasdal et al.	2010/0036225 A1	2/2010	Goode, Jr. et al.	
2008/0287765 A1	11/2008	Rasdal et al.	2010/0041971 A1	2/2010	Goode, Jr. et al.	
2008/0287766 A1	11/2008	Rasdal et al.	2010/0045465 A1	2/2010	Brauker et al.	
2008/0296155 A1	12/2008	Shults et al.	2010/0049024 A1	2/2010	Saint et al.	
2008/0300572 A1	12/2008	Rankers et al.	2010/0076283 A1	3/2010	Simpson et al.	
2008/0305009 A1	12/2008	Gamsey et al.	2010/0081908 A1	4/2010	Dobbles et al.	
2008/0305506 A1	12/2008	Suri	2010/0081910 A1	4/2010	Brister et al.	
2008/0306368 A1	12/2008	Goode, Jr. et al.	2010/0161269 A1	6/2010	Kamath et al.	
2008/0306433 A1	12/2008	Cesaroni	2010/0179401 A1	7/2010	Rasdal et al.	
2008/0306434 A1	12/2008	Dobbles et al.	2010/0179407 A1	7/2010	Goode, Jr. et al.	
2008/0306435 A1	12/2008	Kamath et al.	2010/0179408 A1	7/2010	Kamath et al.	
2008/0306444 A1	12/2008	Brister et al.	2010/0179409 A1	7/2010	Kamath et al.	
2009/0005666 A1	1/2009	Shin et al.	2010/0234707 A1	9/2010	Goode, Jr. et al.	
2009/0012379 A1	1/2009	Goode, Jr. et al.	2010/0235106 A1	9/2010	Kamath et al.	
2009/0018418 A1	1/2009	Markle et al.	2010/0240975 A1	9/2010	Goode, Jr. et al.	
2009/0018424 A1	1/2009	Kamath et al.	2010/0240976 A1	9/2010	Goode, Jr. et al.	
2009/0018426 A1	1/2009	Markle et al.	2010/0331656 A1	12/2010	Mensinger et al.	
2009/0036758 A1	2/2009	Brauker et al.	2010/0331657 A1	12/2010	Mensinger et al.	
2009/0043181 A1	2/2009	Brauker et al.	2011/0009727 A1	1/2011	Mensinger et al.	
2009/0043182 A1	2/2009	Brauker et al.	2011/0118579 A1	5/2011	Goode, Jr. et al.	
2009/0043525 A1	2/2009	Brauker et al.	2011/0124997 A1	5/2011	Goode, Jr. et al.	
2009/0043541 A1	2/2009	Brauker et al.	2011/0130970 A1	6/2011	Goode, Jr. et al.	
2009/0043542 A1	2/2009	Brauker et al.	2011/0137601 A1	6/2011	Goode, Jr. et al.	
2009/0061528 A1	3/2009	Suri	2011/0201910 A1	8/2011	Rasdal et al.	
2009/0062635 A1	3/2009	Brauker et al.	2011/0218414 A1	9/2011	Kamath et al.	
2009/0062645 A1	3/2009	Fehre et al.	2011/0231107 A1	9/2011	Brauker et al.	
2009/0076356 A1	3/2009	Simpson et al.	2011/0231140 A1	9/2011	Goode, Jr. et al.	
2009/0076360 A1	3/2009	Brister et al.	2011/0231141 A1	9/2011	Goode, Jr. et al.	
2009/0076361 A1	3/2009	Kamath et al.	2011/0231142 A1	9/2011	Goode, Jr. et al.	
2009/0081803 A1	3/2009	Gamsey et al.	2011/0257895 A1	10/2011	Brauker et al.	
2009/0099434 A1	4/2009	Liu et al.	2011/0270158 A1	11/2011	Brauker et al.	
2009/0124877 A1	5/2009	Goode, Jr. et al.	2012/0059673 A1	3/2012	Cohen et al.	
2009/0124878 A1	5/2009	Goode, Jr. et al.	2012/0097289 A1	4/2012	Chun et al.	
2009/0124964 A1	5/2009	Leach et al.	2012/0186581 A1	7/2012	Brauker et al.	
2009/0131768 A1	5/2009	Simpson et al.	2012/0190953 A1	7/2012	Brauker et al.	
2009/0131769 A1	5/2009	Leach et al.	2012/0191063 A1	7/2012	Brauker et al.	
2009/0131776 A1	5/2009	Simpson et al.	2012/0215201 A1	8/2012	Brauker et al.	
2009/0131777 A1	5/2009	Simpson et al.	2012/0220979 A1	8/2012	Brauker et al.	
2009/0137886 A1	5/2009	Shariati et al.	2012/0227737 A1	9/2012	Mastrototaro et al.	
2009/0137887 A1	5/2009	Shariati et al.	2012/0238852 A1	9/2012	Brauker et al.	
2009/0143659 A1	6/2009	Li et al.	2012/0259278 A1	10/2012	Hayes et al.	
2009/0156924 A1	6/2009	Shariati et al.	2012/0296311 A1	11/2012	Brauker et al.	
2009/0177143 A1	7/2009	Markle et al.	2018/0043096 A1	2/2018	Dobbles et al.	
2009/0178459 A1	7/2009	Li et al.	2018/0185587 A1	7/2018	Brauker et al.	
2009/0182217 A1	7/2009	Li et al.	2019/0070360 A1	3/2019	Sloan et al.	
2009/0192366 A1	7/2009	Mensinger et al.	2019/0209009 A1	7/2019	Brister et al.	
2009/0192380 A1	7/2009	Shariati et al.				
2009/0192722 A1	7/2009	Shariati et al.				
2009/0192724 A1	7/2009	Brauker et al.				
2009/0192745 A1	7/2009	Kamath et al.				
2009/0192751 A1	7/2009	Kamath et al.				
2009/0203981 A1	8/2009	Brauker et al.				
2009/0204341 A1	8/2009	Brauker et al.				
2009/0216103 A1	8/2009	Brister et al.				
2009/0240120 A1	9/2009	Mensinger et al.				
2009/0240128 A1	9/2009	Mensinger et al.				
2009/0240193 A1	9/2009	Mensinger et al.				
2009/0242399 A1	10/2009	Kamath et al.				
2009/0242425 A1	10/2009	Kamath et al.				
2009/0264719 A1	10/2009	Markle et al.				
2009/0264856 A1	10/2009	Lebel et al.				
2009/0287074 A1	11/2009	Shults et al.				
2009/0299155 A1	12/2009	Yang et al.				
2009/0299156 A1	12/2009	Simpson et al.				

## FOREIGN PATENT DOCUMENTS

EP	0107634 A2	5/1984
EP	0127958 A2	12/1984
EP	0286118 A2	10/1988
EP	0288793 A2	11/1988
EP	0320109 A1	6/1989
EP	0352610 A2	1/1990
EP	0352631 A2	1/1990
EP	0353328 A1	2/1990
EP	0390390 A1	10/1990
EP	0396788 A1	11/1990
EP	0406473 A1	1/1991
EP	0440044 A1	8/1991
EP	0441252 A2	8/1991
EP	0441394 A2	8/1991
EP	0467078 A2	1/1992

US 12,115,357 B2

Page 12

References Cited			WO	WO-0019887 A1	4/2000
FOREIGN PATENT DOCUMENTS			WO	WO-0032098 A1	6/2000
EP	0534074 A1	3/1993	WO	WO-0059373 A1	10/2000
EP	0535898 A1	4/1993	WO	WO-0074753 A1	12/2000
EP	0539751 A1	5/1993	WO	WO-0078210 A1	12/2000
EP	0563795 A1	10/1993	WO	WO-0112158 A1	2/2001
EP	0323605 B1	1/1994	WO	WO-0116579 A1	3/2001
EP	0647849 A2	4/1995	WO	WO-0120019 A2	3/2001
EP	0424633 B1	1/1996	WO	WO-0120334 A1	3/2001
EP	0729366 A1	9/1996	WO	WO-0134243 A1	5/2001
EP	0747069 A2	12/1996	WO	WO-0143660 A2	6/2001
EP	0776628 A2	6/1997	WO	WO-0152727 A1	7/2001
EP	0817809 A1	1/1998	WO	WO-0158348 A2	8/2001
EP	0838230 A2	4/1998	WO	WO-0168901 A2	9/2001
EP	0880936 A2	12/1998	WO	WO-0169222 A2	9/2001
EP	0885932 A2	12/1998	WO	WO-0188524 A1	11/2001
EP	0967788 A2	12/1999	WO	WO-0188534 A2	11/2001
EP	0995805 A1	4/2000	WO	WO-0205702 A2	1/2002
EP	1077634 A1	2/2001	WO	WO-0224065 A1	3/2002
EP	1078258 A1	2/2001	WO	WO-0078210 A9	5/2002
EP	1102194 A2	5/2001	WO	WO-02082989 A1	10/2002
EP	0789540 B1	9/2001	WO	WO-02089666 A2	11/2002
EP	1153571 A1	11/2001	WO	WO-02100266 A1	12/2002
EP	0817809 B1	7/2002	WO	WO-03000127 A2	1/2003
EP	1266607 A2	12/2002	WO	WO-03022125 A2	3/2003
EP	1338295 A1	8/2003	WO	WO-03022327 A2	3/2003
EP	1067862 B1	5/2004	WO	03047426 A1	6/2003
EP	1498067 A1	1/2005	WO	WO-03063700 A1	8/2003
EP	1571582 A2	9/2005	WO	WO-03072269 A1	9/2003
EP	2223710 A1	9/2010	WO	WO-03101862 A1	12/2003
EP	2226086 A1	9/2010	WO	WO-2004009161 A1	1/2004
EP	2228642 A1	9/2010	WO	WO-2004110256 A2	12/2004
FR	2656423 A1	6/1991	WO	WO-2005011489 A1	2/2005
FR	2760962 A1	9/1998	WO	WO-2005012873 A2	2/2005
GB	1442303 A	7/1976	WO	WO-2005026689 A2	3/2005
GB	2149918 A	6/1985	WO	WO-2005032400 A2	4/2005
JP	S6283649 A	4/1987	WO	WO-2005057168 A2	6/2005
JP	S6283849 A	4/1987	WO	WO-2005057175 A2	6/2005
JP	H0783871 A	3/1995	WO	WO-2005078424 A1	8/2005
JP	2000060826 A	2/2000	WO	WO-2005026689 A9	10/2005
JP	2002515302 A	5/2002	WO	WO-2005093629 A2	10/2005
JP	2002189015 A	7/2002	WO	2005106446 A1	11/2005
JP	2003108679 A	4/2003	WO	WO-2006017358 A1	2/2006
JP	2004000555 A	1/2004	WO	WO-2006021430 A2	3/2006
WO	WO-8902720 A1	4/1989	WO	WO-2006050405 A1	5/2006
WO	WO-9000738 A1	1/1990	WO	WO-2006105146 A2	10/2006
WO	WO-9010861 A1	9/1990	WO	WO-2006118713 A1	11/2006
WO	WO-9013021 A1	11/1990	WO	WO-2006131288 A1	12/2006
WO	WO-9116416 A1	10/1991	WO	WO-2007002209 A2	1/2007
WO	WO-9213271 A1	8/1992	WO	WO-2007002579 A2	1/2007
WO	WO-9314693 A1	8/1993	WO	WO-2007065285 A2	6/2007
WO	WO-9323744 A1	11/1993	WO	WO-2007097754 A1	8/2007
WO	WO-9422367 A1	10/1994	WO	WO-2007114943 A2	10/2007
WO	WO-9507109 A1	3/1995	WO	WO-2007127606 A1	11/2007
WO	WO-9513838 A1	5/1995	WO	WO-2007137286 A2	11/2007
WO	WO-9601611 A1	1/1996	WO	WO-2007143225 A2	12/2007
WO	WO-9603117 A1	2/1996	WO	WO-2008001091 A1	1/2008
WO	WO-9614026 A1	5/1996	WO	WO-2008076868 A2	6/2008
WO	WO-9625089 A1	8/1996			
WO	WO-9630431 A1	10/1996			
WO	WO-9632076 A1	10/1996			
WO	WO-9637246 A1	11/1996			
WO	WO-9701986 A1	1/1997			
WO	WO-9706727 A1	2/1997			
WO	WO-9719188 A1	5/1997			
WO	WO-9728737 A1	8/1997			
WO	WO-9743633 A1	11/1997			
WO	WO-9824358 A2	6/1998			
WO	WO-9838906 A1	9/1998			
WO	WO-9948419 A1	9/1999			
WO	WO-9956613 A1	11/1999			
WO	WO-9958051 A1	11/1999			
WO	WO-9958973 A1	11/1999			
WO	WO-9959657 A1	11/1999			
WO	WO-0012720 A2	3/2000			
WO	WO-0013002 A2	3/2000			
WO	WO-0013003 A1	3/2000			

(56)

**References Cited****OTHER PUBLICATIONS**

- Adilman, et al., "Videogames: Knowing The Score, Creative Computing," Dec. 1983, Dialog: File 148; IAC Trade & Industry Database, vol. 9, p. 224(5) (9 pages).
- Alcock S.J., et al., "Continuous Analyte Monitoring To Aid Clinical Practice," IEEE Engineering in Medicine & Biology, 1994, vol. 13, pp. 319-325.
- Amer M.M.B., "An Accurate Amperometric Glucose Sensor Based Glucometer with Eliminated Cross-Sensitivity," Journal of Medical Engineering & Technology, vol. 26 (5), Sep./Oct. 2002, pp. 208-213.
- American Diabetes Association., "Position Statement: Diagnosis and Classification of Diabetes Mellitus," Diabetes Care, vol. 30, Supplement 01, Jan. 2007, pp. S42-S47.
- American Diabetes Association., "Position Statement: Standards of Medical Care in Diabetes," Diabetes Care, vol. 30, Supplement 01, Jan. 2007, pp. S4-S41.
- American Diabetes Association., "Summary of Revisions for the 2007 Clinical Practice Recommendations," Diabetes Care, vol. 30, Supplement 01, Jan. 2007, pp. S3.
- Amin R., et al., "Hypoglycemia Prevalence in Prepubertal Children With Type 1 Diabetes on Standard Insulin Regimen: Use of Continuous Glucose Monitoring System," Diabetes Care, 2003, vol. 26, No. 3, pp. 662-667.
- Armour J.C., et al., "Application of Chronic Intravascular Blood Glucose Sensor in Dogs," Diabetes, Dec. 1990, vol. 39, pp. 1519-1526.
- Asberg P., et al., "Hydrogels of a Conducting Conjugated Polymer as 3-D Enzyme Electrode," Biosensors Bioelectronics, 2003, vol. 19, pp. 199-207.
- Assolant-Vinet C.H., et al., "New Immobilized Enzyme Membranes for Tailor-Made Biosensors," Analytical Letters, 1986, vol. 19(7 &8), pp. 875-885.
- Atanasov P., et al., "Biosensor for Continuous Glucose Monitoring," Biotechnology and Bioengineering, John Wiley & sons Inc, 1994, vol. 43, pp. 262-266.
- Atanasov P., et al., "Implantation of a Refillable Glucose Monitoring-Telemetry Device," Biosensors and Bioelectronics, vol. 12 (7), 1997, pp. 669-680.
- Aussedat B., et al., "A User-Friendly Method For Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycaemic Alarm," Elsevier Science Limited, Biosensors & Bioelectronic, 1997, vol. 12, No. 11, pp. 1061-1071.
- Aussedat B., et al., "Interstitial Glucose Concentration and Glycemia: Implications for Continuous Subcutaneous Glucose Monitoring," American Journal of Physiology—Endocrinology and Metabolism, vol. 278 (4), Apr. 1, 2000, pp. E716-E728.
- Bailey T.S., et al., "Reduction in Hemoglobin A1C with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study," Diabetes Technology & Therapeutics, vol. 9 (3), 2007, pp. 203-210.
- Baker D.A., et al., "Dynamic Concentration Challenges for Biosensor Characterization," Biosensors & Bioelectronics, vol. 8, 1993, pp. 433-441.
- Baker D.A., et al., "Dynamic Delay and Maximal Dynamic Error in Continuous Biosensors," Analytical Chemistry, vol. 68 (8), Apr. 15, 1996, pp. 1292-1297.
- Bard A.J., et al., "Electrochemical Methods," Fundamentals and Applications, John Wiley & Sons, New York, 1980, pp. 173-175.
- Bardeletti G., et al., "A Reliable L-Lactate Electrode with a New Membrane for Enzyme Immobilization for Amperometric Assay of Lactate," Analytica Chemica Acta, vol. 187, 1986, pp. 47-54.
- Beach R.D., et al., "Subminiature Implantable Potentiostat and Modified Commercial Telemetry Device for Remote Glucose Monitoring," IEEE Transactions on Instrumentation and Measurement, vol. 48 (6), Dec. 1999, pp. 1239-1245.
- Bellucci F., et al., "Electrochemical Behaviour of Graphite-Epoxy Composite Materials (GECM) in Aqueous Salt Solutions," Journal of Applied Electrochemistry, vol. 16 (1), Jan. 1986, pp. 15-22.
- Berger M., et al., "Computer Programs to Assist the Physician in the Analysis of Self-Monitored Blood Glucose Data," Proceedings of the Annual Symposium on Computer Applications in Medical Care, 1988, pp. 52-57.
- Bertrand C., et al., "Multipurpose Electrode with Different Enzyme Systems Bound to Collagen Films," Analytica Chemica Acta, 1981, vol. 126, pp. 23-34.
- Bessman S.P., et al., "Progress toward a Glucose Sensor for the Artificial Pancreas," Proceedings of a Workshop on Ion-Selective Microelectrodes, Jun. 4-5, 1973, Boston University, 1973, pp. 189-197.
- Biermann E., et al., "How Would Patients Behave if they were Continually Informed of their Blood Glucose Levels? A Simulation Study Using a "Virtual" Patient," Diabetes Technology & Therapeutics, vol. 10 (3), 2008, pp. 178-187.
- Bindra D.S., et al., "Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring," Analytical Chemistry, vol. 63, Sep. 1, 1991, pp. 1692-1696.
- Bindra D.S., et al., "Pulsed Amperometric Detection of Glucose in Biological Fluids at a Surface-Modified Gold Electrode," Analytical Chemistry, vol. 61 (22), Nov. 15, 1989, pp. 2566-2570.
- Bisenberger M., et al., "A Triple-Step Potential Waveform at Enzyme Multisensors with Thick-Film Gold Electrodes for Detection of Glucose and Sucrose," Sensors and Actuators B, vol. 28, 1995, pp. 181-189.
- Bland J.M., et al., "A Note on the Use of the Intraclass Correlation Coefficient in the Evaluation of Agreement between Two Methods of Measurement," Computers in Biology and Medicine, vol. 20 (5), 1990, pp. 337-340.
- Bland J.M., et al., "Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement," The Lancet, Feb. 8, 1986, pp. 307-310.
- Bobbioni-Harsch E., et al., "Lifespan of Subcutaneous Glucose Sensors and their Performances during Dynamic Glycaemia Changes in Rats," J. Biomed. Eng., vol. 15, 1993, pp. 457-463.
- Bode B.W., "Clinical Utility of the Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S35-S41.
- Bode B.W., et al., "Continuous Glucose Monitoring Used to Adjust Diabetes Therapy Improves Glycosylated Hemoglobin: A Pilot Study," Diabetes Research and Clinical Practice, vol. 46, 1999, pp. 183-190.
- Bode B.W., et al., "Using the Continuous Glucose Monitoring System to Improve the Management of Type 1 Diabetes," Diabetes Technology & Therapeutics, vol. 2, Supplement 1, 2000, pp. S43-S48.
- Boedeker Plastics Inc, "Polyethylene Specifications," Polyethylene Data Sheet, Retrieved from <http://www.boedeker.com/polye.sub.--p.htm> on Aug. 19, 2009, 4 pages.
- Boland E., et al., "Limitations of Conventional Methods of Self-Monitoring of Blood Glucose," Diabetes Care, vol. 24 (11), Nov. 2001, pp. 1858-1862.
- Bolinder J., et al., "Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison with Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue during Ordinary Life Conditions," Diabetes Care, vol. 20 (1), Jan. 1997, pp. 64-70.
- Bolinder J., et al., "Microdialysis Measurement of the Absolute Glucose Concentration in Subcutaneous Adipose Tissue Allowing Glucose Monitoring in Diabetic Patients," Rapid Communication, Diabetologia, vol. 35, 1992, pp. 1177-1180.
- Bott A.W., "A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry," Current Separations, vol. 16 (1), 1997, pp. 23-26.
- Bott A.W., "Electrochemical Methods for the Determination of Glucose," Current Separations, vol. 17 (1), 1998, pp. 25-31.
- Bowman L., et al., "The Packaging of Implantable Integrated Sensors," IEEE Transactions in Biomedical Engineering, vol. BME-33 (2), Feb. 1986, pp. 248-255.
- Brauker, et al., "Sustained Expression of High Levels of Human Factor IX from Human Cells Implanted within an Immunoisolation Device into Athymic Rodents," Human Gene Therapy, Apr. 10, 1998, vol. 9, pp. 879-888.

(56)

**References Cited****OTHER PUBLICATIONS**

- Brauker J., et al., "Local Inflammatory Response Around Diffusion Chambers Containing Xenografts," *Transplantation*, vol. 61 (12), Jun. 27, 1996, pp. 1671-1677.
- Brauker J H., et al., "Neovascularization of Synthetic Membranes Directed by Membrane Microarchitecture," *Journal of Biomedical Material Research*, 1995, vol. 29, pp. 1517-1524.
- Brauker J., "Unraveling Mysteries at the Biointerface: Molecular Mediator of Inhibition of Blood Vessel Formation in the Foreign Body Capsule Revealed," *SurFACTS in Biomaterials*, vol. 6 (3), 2001, pp. 1,5.
- Braunwald E., "Biomarkers in Heart Failure," *Medical Progress*, *The New England Journal of Medicine*, vol. 358, May 15, 2008, pp. 2148-2159.
- Bremer T., et al., "Is Blood Glucose Predictable from Previous Values? A Solicitation for Data," *Perspectives in Diabetes*, vol. 48, Mar. 1999, pp. 445-451.
- Bremer T.M., et al., "Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies," *Diabetes Technology & Therapeutics*, vol. 3 (3), 2001, pp. 409-418.
- Brooks S.L., et al., "Development of an On-line Glucose Sensor for Fermentation Monitoring," *Biosensors*, vol. 3, 1987/1988, pp. 45-56.
- Bruckel J., et al., "In Vivo Measurement of Subcutaneous Glucose Concentrations with an Enzymatic Glucose Sensor and a Wick Method," *Klin Wochenschr*, vol. 67, 1989, pp. 491-495.
- Brunner G.A., et al., "Validation of Home Blood Glucose Meters with Respect to Clinical and Analytical Approaches," *Diabetes Care*, vol. 21, No. 4, Apr. 1998, pp. 585-590.
- Brunstein E., et al., "Preparation and Validation of Implantable Electrodes for the Measurement of Oxygen and Glucose," *Biomed Biochim Acta*, vol. 48 (11/12), 1989, pp. 911-917.
- Cai Q., et al., "A Wireless, Remote Query Glucose Biosensor Based on a pH-Sensitive Polymer," *Analytical Chemistry*, vol. 76 (14), Jul. 15, 2004, pp. 4038-4043.
- Cameron T., et al., "Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs," *IEEE Transactions on Biomedical Engineering*, vol. 44 (9), Sep. 1997, pp. 781-790.
- Campanella L., et al., "Biosensor for Direct Determination of Glucose and Lactate in Undiluted Biological Fluids," *Biosensors & Bioelectronics*, vol. 8, 1993, pp. 307-314.
- Candas B., et al., "An Adaptive Plasma Glucose Controller Based on a Nonlinear Insulin/Glucose Model," *IEEE Transactions on Biomedical Engineering*, vol. 41 (2), Feb. 1994, pp. 116-124.
- Cass A.E.G., et al., "Ferrocene-Mediated Enzyme Electrodes for Amperometric Determination of Glucose," *Analytical Chemistry*, vol. 56 (4), Apr. 1984, pp. 667-671.
- Cassidy J.F., et al., "Novel Electrochemical Device for the Detection of Cholesterol or Glucose," *Analyst*, vol. 118, Apr. 1993, pp. 415-418.
- Chase H.P., et al., "Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes," *Pediatrics*, vol. 107 (2), Feb. 2001, pp. 222-226.
- Chase J.G., et al., "Targeted Glycemic Reduction in Critical Care Using Closed-Loop Control," *Diabetes Technology & Therapeutics*, vol. 7 (2), 2005, pp. 274-282.
- Chen C., et al., "A Noninterference Polypyrrole Glucose Biosensor," *Biosensors and Bioelectronics*, vol. 22, 2006, pp. 639-643.
- Chen T., et al., "Defining the Period of Recovery of the Glucose Concentration after its Local Perturbation by the Implantation of a Miniature Sensor," *Clinical Chemistry and Laboratory Medicine*, vol. 40 (8), 2002, pp. 786-789.
- Chia C.W., et al., "Glucose Sensors: Toward Closed Loop Insulin Delivery," *Endocrinology and Metabolism Clinics of North America*, vol. 33, 2004, pp. 175-195.
- Choleau C., et al., "Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-point Calibration Method," *Biosensors and Bioelectronics*, vol. 17 (8), 2002, pp. 647-654.
- Choleau C., et al., "Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1. Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current," *Biosensors and Bioelectronics*, vol. 17, 2002, pp. 641-646.
- Ciba Specialty Chemicals, "Ciba® Irgacure® 2959," Coating Effects Segment, Photoinitiator Product Description, Basel Switzerland, Apr. 2, 1998, 3 pages.
- Claremont D.J., et al., "Potentially-Implantable, Ferrocene-Mediated Glucose Sensor," *Journal of Biomedical Engineering*, vol. 8, Jul. 1986, pp. 272-274.
- Claremont D.J., et al., "Subcutaneous Implantation of a Ferrocene-Mediated Glucose Sensor in Pigs," *Diabetologia*, vol. 29, 1986, pp. 817-821.
- Clark L.C., et al., "Configurational Cyclic Voltammetry: Increasing the Specificity and Reliability of Implanted Electrodes," *IEEE/Ninth Annual Conference of the Engineering in Medicine and Biology Society*, 1987, pp. 0782-0783.
- Clark L.C., et al., "Long-Term Stability of Electroenzymatic Glucose Sensors Implanted in Mice," vol. XXXIV, *Transactions—American Society for Artificial Internal Organs*, 1988, vol. 34, pp. 259-265.
- Clark L.C., et al., "One-Minute Electrochemical Enzymic Assay for Cholesterol in Biological Materials," *Clinical Chemistry*, vol. 27 (12), 1981, pp. 1978-1982.
- Clarke W.L., et al., "Evaluating Clinical Accuracy of Systems for Self Monitoring of Blood Glucose," *Technical Articles, Diabetes Care*, vol. 10 (5), Sep.-Oct. 1987, pp. 622-628.
- Colangelo V.J., et al., "Corrosion Rate Measurements in Vivo," *Journal of Biomedical Materials Research*, vol. 1, 1967, pp. 405-414.
- Colowick S.P., et al., "Methods in Enzymology," vol. XLIV, *Immobilized Enzymes*, Edited by Mosbach K, New York Academic Press, 1976, 11 pages.
- Coulet P.R., et al., "Enzymes Immobilized on Collagen Membranes: A Tool for Fundamental Research and Enzyme Engineering," *Journal of Chromatography*, vol. 215, 1981, pp. 65-72.
- Coulet P.R., "Polymeric Membranes and Coupled Enzymes in the Design of Biosensors," *Journal of Membrane Science*, 1992, vol. 68, pp. 217-228.
- Cox D.J., et al., "Accuracy of Perceiving Blood Glucose in IDDM," *Diabetes Care*, vol. 8 (6), Nov.-Dec. 1985, pp. 529-536.
- Csoregi E., et al., "Amperometric Microbiosensors for Detection of Hydrogen Peroxide and Glucose Based on Peroxidase-Modified Carbon Fibers," *Electroanalysis*, vol. 6, 1994, pp. 925-933.
- Csoregi E., et al., "Design, Characterization and One-Point In Vivo Calibration of a Subcutaneously Implanted Glucose Electrode," *American Chemical Society, Analytical Chemistry*, vol. 66 (19), Oct. 1, 1994, pp. 3131-3138.
- Currie J.F., et al., "Novel Non-Intrusive Trans-Dermal Remote Wireless Micro-Fluidic Monitoring System Applied to Continuous Glucose and Lactate Assays for Casualty Care and Combat Readiness Assessment," *RTO HFM Symposium, RTO-MP-HFM-109*, Aug. 16-18, 2004, pp. '24-1'-'24-18'.
- Dai W.S., et al., "Hydrogel Membranes with Mesh Size Asymmetry based on the Gradient Crosslinking of Poly(Vinyl Alcohol)," *Journal of Membrane Science*, 1999, vol. 156, pp. 67-79.
- Danielsson B., et al., "Enzyme Thermistors," *Methods in Enzymology*, vol. 137, 1988, pp. 181-197.
- D'Arrigo G., et al., "Porous-Si Based Bio Reactors for Glucose Monitoring and Drugs Production," *Proceedings of SPIE*, 2003, vol. 4982, pp. 178-184.
- Dassau E., et al., "In Silico Evaluation Platform for Artificial Pancreatic  $\beta$ -Cell Development—A Dynamic Simulator for Closed-Loop Control with Hardware-in-the-loop," *Diabetes Technology & Therapeutics*, vol. 11 (3), 2009, pp. 1-8.
- Davies M.L., et al., "Polymer Membranes in Clinical Sensor Applications," An overview of membrane function, *Biomaterials*, vol. 13 (14), 1992, pp. 971-978.
- Davis G., et al., "Bioelectrochemical Fuel Cell and Sensor Based on a Quinoprotein, Alcohol Dehydrogenase," *Enzyme and Microbial Technology*, vol. 5 (5), Sep. 1983, pp. 383-388.
- De Vos P., et al., "Considerations for Successful Transplantation of Encapsulated Pancreatic Islets," *Diabetologia*, vol. 45, 2002, pp. 159-173.

(56)

**References Cited****OTHER PUBLICATIONS**

- Deutsch T., et al., "Time Series Analysis and Control of Blood Glucose Levels in Diabetic Patients," *Computer Methods and Programs in Biomedicine*, Elsevier Scientific Publishers, vol. 41, 1994, pp. 167-182.
- Dixon B.M., et al., "Characterization in Vitro and in Vivo of the Oxygen Dependence of an Enzyme/Polymer Biosensor for Monitoring Brain Glucose," *Journal of Neuroscience Methods*, vol. 119, 2002, pp. 135-142.
- DuPont, "Dimension® AR Clinical Chemistry System," The Chemistry Analyzer that Makes the most of your Time, Money and Effort, Dade International, Chemistry Systems, Newark, 1998, 18 pages.
- Durliat H., et al., "Spectrophotometric and Electrochemical Determinations of L(+) -Lactate in Blood by Use of Lactate Dehydrogenase from Yeast," *Clinical Chemistry*, vol. 22 (11), 1976, pp. 1802-1805.
- Edwards Lifesciences, "Accuracy for You and Your Patients," Marketing materials, 2002, 4 pages.
- El Degheidy M.M., et al., "Optimization of an Implantable Coated Wire Glucose Sensor," *Journal of Biomedical Engineering*, vol. 8, Apr. 1986, pp. 121-129.
- ELCO Diagnostics Company, "Direct 30/30® Blood Glucose Sensor," *Markwell Medical Catalog*, 1990, 1 page.
- El-Khatib F.H., et al., "Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Dual Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine," *Journal of Diabetes Science and Technology*, Diabetes Technology Society, vol. 1 (2), 2007, pp. 181-192.
- El-Sa'ad L., et al., "Moisture Absorption by Epoxy Resins: The Reverse Thermal Effect," *Journal of Materials Science*, vol. 25, 1990, pp. 3577-3582.
- Ernst H., et al., "Reliable Glucose Monitoring Through the Use of Microsystem Technology," *Analytical Bioanalytical Chemistry*, vol. 373, 2002, pp. 758-761.
- Fabietti P.G., et al., "Clinical Validation of a New Control-Oriented Model of Insulin and Glucose Dynamics in Subjects with Type 1 Diabetes," *Diabetes Technology & Therapeutics*, vol. 9 (4), 2007, pp. 327-338.
- Fahy B.G., et al., "An Analysis: Hyperglycemic Intensive Care Patients Need Continuous Glucose Monitoring-Easier Said Than Done," *Journal of Diabetes Science and Technology*, Diabetes Technology Society, vol. 2 (2), Mar. 2008, pp. 201-204.
- Fare T.L., et al., "Functional Characterization of a Conducting Polymer-Based Immunoassay System," *Biosensors & Bioelectronics*, vol. 13 (3-4), 1998, pp. 459-470.
- Feldman B., et al., "A Continuous Glucose Sensor Based on Wired EnzymeTM Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes," *Diabetes Technology & Therapeutics*, vol. 5 (5), 2003, pp. 769-779.
- Fischer U., et al., "Assessment of Subcutaneous Glucose Concentration: Validation of the Wick Technique as a Reference for Implanted Electrochemical Sensors in Normal and Diabetic Dogs," *Diabetologia*, vol. 30, 1987, pp. 940-945.
- Fischer U., et al., "Hypoglycaemia-Warning by Means of Subcutaneous Electrochemical Glucose Sensors: An Animal Study," *Horm. Metab. Res.*, vol. 27, 1995, p. 53. (Abstract Only).
- Fischer U., et al., "Oxygen Tension at the Subcutaneous Implantation Site of Glucose Sensors," *Biomed. Biochim. Acta*, vol. 48 (11/12), 1989, pp. 965-971.
- Freedman D., et al., "Statistics," Second Edition, W.W. Norton & Company, New York & London, 1991, p. 74 (3 pages).
- Freiberger P., "Video Game Takes on Diabetes Superhero 'Captain Novolin' Offers Treatment Tips," Fourth Edition, Jun. 26, 1992, Business Section, 2 pages.
- Frohnauer M.K., et al., "Graphical Human Insulin Time-Activity Profiles Using Standardized Definitions," *Diabetes Technology & Therapeutics*, vol. 3 (3), 2001, pp. 419-429.
- Frost M.C., et al., "Implantable Chemical Sensors for Real-Time Clinical Monitoring: Progress and Challenges," *Current Opinion in Chemical Biology*, *Analytical Techniques*, vol. 6, 2002, pp. 633-641.
- Gabby R.A., et al., "Optical Coherence Tomography-Based Continuous Noninvasive Glucose Monitoring in Patients with Diabetes," *Diabetes Technology & Therapeutics*, vol. 10, Nov. 3, 2008, pp. 188-193.
- Ganesan N., et al., "Gold Layer-Based Dual Crosslinking Procedure of Glucose Oxidase with Ferrocene Monocarboxylic Acid Provides a Stable Biosensor," *Analytical Biochemistry, Notes & Tips*, vol. 343, 2005, pp. 188-191.
- Ganesh A., et al., "Evaluation of the Via® Blood Chemistry Monitor for Glucose in Healthy and Diabetic Volunteers," *Journal of Diabetes Science and Technology*, vol. 2 (2), Mar. 2008, pp. 182-193.
- Garg S.K., et al., "Correlation of Fingerstick Blood Glucose Measurements With GlucoWatch Biographer Glucose Results in Young Subjects With Type 1 Diabetes," *Emerging Treatments and Technologies*, *Diabetes Care*, vol. 22 (10), Oct. 1999, pp. 1708-1714.
- Garg S.K., et al., "Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults With Type 1 Diabetes," *Emerging Treatments and Technologies*, *Diabetes Care*, vol. 27 (3), 2004, pp. 734-738.
- Garg S.K., "New Insulin Analogs," *Diabetes Technology & Therapeutics*, vol. 7 (5), 2005, pp. 813-817.
- Geller R.I., et al., "Use of an Immunoisolation Device for Cell Transplantation and Tumor Immunotherapy," *Annals of the New York Academy of Science*, 1997, vol. 831, pp. 438-451.
- Gerritsen M., et al., "Influence of Inflammatory Cells and Serum on the Performance of Implantable Glucose Sensors," *Journal of Biomedical Material Research*, 2001, vol. 54, pp. 69-75.
- Gerritsen M., et al., "Performance of Subcutaneously Implanted Glucose Sensors for Continuous Monitoring," *The Netherlands Journal of Medicine*, vol. 54, 1999, pp. 167-179.
- Gerritsen M., et al., "Problems Associated with Subcutaneously Implanted Glucose Sensors," *Diabetes Care*, vol. 23 (2), Feb. 2000, pp. 143-145.
- Gilligan B.J., et al., "Evaluation of a Subcutaneous Glucose Sensor Out to 3 Months in a Dog Model" *Diabetes Care*, vol. 17 (8), Aug. 1994, pp. 882-887.
- Gilligan B.J., et al., "Feasibility of Continuous Long-Term Glucose Monitoring from a Subcutaneous Glucose Sensor in Humans," *Diabetes Technology & Therapeutics*, vol. 6 (3), 2004, pp. 378-386.
- Godsland I.F., et al., "Maximizing the Success Rate of Minimal Model Insulin Sensitivity Measurement in Humans: The Importance of Basal Glucose Levels," *The Biochemical Society and the Medical Research Society, Clinical Science*, vol. 101, 2001, pp. 1-9.
- Gouda M.D., et al., "Thermal Inactivation of Glucose Oxidase," *The Journal of Biological Chemistry*, vol. 278 (27), Issue of Jul. 4, 2003, pp. 24324-24333.
- Gough D.A., et al., "Frequency Characterization of Blood Glucose Dynamics," *Annals of Biomedical Engineering*, vol. 31, 2003, pp. 91-97.
- Gough D.A., et al., "Immobilized Glucose Oxidase in Implantable Glucose Sensor Technology," *Diabetes Technology & Therapeutics*, vol. 2 (3), 2000, pp. 377-380.
- Gough D.A., "The implantable Glucose Sensor: An Example of Bioengineering Design," *Introduction to Bioengineering*, 2001, Chapter 3, pp. 57-66.
- Gregg B.A., et al., "Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications," *Anal Chem*, 1990, vol. 62, pp. 258-263.
- Gross, et al., "Diabetes Technology & Therapeutics," Letters to the Editor, *Diabetes Technology & Therapeutics*, vol. 3 (1), 2001, pp. 129-131.
- Gross T.M., et al., "Efficacy and Reliability of the Continuous Glucose Monitoring System," *Diabetes Technology & Therapeutics*, vol. 2, Supplement 1, 2000, pp. S19-S26.
- Gross T.M., et al., "Performance Evaluation Of The Minimed® Continuous Glucose Monitoring System During Patient Home Use," *Diabetes Technology & Therapeutics*, vol. 2(1), 2000, pp. 49-56.
- Guerci B., et al., "Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs," *Diabetes Care*, vol. 26, 2003, pp. 582-589.

(56)

**References Cited****OTHER PUBLICATIONS**

- Hagvik J., "Glucose Measurement: Time for a Gold Standard," *Journal of Diabetes Science and Technology*, vol. 1 (2), Mar. 2007, pp. 169-172.
- Hall S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part I. An Adsorption-controlled Mechanism," *Electrochimica Acta*, vol. 43, Nos. 5/6, 1998, pp. 579-588.
- Hall S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part II: Effect of potential," *Electrochimica Acta*, vol. 43 (14-15), 1998, pp. 2015-2024.
- Hall S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part III: Effect of Temperature," *Electrochimica Acta*, vol. 44, 1999, pp. 2455-2462.
- Hall S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part IV: Phosphate Buffer Dependence," *Electrochimica Acta*, vol. 44, 1999, pp. 4573-4582.
- Hall S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part V: Inhibition by Chloride," *Electrochimica Acta*, vol. 45, 2000, pp. 3573-3579.
- Hamilton, "Complete Guide to Selecting the Right Hamilton Gastight, Microliter, and Specialty Syringe for your Application," Syringe Selection, [www.hamiltoncompany.com](http://www.hamiltoncompany.com) 2006, 20 pages.
- Harrison, et al., "Characterization of Perfluorosulfonic Acid Polymer Coated Enzyme Electrodes and a Miniaturized Integrated Potentiostat for Glucose Analysis in Whole Blood," *Analytical Chemistry*, 1988, vol. 60, pp. 2002-2007.
- Hashiguchi Y., et al., "Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor with Microdialysis Sampling Method: Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients," *Diabetes Care*, vol. 17, No. 5, May 1994, pp. 387-396.
- Heinemann L., et al., "Review: Measurement of Insulin Absorption and Insulin Action," *Diabetes Technology & Therapeutics*, vol. 6 (5), 2004, pp. 698-718.
- Heinemann L., "Measurement Quality of Blood Glucose Meters: Is There a Need for an Institution with an Unbiased View?," *Journal of Diabetes Science and Technology*, vol. 1 (2), Mar. 2007, pp. 178-180.
- Heinemann L., "Review: Variability of Insulin Absorption and Insulin Action," *Diabetes Technology & Therapeutics*, vol. 4 (5), 2002, pp. 673-682.
- Heise T., et al., "Hypoglycemia warning signal and glucose sensors: Requirements and concepts," *Diabetes Technology & Therapeutics*, vol. 5, No. 4, 2003, pp. 563-571.
- Heller A., "Electrical Connection of Enzyme Redox Centers to Electrodes," *J. Phys. Chem.*, vol. 96, 1992, pp. 3579-3587.
- Heller A., "Electrical Wiring of Redox Enzymes," *Acc. Chem. Res.*, vol. 23, 1990, pp. 128-134.
- Heller A., "Implanted Electrochemical Glucose Sensors for the Management of Diabetes," *Annu. Rev. Biomed Eng.*, vol. 1, 1999, pp. 153-175.
- Heller A., "Plugging Metal Connectors into Enzymes," *Nature Biotechnology*, vol. 21, No. 6, Jun. 2003, pp. 631-632.
- Hicks J.M., "In Situ Monitoring," *Clinical Chemistry*, vol. 31 (12), 1985, pp. 1931-1935.
- Hitchman M.L., "Measurement of Dissolved Oxygen," Edited by Elving P.J. et al., *Chemical Analysis*, New York, John Wiley & Sons, vol. 49, Chapter 3, 1978, pp. 34-49 and 59-123.
- Hoel P.G., "Elementary Statistics," Fourth Edition, John Wiley & Sons, Inc., 1976, pp. 113-114.
- Houghton Mifflin Company, "American Heritage Dictionary," 4th Edition, 2000, pp. 82.
- Houghton Mifflin Company, "Xenogenic, the American Heritage Stedman's Medical Dictionary," 2002, Answers.Com, retrieved from <http://www.answers.com/topic/xenogenic>, on Nov. 7, 2006, 2 Pages.
- Hovorka R., et al., "Closing the Loop: The Adicol Experience," *Diabetes Technology & Therapeutics*, vol. 6 (3), 2004, pp. 307-318.
- Hrapovic S., et al., "Picoamperometric Detection of Glucose at Ultrasmall Platinum-Based Biosensors Preparation and Characterization," *Anal. Chem.*, vol. 75, 2003, pp. 3308-3315.
- Hu Y., et al., "A Needle-Type Enzyme-Based Lactate Sensor for In Vivo Monitoring," *Analytica Chimica Acta*, vol. 281, 1993, pp. 503-511.
- Huang C., et al., "Electrochemical Generation of Oxygen. 1: The Effects of Anions and Cations on Hydrogen Chemisorption and Anodic Oxide Film Formation on Platinum Electrode. 2: The Effects of Anions and Cations on Oxygen Generation on Platinum Electrode," U.S. Department of Commerce/NTIS, 1975, 126 pages.
- Huang Q., et al., "A 0.5mW Passive Telemetry IC for Biomedical Applications," Proceedings of the 23rd European Solid-State Circuits Conference (ESSCIRC '97), Southampton, UK, Sep. 16-18, 1997, pp. 172-175.
- Hunsley B., et al., "Whole Blood Glucose Standard Is Key to Accurate Insulin Dosages," *Journal of Diabetes Science and Technology*, vol. 1 (2), Mar. 2007, pp. 173-177.
- Hunter I., et al., "Minimally Invasive Glucose Sensor and Insulin Delivery System," MIT Home Automation and Healthcare Consortium, Mar. 31, 2000, Progress Report No. 25, 17 pages.
- International Preliminary Report on Patentability for Application No. PCT/US2005/006301, mailed Aug. 30, 2006, 4 pages.
- International Preliminary Report on Patentability for Application No. PCT/US2007/080848 mailed Apr. 13, 2010, 6 page.
- International Preliminary Report on Patentability for Application No. PCT/US2008/058158, mailed Sep. 29, 2009, 9 pages.
- International Preliminary Report on Patentability for Application No. PCT/US2008/065978 mailed Jun. 19, 2008, 14 pages.
- International Search Report and Written Opinion for Application No. PCT/US2005/006301, mailed Jun. 22, 2005, 4 pages.
- International Search Report and Written Opinion for Application No. PCT/US2007/080848 mailed Aug. 28, 2008, 6 pages.
- International Search Report and Written Opinion for Application No. PCT/US2008/058158, mailed Aug. 8, 2008, 10 pages.
- International Search Report and Written opinion for Application No. PCT/US2008/065978 mailed Oct. 2, 2008, 14 pages.
- Ishikawa M., et al., "Initial Evaluation of A 290-Mm Diameter Subcutaneous Glucose Sensor: Glucose Monitoring With A Biocompatible, Flexible-Wire, Enzyme-Based Amperometric Microsensor in Diabetic and Nondiabetic Humans," *Journal of Diabetes and Its Complications*, vol. 12, 1998, pp. 295-301.
- Jablecki M., et al., "Simulations of the Frequency Response of Implantable Glucose Sensors," *Analytical Chemistry*, vol. 72, 2000, 1853-1859.
- Jaffari S.A., et al., "Recent Advances in Amperometric Glucose Biosensors for In Vivo Monitoring," *Physiological Measurement*, 1995, vol. 16, pp. 1-15.
- Jaremkow J., et al., "Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes," *Diabetes Care*, vol. 21 (3), Mar. 1998, pp. 444-450.
- Jensen M.B., et al., "Fast Wave Forms for Pulsed Electrochemical Detection of Glucose by Incorporation of Reductive Desorption of Oxidation Products," *Analytical Chemistry*, vol. 69 (9), May 1997, pp. 1776-1781.
- Jeong R.A., et al., "In Vivo Calibration of the Subcutaneous Amperometric Glucose Sensors Using a Non-Enzyme Electrode," *Biosensors and Bioelectronics*, Elsevier, vol. 19, 2003, pp. 313-319.
- Jeutter D.C., "A Transcutaneous Implanted Battery Recharging and Biotelemeter Power Switching System," *IEEE Transactions on Biomedical Engineering*, vol. BME-29 (5), May 1982, pp. 314-321.
- Jeutter D.C., et al., "Design of a Radio-Linked Implantable Cochlear Prosthesis Using Surface Acoustic Wave Devices," *IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control*, vol. 40 (5), Sep. 1993, pp. 469-477.
- Jobst G., et al., "Thin-Film Microbiosensors for Glucose-Lactate Monitoring," *Anal. Chem.*, Sep. 15, 1996, vol. 68(18), pp. 3173-3179.
- Johnson K.W., et al., "In Vivo Evaluation of an Electroenzymatic Glucose Sensor Implanted in Subcutaneous Tissue," *Biosensors and Bioelectronics*, 1992, vol. 7, pp. 709-714.

(56)

**References Cited****OTHER PUBLICATIONS**

- Johnson K.W., "Reproducible Electrodeposition of Biomolecules for the Fabrication of Miniature Electroenzymatic Biosensors," *Sensors and Actuators B*, vol. 5, 1991, pp. 85-89.
- Jones S.M., et al., "Optimal Insulin Pump Dosing and Postprandial Glycemia Following a Pizza Meal Using the Continuous Glucose Monitoring System," *Diabetes Technology & Therapeutics*, vol. 7 (2), Apr. 2005, pp. 233-240.
- Joung G.B., et al., "An Energy Transmission System for an Artificial Heart Using Leakage Inductance Compensation of Transcutaneous Transformer," *IEEE Transactions on Power Electronics*, vol. 13 (6), Nov. 1998, pp. 1013-1022.
- Jovanovic L.M.D., "The Role of Continuous Glucose Monitoring in Gestational Diabetes Mellitus," *Diabetes Technology and Therapeutics*, vol. 2 (1), 2000, pp. S67-S71.
- Kacaniklic V., et al., "Amperometric Biosensors for Detection of L- and D-Amino Acids Based on Coimmobilized Peroxidase and L- and D-Amino Acid Oxidases in Carbon Paste Electrodes," *Electroanalysis*, vol. 6, May-Jun. 1994, pp. 381-390.
- Kamath A., et al., "Calibration of a Continuous Glucose Monitor: Effect of Glucose Rate of Change," Eighth Annual Diabetes Technology Meeting, Nov. 13-15, 2008, pp. A88 (2 pages).
- Kang S.K., et al., "In Vitro and Short-Term In Vivo Characteristics of a Kel-F Thin Film Modified Glucose Sensor," *Analytical Sciences*, vol. 19, Nov. 2003, pp. 1481-1486.
- Kaplan S.M., "Wiley Electrical and Electronics Engineering Dictionary," IEEE Press, John Wiley & Sons, Inc., 2004, pp. 141, 142, 548 & 549.
- Kargol M., et al., "Studies on the Structural Properties of Porous Membranes: Measurement of Linear Dimensions of Solutes," *Biophysical Chemistry*, 2001, vol. 91, pp. 263-271.
- Karube I., et al., "Microbiosensors for Acetylcholine and Glucose," *Biosensors & Bioelectronics*, 1993, vol. 8, pp. 219-228.
- Kaufman F.R., et al., "A Pilot Study of the Continuous Glucose Monitoring System," *Diabetes Care*, vol. 24 (12), Dec. 2001, pp. 2030-2034.
- Kaufman F.R., "Role of the Continuous Glucose Monitoring System in Pediatric Patients," *Diabetes Technology and Therapeutics*, vol. 2 (1), 2000, S49-S52.
- Kawagoe J.L., et al., "Enzyme-Modified Organic Conducting Salt Microelectrode," *Analytical Chemistry*, vol. 63, 1991, pp. 2961-2965.
- Keedy F.H., et al., "Determination of Urate in Undiluted Whole Blood by Enzyme Electrode," *Biosensors and Bioelectronics*, vol. 6, 1991, pp. 491-499.
- Kerner, et al., "A Potentially Implantable Enzyme Electrode for Amperometric Measurement of Glucose," *Hormone and Metabolic Research Supplement*, vol. 20, 1988, pp. 8-13.
- Kerner W., et al., "The Function of a Hydrogen Peroxide-Detecting Electroenzymatic Glucose Electrode is Markedly Impaired in Human Sub-Cutaneous Tissue and Plasma," *Biosensors and Bioelectronics*, vol. 8, 1993, pp. 473-482.
- Kerner W., "Implantable Glucose Sensors: Present Status and Future Developments," *Experimental and Clinical Endocrinol Diabetes*, vol. 109 (2), 2001, pp. S341-S346.
- Kiechle F.L., "The Impact of Continuous Glucose Monitoring on Hospital Point-of-Care Testing Programs," *Diabetes Technology and Therapeutics*, vol. 3 (4), 2001, pp. 647-649.
- Kizilel S., et al., "Review: The Bioartificial Pancreas: Progress and Challenges," *Diabetes Technology & Therapeutics*, vol. 7 (6), 2005, pp. 968-985.
- Klonoff D., et al., "Performance Metrics for Continuous Interstitial Glucose Monitoring: Approved Guideline," *Clinical and Laboratory Standards Institute, POCT05-A*, vol. 28 (33), 2008, 72 pages.
- Klonoff D.C., "Editorial: Current, Emerging, and Future Trends in Metabolic Monitoring," *Diabetes Technology & Therapeutics*, vol. 4 (5), 2002, pp. 583-588.
- Klueh U., et al., "Inflammation and Glucose Sensors: Use of Dexamethasone to Extend Glucose Sensor Function and Life Span in Vivo," *Journal of Diabetes Science and Technology*, vol. 1 (4), Jul. 2007, pp. 496-504.
- Klueh U., et al., "Use of Vascular Endothelial Cell Growth Factor Gene Transfer to Enhance Implantable Sensor Function in Vivo," *Biosensor Function and VEGF-Gene Transfer*, vol. 67 (4), 2003, pp. 1072-1086.
- Kondo T., et al., "A Miniature Glucose Sensor, Implantable in the Blood Stream," *Diabetes Care*, vol. 5 (3), May-Jun. 1982, 218-221.
- Koschinsky T., et al., "Sensors For Glucose Monitoring: Technical And Clinical Aspects," *Diabetes Metabolism Research and Reviews*, vol. 17, No. 2, Jan. 1, 2001, pp. 113-123.
- Koschinsky T., et al., "New Approach to Technical and Clinical Evaluation of Devices for Self-Monitoring of Blood Glucose," *Diabetes Care*, vol. 11 (8), Sep. 1988, pp. 619-629.
- Koschinsky T., et al., "Review: Glucose Sensors and the Alternate Site Testing-like Phenomenon: Relationship Between Rapid Blood Glucose Changes and Glucose Sensor Signals," *Diabetes Technology & Therapeutics*, vol. 5 (5), 2003, pp. 829-842.
- Kost J., et al., "Glucose-Sensitive Membranes Containing Glucose Oxidase: Activity, Swelling, And Permeability Studies," *Journal of Biomedical Materials Research*, vol. 19, 1985, pp. 1117-1133.
- Koudelka M., et al., "In Vivo Response of Microfabricated Glucose Sensors to Glycemia Changes in Normal Rats," *Biomed. Biochim. Acta*, vol. 48 (11/12), Nov.-Dec. 1989, pp. 953-956.
- Koudelka M., et al., "In-Vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors," *Biosensors and Bioelectronics*, vol. 6, 1991, pp. 31-36.
- Kovatchev B.P., et al., "Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors: Continuous Glucose-Error Grid Analysis Illustrated by TheraSense Freestyle Navigator Data," *Diabetes Care*, vol. 27 (8), Aug. 2004, pp. 1922-1928.
- Kraver., et al., "A Mixed-Signal Sensor Interface Microinstrument," *Sensors and Actuators A, Physical* 2001, vol. 91, pp. 266-277.
- Krouwer U.S., "Setting Performance Goals and Evaluating Total Analytical Error for Diagnostic Assays," *Clinical Chemistry*, vol. 48 (6), 2002, pp. 919-927.
- Kruger D., et al., "Psychological Motivation and Patient Education: A Role for Continuous Glucose Monitoring," *Diabetes Technology and Therapeutics*, vol. 2 (1), 2000, pp. S93-S97.
- Kulys J., et al., "Carbon-Paste Biosensors Array for Long-Term Glucose Measurement," *Biosensors & Bioelectronics*, vol. 9, 1994, pp. 491-500.
- Kunjan K., et al., "Automated Blood Sampling and Glucose Sensing in Critical Care Settings," *Journal of Diabetes Science and Technology*, vol. 2 (2), Mar. 2008, pp. 194-200.
- Kunzler J., et al., "Hydrogels based on Hydrophilic Side Chain Siloxanes," *Poly Mat Sci and Eng*, 1993, vol. 69, pp. 226-227.
- Kunzler J.F., et al., "Contact Lens Materials," *Chemistry & Industry*, Aug. 21, 1995, pp. 651-655.
- Kurnik R.T., et al., "Application of the Mixtures of Experts Algorithm for Signal Processing in a Noninvasive Glucose Monitoring System," *Sensors and Actuators B*, vol. 60, 1999, pp. 19-26.
- Kurtz T.W., et al., "Recommendations for Blood Pressure Measurement in Humans and Experimental Animals, Part 2: Blood Pressure Measurement In Experimental Animals: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research," *Hypertension*, Feb. 2005, vol. 45, pp. 299-310.
- Lacourse W.R., et al., "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry," *Analytical Chemistry*, vol. 65, 1993, pp. 50-52.
- Ladd M.F.C., et al., "Structure Determination By X-Ray Crystallography," 3rd Edition, Plenum Press, 1994, Ch. 1, pp. xxi-xxiv and 1-58.
- Lee E., et al., "Effects of Pore Size, Void Volume and Pore Connectivity on Tissue Responses to Porous Silicone Implants," *Society for Biomaterials, 25th Annual Meeting*, 1999, p. 171.
- Lee S.W., et al., "Combined Insulin Pump Therapy with Real-Time Continuous Glucose Monitoring Significantly Improves Glycemic Control Compared to Multiple Daily Injection Therapy in Pump

(56)

**References Cited****OTHER PUBLICATIONS**

- Naïve Patients with Type 1 Diabetes; Single Center Pilot Study Experience," *Journal of Diabetes Science and Technology*, vol. 1 (3), May 2007, pp. 400-404.
- Lehmann E.D., et al., Retrospective Validation of a Physiological Model of Glucose-Insulin Interaction in Type 1 Diabetes Mellitus. *Medical Engineering & Physics*, vol. 16, May 1994, pp. 193-202.
- Lerner, et al., "An Implantable Electrochemical Glucose Sensor," *Ann. N. Y. Acad. Sci.*, vol. 428, May 1984, pp. 263-278.
- Lewandowski J.J., et al., "Evaluation of a Miniature Blood Glucose Sensor," *Transactions—American Society for Artificial Internal Organs*, vol. 34, 1988, pp. 255-258.
- Leyboldt J.K., et al., "Model of a Two-Substrate Enzyme Electrode for Glucose," *Analytical Chemistry*, vol. 56, 1984, pp. 2896-2904.
- Linke B., et al., "Amperometric Biosensor for In Vivo Glucose Sensing Based on Glucose Oxidase Immobilized In A Redox Hydrogel," *Biosensors and Bioelectronics*, vol. 9, 1994, pp. 151-158.
- Löffler P., et al., "Separation and Determination of Traces of Ammonia in Air by Means of Chromatomembrane Cells," *Fresenius Journal of Analytical Chemistry*, 1995, vol. 352, pp. 613-614.
- Lohn A., et al., "A Knowledge-Based System for Real-Time Validation of Calibrations and Measurements," *Chemometrics and Intelligent Laboratory Systems*, vol. 46, 1999, pp. 57-66.
- Lowe C.R., "Biosensors," *Trends in Biotechnology*, vol. 2 (3), 1984, pp. 59-65.
- Luong J.H.T., et al., "Solubilization of Multiwall Carbon Nanotubes by 3-Aminopropyltriethoxysilane towards the Fabrication of Electrochemical Biosensors with Promoted Electron Transfer," *Electroanalysis*, vol. 16 (1-2), 2004, pp. 132-139.
- Lyandres O., et al. "Progress toward an In Vivo Surface-Enhanced Raman Spectroscopy Glucose Sensor," *Diabetes Technology and Therapeutics*, vol. 10 (4), 2008, pp. 257-265.
- Lyman D J., "Polyurethanes. I. The Solution Polymerization of Diisocyanates with Ethylene Glycol," *Journal of Polymer Science*, 1960, vol. XLV, pp. 49-59.
- Lynch S.M., et al., "Estimation-Based Model Predictive Control of Blood Glucose in Type I Diabetics: A Simulation Study," *Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference*, 2001, pp. 79-80.
- Lynn P.A., "Recursive Digital Filters for Biological Signals," *Med. & Biol. Engineering*, vol. 9, 1971, pp. 37-43.
- Madaras M B., et al., "Microfabricated Amperometric Creatine and Creatinine Biosensors," *Analytica Chimica Acta*, 1996, vol. 319, pp. 335-345.
- Maidan R., et al., "Elimination of Electrooxidizable Interferent-Produced Currents in Amperometric Biosensors," *Analytical Chemistry*, vol. 64, 1992, pp. 2889-2896.
- Makale M.T., et al., "Tissue Window Chamber System for Validation of Implanted Oxygen Sensors," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 284, Feb. 21, 2003, pp. 1-27.
- Malin S.F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy," *Clinical Chemistry*, vol. 45 (9), 1999, pp. 1651-1658.
- Mancy K.H., et al., "A Galvanic Cell Oxygen Analyzer," *Journal of Electroanalytical Chemistry*, vol. 4, 1962, pp. 65-92.
- Maran A., et al., "Continuous Subcutaneous Glucose Monitoring in Diabetic Patients," A Multicenter Analysis, *Diabetes Care*, vol. 25 (2), Feb. 2002, pp. 347-352.
- March W.F., "Dealing with the Delay," *Diabetes Technology & Therapeutics*, vol. 4 (1), 2002, pp. 49-50.
- Marena S., et al., "The Artificial Endocrine Pancreas in Clinical Practice and Research," *Panminerva Medica*, vol. 35 (2), 1993, pp. 67-74.
- Martin R.F., "General Deming Regression for Estimating Systematic Bias and its Confidence Interval in Method-Comparison Studies," *Clinical Chemistry*, vol. 46 (1), 2000, pp. 100-104.
- Mascini M., et al., "Glucose Electrochemical Probe with Extended Linearity for Whole Blood," *Journal Pharmaceutical and Biomedical Analysis*, vol. 7 (12), 1989, pp. 1507-1512.
- Mastrototaro J.J., et al., "An Electroenzymatic Glucose Sensor Fabricated on a Flexible Substrate," *Sensors and Actuators B*, vol. 5, 1991, pp. 139-144.
- Mastrototaro J.J., et al., "Reproducibility of the Continuous Glucose Monitoring System Matches Previous Reports and the Intended Use of the Product," *Diabetes Care*, vol. 26 (1), Jan. 2003, pp. 256-257.
- Mastrototaro J.J., "The MiniMed Continuous Glucose Monitoring System," *Diabetes Technology & Therapeutics*, vol. 2, Supplement 1, 2000, pp. S13-S18.
- Matsuki H., "Energy Transfer System Utilizing Amorphous Wires For Implantable Medical Devices," *IEEE Transactions on Magnetics*, vol. 31 (2), 1994, pp. 1276-1282.
- Matsumoto T., et al., "A long-Term Lifetime Amperometric Glucose Sensor with a Perfluorocarbon Polymer Coating," *Biosensors & Bioelectronics*, vol. 16, 2001, pp. 271-276.
- Matsumoto T., et al., "A Micro-Planar Amperometric Glucose Sensor Unsusceptible to Interference Species," *Sensors and Actuators B*, 49, 1998, pp. 68-72.
- Matthews D.R., et al., "An Amperometric Needle-Type Glucose Sensor Testing in Rats and Man," *Diabetic Medicine*, vol. 5, 1988, pp. 248-252.
- Mazze R.S., et al., "Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis," *Diabetes Technology & Therapeutics*, vol. 10 (3), 2008, pp. 149-159.
- Mazzola F., et al., "Video Diabetes: A Teaching Tool for Children with Insulin-Dependent Diabetes," *IEEE, Proceedings 7th Annual Symposium on Computer Applications in Medical Care*, Oct. 1983, 1 page Abstract.
- McCartney L.J., et al., "Near-Infrared Fluorescence Lifetime Assay for Serum Glucose Based on Allophycocyanin-Labeled Concanavalin A," *Analytical Biochemistry*, vol. 292, 2001, pp. 216-221.
- McGrath M.J., et al., "The Use of Differential Measurements with a Glucose Biosensor for Interference Compensation During Glucose Determinations by Flow Injection Analysis," *Biosens Bioelectron*, vol. 10, 1995, pp. 937-943.
- McKean B.D., et al., "A Telemetry Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors," *IEEE Transactions on Biomedical Engineering*, vol. 35 (7), Jul. 1988, pp. 526-532.
- Memoli A., et al., "A Comparison between Different Immobilised Glucoseoxidase-Based Electrodes," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 29, 2002, pp. 1045-1052.
- Merriam Webster Online Dictionary, Definition for "Aberrant," retrieved from <https://www.merriam-webster.com/dictionary/aberrant> Aug. 19, 2008, 1 page.
- Merriam-Webster Online Dictionary, Definition of "Acceleration" retrieved from <http://www.merriam-webster.com/dictionary/Acceleration> Jan. 11, 2010, 1 page.
- Merriam-Webster Online Dictionary, Definition of "Nominal" retrieved from <http://www.merriam-webster.com/dictionary/nominal> Apr. 23, 2007, 1 page.
- Merriam-Webster Online Dictionary, Definition of "System". <http://www.merriam-webster.com/dictionary/System> Jan. 11, 2010, 2 pages.
- Metzger M., et al., "Reproducibility of Glucose Measurements using the Glucose Sensor," *Diabetes Care*, vol. 25 (6), Jul. 2002, pp. 1185-1191.
- Meyerhoff C., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose in Men by Combining Portable Glucosensor With Microdialysis," *Diabetologia*, vol. 35 (11), 1992, pp. 1087-1092.
- Miller J.A., et al., "Development of an Autotuned Transcutaneous Energy Transfer System," *ASAIO Journal*, vol. 39, 1993, pp. M706-M710.
- Miller K.M., et al., "Generation of IL-1 like Activity in Response to Biomedical Polymer Implants: a Comparison of in Vitro and in Vivo Models," *Journal of Biomedical Materials Research*, vol. 23(9), 1989, pp. 1007-1026.
- Miller K.M., et al., "Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers," *Journal of Biomedical Materials Research*, vol. 22 (8), 1988, pp. 713-731.

(56)

**References Cited****OTHER PUBLICATIONS**

- Miller K.M., et al., "In Vitro Stimulation of Fibroblast Activity by Factors Generated from Human Monocytes Activated by Biomedical Polymers," *Journal of Biomedical Materials Research*, vol. 23(8), 1989, pp. 911-930.
- Moatti-Sirat D., et al., "Evaluating In Vitro and In Vivo the Interference of Ascorbate and Acetaminophen on Glucose Detection by a Needle-Type Glucose Sensor," *Biosensors and Bioelectronics*, vol. 7, 1992, pp. 345-352.
- Moatti-Sirat D., et al., "Reduction of Acetaminophen Interference in Glucose Sensors by a Composite Nafion Membrane: Demonstration in Rats and Man," *Diabetologia*, vol. 37 (6), Jun. 1994, pp. 610-616.
- Moatti-Sirat, et al., "Towards Continuous Glucose Monitoring: In Vivo Evaluation of a Miniaturized Glucose Sensor Implanted for Several Days in Rat Subcutaneous Tissue," *Diabetologia*, vol. 35, 1992, pp. 224-230.
- Monsod T.P., et al., "Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia And Hyperinsulinemia?" *Diabetes Care*, vol. 25 (5), 2002, pp. 889-893.
- Morff R.J., et al., "Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors," Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 12 (2), 1990, pp. 0483-0484.
- Mosbach K., et al., "Determination of Heat Changes in the Proximity of Immobilized Enzymes with an Enzyme Thermistor and its Use for the Assay of Metabolites," *Biochimica Biophysica Acta*, vol. 403, 1975, pp. 256-265.
- Motonaka J., et al., "Determination of Cholesterol and Cholesterol Ester with Novel enzyme Microsensors," *Anal. Chem.*, vol. 65, 1993, pp. 3258-3261.
- Moussy F., et al., "A Miniaturized Nafion-Based Glucose Sensor: In Vitro and In Vivo Evaluation in Dogs," *International Journals of Artificial Organs*, vol. 17 (2), 1994, pp. 88-94.
- Moussy F., et al., "Biomaterials community examines biosensor biocompatibility," *Diabetes Technology & Therapeutics*, vol. 2(3), 2000, pp. 473-477.
- Moussy F., et al., "Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating," *Analytical Chemistry*, vol. 65, Aug. 1, 1993, pp. 2072-2077.
- Moussy F., "Implantable Glucose Sensor: Progress and Problems," IEEE, Nov. 2002, pp. 270-273.
- Mowery K.A., et al., "Preparation and Characterization by Hydrophobic Polymeric Films that are Thromboresistant via Nitric Oxide Release," *Biomaterials*, vol. 21, 2000, pp. 9-21.
- Murphy S.M., et al., "Polymer Membranes in Clinical Sensor Applications, II. The Design and Fabrication of Periselective Hydrogels for Electrochemical Devices," *Biomaterials*, 1992, vol. 13 (14), pp. 979-990.
- Muslu, "Trickling Filter Performance," *Applied Biochemistry and Biotechnology*, vol. 37, 1992, pp. 211-224.
- Myler S., et al., "Ultra-Thin-Polysiloxane-Film-Composite Membranes for the Optimisation of Amperometric Oxidase Enzyme Electrodes," *Biosensors & Bioelectronics*, vol. 17, 2002, pp. 35-43.
- Nakayama Y., et al., "Surface Fixation of Hydrogels: Heparin and Glucose Oxidase Hydrogelated Surfaces" *ASAIO Journal*, 1992, pp. M421-M424.
- Nam Y.S., et al., "A Novel Fabrication Method of Macroporous Biodegradable Polymer Scaffolds Using Gas Foaming Salt as a Porogen Additive," *J Biomed Mater Res*, 2000, vol. 53, pp. 1-7.
- Neuburger G.G., et al., "Pulsed Amperometric Detection of Carbohydrates at Gold Electrodes with a Two-Step Potential Waveform," *Anal. Chem.*, vol. 59, 1987, pp. 150-154.
- NewsRx, "Glucose Monitoring: FDA OKs New Device to Manage Diabetes," *Medical Letter on the CDC & FDA* via NewsRx.com, Aug. 3, 2003, 1 page.
- Nintendo Healthcare, Wired, Dec. 1993, 1 page.
- Novo Nordisk Pharmaceuticals Inc., "Diabetes Educational Video Game Recognized by Software Publishers Association," Press Release, Mar. 14, 1994, 4 pages.
- Ohara T.J., et al., "Glucose Electrodes Based On Cross-Linked [Os(bpy)2Cl](+/-) Complexed Poly(1-Vinylimidazole) Films," *Analytical Chemistry*, vol. 65, Dec. 1993, pp. 3512-3517.
- Ohara T.J., et al., "'Wired' Enzyme Electrodes for Amperometric Determination of Glucose or Lactate in the Presence of Interfering Substances," *Anal Chem*, vol. 66, 1994, pp. 2451-2457.
- Okuda, et al., "Mutarotate Effect on Micro Determinations of D-Glucose and its Anomers with  $\beta$ -D-Glucose Oxidase," *Anal Biochem*, vol. 43 (1), 1971, pp. 312-315.
- Oxford English Dictionary Online, Definition of "Impending," [http://www.askoxford.com/results/?view=devdictfield-12668446\\_Impending&branch](http://www.askoxford.com/results/?view=devdictfield-12668446_Impending&branch) Jan. 11, 2010, 1 page.
- Palmisano F., et al., "Simultaneous Monitoring of Glucose and Lactate by an Interference and Cross-Talk Free Dual Electrode Amperometric Biosensor Based on Electropolymerized Thin Films," *Biosensors & Bioelectronics*, vol. 15, 2000, pp. 531-539.
- Panetti T.S., "Differential Effects of Sphingosine 1-Phosphate and Lysophosphatidic Acid on Endothelial Cells," *Biochimica et Biophysica Acta*, vol. 1582, 2002, pp. 190-196.
- Panteleon A.E., et al., "The Role of the Independent Variable to Glucose Sensor Calibration," *Diabetes Technology & Therapeutics*, vol. 5 (3), 2003, pp. 401-410.
- Parker R.S., et al., "A Model-Based Algorithm for Blood Glucose Control In Type I Diabetic Patients," *IEEE Trans Biomed Engg (BME)*, vol. 46(2), 1999, pp. 148-157.
- Patel H., et al., "Amperometric Glucose Sensors Based on Ferrocene Containing Polymeric Electron Transfer Systems—A Preliminary Report," *Biosensors & Bioelectronics*, vol. 18, 2003, pp. 1073-1076.
- Peacock W.F., et al., "Cardiac Troponin and Outcome in Acute Heart Failure," *N. Engl. J. Med.*, vol. 358, 2008, pp. 2117-2126.
- Peguin S., et al., "Pyruvate Oxidase and Oxaloacetate Decarboxylase Enzyme Electrodes—Simultaneous Determination of Transaminases with a Two-electrode-based Analyzer," *Analytica Chimica Acta*, vol. 222, 1989, pp. 83-93.
- Pfeiffer E.F., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose is Feasible by Combining Portable Glucosensor with Microdialysis," *Horm. Metab. Res.*, vol. 25, 1993, pp. 121-124.
- Pfeiffer E.F., "The Glucose Sensor: The Missing Link in Diabetes Therapy," *Horm Metab Res Suppl.*, vol. 24, 1990, pp. 154-164.
- Phillips R.E., et al., "Biomedical Applications of Polyurethanes: Implications of Failure Mechanisms," *Journal of Biomedical application*, vol. 3, Oct. 1988, pp. 206-227.
- Phillips R.P., "A High Capacity Transcutaneous Energy Transmission System," *ASIAO Journal*, vol. 41, 1995, pp. M259-M262.
- Pichert J.W., et al., "Issues for the Coming Age of Continuous Glucose Monitoring," *Diabetes Educator*, vol. 26 (6), Nov.-Dec. 2000, pp. 969-980.
- Pickup J.C., et al., "Developing Glucose Sensors for In Vivo Use," Elsevier Science Publishers Ltd (UK), *Tibtech*, vol. 11, 1993, pp. 285-291.
- Pickup J.C., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensor Strategy," *Biosensors*, vol. 3, (1987/1988), pp. 335-346.
- Pickup J.C., et al., "In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer," *Diabetologia*, vol. 32, 1989, pp. 213-217.
- Pickup J.C., et al., "Potentially-Implantable, Amperometric Glucose Sensors with Mediated Electron Transfer: Improving the Operating Stability," *Biosensors*, vol. 4, 1989, pp. 109-119.
- Pickup J.C., et al., "Progress Towards in Vivo Glucose Sensing with a Ferrocene-Mediated Amperometric Enzyme Electrode," *Horm Metab Res Suppl*, vol. 20, 1988, pp. 34-36.
- Pickup J.C., et al., "Responses and Calibration of Amperometric Glucose Sensors Implanted in the Subcutaneous Tissue of Man," *ACTA Diabetol*, vol. 30, 1993, pp. 143-148.
- Pineda L.M., et al., "Bone Regeneration with Resorbable Polymeric Membranes. III. Effect of Poly(L-lactide) Membrane Pore Size on the Bone Healing Process in Large Defects," *Journal of Biomedical Materials Research*, vol. 31, 1996, pp. 385-394.
- Pinner S.H., et al., "Cross-Linking of Cellulose Acetate by Ionizing Radiation," *Nature*, vol. 184, Oct. 24, 1959, pp. 1303-1304.

(56)

**References Cited****OTHER PUBLICATIONS**

- Pishko M.V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels," *Analytical Chemistry*, vol. 63 (20), 1991, pp. 2268-2272.
- Pitzer K.R., et al., "Detection of Hypoglycemia with the Glucowatch Biographer," *Diabetes Care*, vol. 24 (5), 2001, pp. 881-885.
- Poirier J.Y., et al., "Clinical and Statistical Evaluation of Self-Monitoring Blood Glucose Meters," *Diabetes Care*, vol. 21 (11), Nov. 1998, pp. 1919-1924.
- Poitout V., et al., "A Glucose Monitoring System for on Line Estimation in Man of Blood Glucose Concentration Using a Miniaturized Glucose Sensor Implanted in the Subcutaneous Tissue and a Wearable Control Unit," *Diabetologia*, vol. 36, 1993, pp. 658-663.
- Poitout V., et al., "Development of a Glucose Sensor for Glucose Monitoring in Man: The Disposable Implant Concept," *Clinical Materials*, vol. 15, 1994, pp. 241-246.
- Poitout V., et al., "In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor," *ASAIO Transactions*, vol. 37, 1991, pp. M298-M300.
- Postlethwaite T.A., et al., "Interdigitated Array Electrode as an Alternative to the Rotated Ring-Disk Electrode for Determination of the Reaction Products of Dioxigen Reduction," *Analytical Chemistry*, vol. 68 (17), Sep. 1996, pp. 2951-2958.
- Prabhu V.G., et al., "Electrochemical Studies of Hydrogen Peroxide at a Platinum Disc Electrode," *Electrochimica Acta*, vol. 26 (6), 1981, pp. 725-729.
- Quinn C.A.P., et al., "Biocompatible, Glucose-Permeable Hydrogel for In situ Coating of Implantable Biosensors," *Biomaterials*, vol. 18 (24), 1997, pp. 1665-1670.
- Quinn C.P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors," *The American Physiological Society*, vol. 269, 1995, pp. E155-E161.
- Rabah M.A., et al., "Electrochemical Wear of Graphite Anodes During Electrolysis of Brine," *Carbon*, vol. 29 (2), 1991, pp. 165-171.
- Rafael E., "Cell Transplantation and Immunoisolation: Studies on a Macroencapsulation Device," *Departments of Transplantation Surgery and Pathology, Karolinska Institutet, Huddinge Hospital, Stockholm, Sweden*, 1999, pp. 1-83.
- Ratner B.D., "Reducing Capsular Thickness and Enhancing Angiogenesis around Implant Drug Release Systems," *Journal of Controlled Release*, vol. 78, 2002, pp. 211-218.
- Raya Systems Pioneers, "Raya Systems Pioneers Healthy Video Games," *PlayRight*, Nov. 1993, pp. 14-15.
- Reach G., "A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors," *Biosensors*, vol. 2, 1986, pp. 211-220.
- Reach G., et al., "Can Continuous Glucose Monitoring Be Used for the Treatment of Diabetes?," *Analytical Chemistry*, vol. 64 (6), Mar. 15, 1992, pp. 381A-386A.
- Reach G., "Which Threshold to Detect Hypoglycemia? Value of Receiver-Operator Curve Analysis to Find a Compromise Between Sensitivity and Specificity," *Diabetes Care*, vol. 24 (5), May 2001, pp. 803-804.
- Rebrin K., et al., "Automated Feedback Control of Subcutaneous Glucose Concentration in Diabetic Dogs," *Diabetologia*, vol. 32, 1989, pp. 573-576.
- Rebrin K., et al., "Subcutaneous Glucose Monitoring by Means of Electrochemical Sensors: Fiction or Reality?," *Journal of Biomedical Engineering*, vol. 14, Jan. 1992, pp. 33-40.
- Rebrin K., et al., "Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring," *The American Physiological Society*, vol. 277, 1999, pp. E561-E571.
- Renard E., "Implantable Closed-Loop Glucose Sensing and Insulin Delivery: The Future for Insulin Pump Therapy," *Current Opinion in Pharmacology*, vol. 2 (6), 2002, pp. 708-716.
- Reush, "Organometallic Compounds," *Chemical Reactivity, Virtual Textbook of Organic Chemistry*, Retrieved from <http://www.cem.msu.edu/~reusch/VirtualText/orgmetal.htm> 2004, pp. 1-16.
- Rhodes R.K., et al., "Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis," *Analytical Chemistry*, vol. 66 (9), May 1, 1994, pp. 1520-1529.
- Rigla M., et al., "Real-Time Continuous Glucose Monitoring Together with Telemedical Assistance Improves Glycemic Control and Glucose Stability in Pump-Treated Patients," *Diabetes Technology & Therapeutics*, vol. 10 (3), 2008, pp. 194-199.
- Rinken T., et al., "Calibration of Glucose Biosensors By Using Pre-Steady State Kinetic Data," *Biosensors & Bioelectronics*, vol. 13, 1998, pp. 801-807.
- Ristic S., et al., "Review: Effects of Rapid-Acting Insulin Analogs on Overall Glycemic Control in Type 1 and Type 2 Diabetes Mellitus," *Diabetes Technology & Therapeutics*, vol. 5 (1), 2003, pp. 57-66.
- Rivers E.P., et al., "Central Venous Oxygen Saturation Monitoring in the Critically Ill Patient," *Current Opinion in Critical Care*, 2001, vol. 7, pp. 204-211.
- Sachlos E., et al., "Making Tissue Engineering Scaffolds Work Review on the Application of Solid Freeform Fabrication Technology to the Production of Tissue Engineering Scaffolds," *European Cells and Materials*, vol. 5, 2003, pp. 29-40.
- Sakakida M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations," *Artif. Organs Today*, vol. 2 (2), 1992, pp. 145-158.
- Sakakida M., et al., "Ferrocene-Mediated Needle Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane," *Sensors and Actuators B*, vol. 13-14, 1993, pp. 319-322.
- Salardi S., et al., "The Glucose Area Under the Profiles Obtained with Continuous Glucose Monitoring System Relationships with HbA1C in Pediatric Type 1 Diabetic Patients," *Diabetes Care*, vol. 25 (10), Oct. 2002, pp. 1840-1844.
- Samuels M.P., "The Effects of Flight and Altitude," *Arch Dis Child*, vol. 89, 2004, pp. 448-455.
- San Diego Plastics Inc, "Polyethylene," *Datasheet*, Retrieved from <http://www.sdpplastics.com/polyeth.html> on Aug. 19, 2009, 7 pages.
- Sanders E., et al., "Fibrous Encapsulation of Single Polymer Microfibers Depends on their Vertical Dimension in Subcutaneous Tissue Polymer Microfibers," *Journal of Biomedical Material Research*, vol. 67A, 2003, pp. 1181-1187.
- Sansen W., et al., "A Smart Sensor for the Voltammetric Measurement of Oxygen or Glucose Concentrations," *Sensors and Actuators B*, 1990, pp. 298-302.
- Sansen W., et al., "Glucose Sensor with Telemetry System," In *Implantable Sensors for Closed Loop Prosthetic Systems* edited by Ko W.H, Chapter 12, 1985, pp. 167-175.
- Schaffar B.P.H., "Thick Film Biosensors for Metabolites in Undiluted Whole Blood and Plasma Samples," *Analytical Bioanalytical Chemistry*, Dec. 2001, vol. 372, pp. 254-260.
- Schmidt F.J., et al., "Calibration of a Wearable Glucose Sensor," *The International Journal of Artificial Organs*, Wichtig Publishing, IT, vol. 15 (1), Jan. 1, 1992, pp. 55-61.
- Schmidt F.J., et al., "Glucose Concentration in Subcutaneous Extracellular Space," *Diabetes Care*, vol. 16 (5), May 1993, pp. 695-700.
- Schmidtko D.W., et al., "Accuracy of the One-Point in Vivo Calibration of "Wired" Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration," *Analytical Chemistry*, vol. 70 (10), May 15, 1998, pp. 2149-2155.
- Schmidtko D.W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin," *Proceedings of the National Academy of Sciences*, vol. 95, Jan. 1998, pp. 294-299.
- Schoemaker M., et al., "The SCGMI System: Subcutaneous Continuous Glucose Monitoring Based on Microdialysis Technique," *Diabetes Technology & Therapeutics*, vol. 5 (4), 2003, pp. 599-608.

(56)

**References Cited****OTHER PUBLICATIONS**

- Schoonen A.J.M., et al., "Development of a Potentially Wearable Glucose Sensor for Patients with Diabetes Mellitus: Design and In-vitro Evaluation," *Biosensors & Bioelectronics*, vol. 5, 1990, pp. 37-46.
- Schuler, et al., "Modified Gas-Permeable Silicone Rubber Membranes for Covalent Immobilisation of Enzymes and their Use in Biosensor Development," *Analyst*, 1999, vol. 124, pp. 1181-1184.
- Selam J.L., "Management of Diabetes with Glucose Sensors and Implantable Insulin Pumps," From the Dream of the 60s to the Realities of the 90s, *ASAIO Journal* 1997, vol. 43, pp. 137-142.
- Service F.J., et al., "Mean Amplitude of Glycemic Excursions, A Measure of Diabetic Instability," *Diabetes*, vol. 19 (9), Sep. 1970, pp. 644-655.
- Service F.J., et al., "Measurements of Glucose Control," *Diabetes Care*, vol. 10 (2), Mar.-Apr. 1987, pp. 225-237.
- Service R.F., "Can Sensors Make a Home in the Body?," *Science, Materials Science: Soft Surface*, vol. 297, Aug. 9, 2002, pp. 962-963.
- Sharkawy A.A., et al., "Engineering the Tissue Which Encapsulates Subcutaneous Implants. I. Diffusion Properties," *Journal of Biomedical Materials Research*, vol. 37, 1996, pp. 401-412.
- Shaw G.W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients," *Biosensors & Bioelectronics*, vol. 6, 1991, pp. 401-406.
- Shichiri M., et al., "Glycaemic Control in Pancreatectomized Dogs with Wearable Artificial Endocrine Pancreas," *Diabetologia*, vol. 24, 1983, pp. 179-184.
- Shichiri M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor," *Diabetes Nutrition & Metabolism*, vol. 2 (4), 1989, pp. 309-313.
- Shichiri M., et al., "Needle Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," In *Implantable Sensors for Closed-Loop Prosthetic Systems* edited by Ko W.H, Chapter 15, 1985, pp. 197-210.
- Shichiri M., et al., "Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals," *Diabetes Care*, vol. 9 (3), May-Jun. 1986, pp. 298-301.
- Shichiri M., et al., "Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor," Preliminary Communication, *Lancet*, vol. 2, Nov. 20, 1982, pp. 1129-1131.
- Shults M.C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors," *IEEE Transactions on Biomedical Engineering*, vol. 41 (10), Oct. 1994, pp. 937-942.
- Sieminski, et al., "Biomaterial-Microvasculature Interactions," *Biomaterials*, 2000, vol. 21, pp. 2233-2241.
- Sigma-Aldrich Corp., "Cellulose Acetate," Product Description, Product No. 419028, St. Louis, MO, 2005, 1 page.
- Sigma-Aldrich Corp. "Nafion® 117 Solution Product Description, Product No. 70160," retrieved from <https://www.sigmaaldrich.com/cgi-bin/hsrun/Suite7/Suite/HAHTpage/Suite.HsExternalProd> on Apr. 7, 2005, 1 page.
- Skyley J.S., "The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System," *Diabetes Technology & Therapeutics*, vol. 2, Supplement 1, 2000, pp. S7-S12.
- Slater-MacLean L., et al., "Accuracy of Glycemic Measurements in the Critically Ill," *Diabetes Technology and Therapeutics*, vol. 10 (3), 2008, pp. 169-177.
- Smith B., et al., "An Externally Powered, Multichannel, Implantable Stimulator-Telemeter for Control of Paralyzed Muscle," *IEEE Transactions on Biomedical Engineering*, vol. 45 (4), Apr. 1998, pp. 463-475.
- Smith, et al., "A Comparison of Islet Transplantation and Subcutaneous Insulin Injections for the Treatment of Diabetes Mellitus," *Computers in Biology and Medicine*, 1991, vol. 21 (6), pp. 417-427.
- Sokol L., et al., "Immobilized-Enzyme Rate-Determination Method for Glucose Analysis," *Clinical Chemistry*, vol. 26 (1), 1980, pp. 89-92.
- Sokolov S., et al., "Metrological Opportunities of the Dynamic Mode of Operating an Enzyme Amperometric Biosensor," *Medical Engineering & Physics*, vol. 17 (6), 1995, pp. 471-476.
- Sparacino G., et al., "Continuous Glucose Monitoring Time Series and Hypo-Hyperglycemia Prevention: Requirements, Methods, Open Problems," *Current Diabetes Reviews*, vol. 4 (3), 2008, pp. 181-192.
- Sproule B.A., et al., "Fuzzy Pharmacology: Theory and Applications," *Trends in Pharmacological Sciences*, vol. 23 (9), Sep. 2002, pp. 412-417.
- Sriyudthsak M., et al., "Enzyme-Epoxy Membrane Based Glucose Analyzing System and Medical Applications," *Biosensors & Bioelectronics*, vol. 11 (8), 1996, pp. 735-742.
- Steil G.M., et al., "Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor," *Diabetes Technology & Therapeutics*, vol. 5 (1), 2003, pp. 27-31.
- Stern M., et al., "Electrochemical Polarization: I. A Theoretical Analysis of the Shape of Polarization Curves," *Journal of the Electrochemical Society*, vol. 104 (1), Jan. 1957, pp. 56-63.
- Sternberg, et al., "Covalent Enzyme Coupling on Cellulose Acetate Membranes for Glucose Sensor Development," *Anal Chem*, Dec. 1988, vol. 60(24), pp. 2781-2786.
- Sternberg F., et al., "Does Fall in Tissue Glucose Precede Fall in Blood Glucose?," *Diabetologia*, vol. 39, 1996, pp. 609-612.
- Sternberg R., et al., "Study and Development of Multilayer Needle-type Enzyme Based Glucose Microsensors," *Biosensors*, Mar. 20, 1988, vol. 4 (1), pp. 27-40.
- Stokes, "Polyether Polyurethanes: Biostable or Not," *Journal of Biomaterials Applications*, Oct. 1988, vol. 3, pp. 228-259.
- Street, et al., "Islet Graft Assessment in the Edmonton Protocol: Implications for Predicting Long-Term Clinical Outcome," *Diabetes*, 2004, vol. 53, pp. 3107-3114.
- Street J.O., et al., "A Note on Computing Robust Regression Estimates Via Iteratively Reweighted Least Squares," *The American Statistician*, vol. 42 (2), May 1988, pp. 152-154.
- Suh, et al., "Behavior of Fibroblasts on a Porous Hyaluronic Acid Incorporated Collagen Matrix," *Yonsei Medical Journal*, 2002, vol. 43 (2), pp. 193-202.
- Sumino T., et al., "Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique," Proceedings of the 20th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 20 (4), 1998, pp. 1775-1778.
- Takatsu I., et al., "Solid State Biosensors Using Thin-Film Electrodes," *Sensors and Actuators*, 1987, vol. 11, pp. 309-317.
- Takegami S., et al., "Pervaporation of Ethanol/Water Mixtures Using Novel Hydrophobic Membranes Containing Polydimethylsiloxane," *Journal of Membrane Science*, vol. 75, 1992, pp. 93-105.
- Tamura T., et al., "Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique and a Null Method—A Numerical Analysis," *Frontiers of Medical & Biological Engineering*, vol. 10 (2), 2000, pp. 147-156.
- Tanenberg R.J., et al., "Continuous Glucose Monitoring System: A New Approach to the Diagnosis of Diabetic Gastroparesis," *Diabetes Technology & Therapeutics*, vol. 2, Supplement 1, 2000, pp. S73-S80.
- Tang, et al., "Fibrin(ogen) Mediates Acute Inflammatory Responses to Biomaterials," *J.Exp.Med*, 1993, vol. 178, pp. 2147-2156.
- Tang, et al., "Inflammatory Responses to Biomaterials," *Am J Clin Pathol*, 1995, vol. 103, pp. 466-471.
- Tang, et al., "Mast Cells Mediate Acute Inflammatory Responses to Implanted Biomaterials," *Proceedings of the National Academy of Sciences of the USA*, 1998, vol. 95, pp. 8841-8846.
- Tang, et al., "Molecular Determinants of Acute Inflammatory Responses to Biomaterials," *J Clin Invest*, 1996, vol. 97, pp. 1329-1334.
- Tatsuma T., et al., "Oxidase/Peroxidase Bilayer-Modified Electrodes as Sensors for Lactate, Pyruvate, Cholesterol and Uric Acid," *Analytica Chimica Acta*, vol. 242, 1991, pp. 85-89.
- Thennadiil S.N., et al., "Comparison of Glucose Concentration in Interstitial Fluid, and Capillary and Venous Blood During Rapid

(56)

**References Cited****OTHER PUBLICATIONS**


- Changes in Blood Glucose Levels," *Diabetes Technology & Therapeutics*, vol. 3 (3), 2001, pp. 357-365.
- Thijssen, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 1, Theory and Simulations, *Analytica chimica Acta*, 1984, vol. 156, pp. 87-101.
- Thijssen, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 3, Variance Reduction ,*Analytica chimica Acta*, 1985, vol. 173, pp. 265-272.
- Thijssen, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 4, Flow Injection Analysis, *Analytica chimica Acta*, 1985, vol. 174, pp. 27-40.
- Thijssen P.C., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 2,Optimal Designs, *Analytica chimica Acta*, vol. 162, 1984, pp. 253-262.
- Thome V., et al., "(Abstract) Can the Decrease in Subcutaneous Glucose Concentration Precede the Decrease in Blood Glucose Level? Proposition for a Push-Pull Kinetics Hypothesis," *Horm. metab. Res.*, vol. 27, 1995, p. 53.
- Thome-Duret V., et al., "Continuous Glucose Monitoring in the Free-Moving Rat," *Metabolism*, vol. 47 (7), Jul. 1998, pp. 799-803.
- Thome-Duret V., et al., "Modification of the Sensitivity of Glucose Sensor Implanted into Subcutaneous Tissue," *Diabetes & Metabolism*, vol. 22, 1996, pp. 174-178.
- Thome-Duret V., et al., "Use of a Subcutaneous Glucose Sensor to Detect Decreases in Glucose Concentration Prior to Observation in Blood," *Analytical Chemistry*, vol. 68 (21), Nov. 1, 1996, pp. 3822-3826.
- Thompson M., et al., "In Vivo Probes: Problems and Perspectives," *Clinical Biochemistry*, vol. 19 (5), Oct. 1986, pp. 255-261.
- Tibell, et al., "Survival of Macroencapsulated Allogeneic Parathyroid Tissue One Year after Transplantation in Nonimmunosuppressed Humans," *Cell Transplantation*, 2001, vol. 10, pp. 591-599.
- Tierney M.J., et al., "Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer," *Diabetes Technology & Therapeutics*, vol. 2 (2), 2000, pp. 199-207.
- Tierney M.J., et al., "The Gluco Watch® Biographer: A Frequent, Automatic and Noninvasive Glucose Monitor," *Annals of Medicine*, vol. 32, 2000, pp. 632-641.
- Tilbury J.B., et al., "Receiver Operating Characteristic Analysis for Intelligent Medical Systems—A New Approach for Finding Confidence Intervals," *IEEE Transactions on Biomedical Engineering*, vol. 47 (7), Jul. 2000, pp. 952-963.
- Torjman M.C., et al., "Glucose Monitoring in Acute Care: Technologies on the Horizon," *Journal of Diabetes Science and Technology*, vol. 2 (2), Mar. 2008, pp. 178-181.
- Trajanoski Z., et al., "Neural Predictive Controller For Insulin Delivery Using The Subcutaneous Route," *IEEE Transactions on Biomedical Engineering*, vol. 45(9), 1998, pp. 1122-1134.
- Trecroci D., "A Glimpse into the Future—Continuous Monitoring of Glucose with a Microfiber," *Diabetes Interview*, Jul. 2002, pp. 42-43.
- Tse P.S.H., et al., "Time-Dependent Inactivation of Immobilized Glucose Oxidase and Catalase," *Biotechnology & Bioengineering*, vol. 29, 1987, pp. 705-713.
- Turner A.P.F., "Amperometric Biosensor based on Mediator-Modified Electrodes," *Methods in Enzymology*, 1988, vol. 137, pp. 90-103.
- Turner A.P.F., et al., "Carbon Monoxide: Acceptor Oxidoreductase from *Pseudomonas Thermocarboxydovorans* Strain C2 and its Use in a Carbon Monoxide Sensor," *Analytica Chimica Acta*, vol. 163, 1984, pp. 161-174.
- Turner A.P.F., et al., "Diabetes Mellitus: Biosensors for Research and Management," *Biosensors*, vol. 1, 1985, pp. 85-115.
- Unger J., et al., "Glucose Control in the Hospitalized Patient," *Emergency Medicine*, vol. 36 (9), 2004, pp. 12-18.
- Updike S.J., et al., "A Subcutaneous Glucose Sensor with Improved Longevity, Dynamic Range, and Stability of Calibration," *Diabetes Care*, vol. 23 (2), Feb. 2000, pp. 208-214.
- Updike S.J., et al., "Continuous Glucose Monitor Based on an Immobilized Enzyme Electrode Detector," *Journal of Laboratory and Clinical Medicine*, vol. 93(4), 1979, pp. 518-527.
- Updike S.J., et al., "Enzymatic Glucose Sensor: Improved Long-Term Performance in Vitro and In Vivo," *ASAIO Journal*, vol. 40 (2), Apr.-Jun. 1994, pp. 157-163.
- Updike S.J., et al., "Implanting the Glucose Enzyme Electrode: Problems, Progress, and Alternative Solutions," *Diabetes Care*, vol. 5 (3), May-Jun. 1982, pp. 207-212.
- Updike S.J., et al., "Laboratory Evaluation of New Reusable Blood Glucose Sensor," *Diabetes Care*, vol. 11 (10), Nov.-Dec. 1988, pp. 801-807.
- Updike S.J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose Form Inside a Subcutaneous Foreign Body Capsule (FBC)," Edited by Fraser D M, *Biosensors in the Body: Continuous in vivo Monitoring*, John Wiley & Sons Ltd., New York, 1997, Chapter 4, pp. 117-137.
- Updike S.J., et al., "The Enzyme Electrode," *Nature*, vol. 214, Jun. 3, 1967, pp. 986-988.
- Utah Medical Products Inc., "Deltran—Disposable Blood Pressure Transducers," Product Specifications, 2003-2006, 6 pages.
- Vadgama P., "Diffusion Limited Enzyme Electrodes," *NATO ASI Series: Series C, Math and Phys. Sci*, vol. 226, 1988, pp. 359-377.
- Vadgama P., "Enzyme Electrodes as Practical Biosensors," *Journal of Medical Engineering & Technology*, vol. 5 (6), Nov. 1981, pp. 293-298.
- Valdes T.I., et al., "In Vitro and In Vivo Degradation of Glucose Oxidase Enzyme used for an Implantable Glucose Biosensor," *Diabetes Technology & Therapeutics*, vol. 2 (3), 2000, pp. 367-376.
- Van Den Berghe, "Tight Blood Glucose Control with Insulin in "Real-Life" Intensive Care," *Mayo Clinic Proceedings*, vol. 79 (8), Aug. 2004, pp. 977-978.
- Velho G., et al., "In Vitro and In Vivo Stability of Electrode Potentials in Needle-Type Glucose Sensors," *Influence of Needle Material*, *Diabetes*, vol. 38, Feb. 1989, pp. 164-171.
- Velho G., et al., "Strategies for Calibrating a Subcutaneous Glucose Sensor," *Biomed. Biochim. Acta*, vol. 48 (11/12), 1989, pp. 957-964.
- Vesper H.W., et al., "Assessment of Trueness of a Glucose Monitor Using Interstitial Fluid and Whole Blood as Specimen Matrix," *Diabetes Technology & Therapeutics*, vol. 8 (1), 2006, pp. 76-80.
- Von Woedtke T., et al., "In Situ Calibration of Implanted Electrochemical Glucose Sensors," *Biomed. Biochim. Acta* 48 vol. 11/12, 1989, pp. 943-952.
- Wade L.G., "Reactions of Aromatic Compounds," *Organic Chemistry*, Chapter 17, 5th edition, 2003, pp. 762-763.
- Wagner, et al., "Continuous Amperometric Monitoring of Glucose in a Brittle Diabetic Chimpanzee with a Miniature Subcutaneous Electrode," *Proc. Natl. Acad. Sci. USA*, vol. 95, May 1998, pp. 6379-6382.
- Wang J., et al., "Highly Selective Membrane-Free Mediator-Free Glucose Biosensor," *Analytical Chemistry*, vol. 66 (21), Nov. 1, 1994, pp. 3600-3603.
- Wang X., et al., "Improved Ruggedness for Membrane-Based Amperometric Sensors using a Pulsed Amperometric Method," *Analytical Chemistry*, vol. 69 (21), Nov. 1, 1997, pp. 4482-4489.
- Ward W.K., et al., "A New Amperometric Glucose Microsensor: In Vitro and Short-Term In Vivo Evaluation," *Biosensors & Bioelectronics*, vol. 17, 2002, pp. 181-189.
- Ward W.K., et al., "Assessment of Chronically Subcutaneous Glucose Sensors in Dogs: The Effect of Surrounding Fluid Masses," *ASAIO Journal*, 1999, vol. 45 (6), pp. 555-561.
- Ward W.K., et al., "Rise in Background Current Over Time in a Subcutaneous Glucose Sensor in the Rabbit," *Relevance to Calibration and Accuracy*, *Biosensors & Bioelectronics*, vol. 15, 2000, pp. 53-61.

(56)


**References Cited****OTHER PUBLICATIONS**

- Ward W.K., et al., "Understanding Spontaneous Output Fluctuations of an Amperometric Glucose Sensor: Effect of Inhalation Anesthesia and Use of a Nonenzyme Containing Electrode," *ASAIO Journal*, 2000, pp. 540-546.
- Wentholt I.M.E., et al., "Relationship between Interstitial and Blood Glucose in Type 1 Diabetes Patients: Delay and the Push-pull Phenomenon Revisited," *Diabetes Technology & Therapeutics*, vol. 9 (2), 2007, pp. 169-175.
- Wientjes K.J.C., "Development of a Glucose Sensor for Diabetic Patients," (Ph.D. Thesis), 2000, 212 pages.
- Wikipedia., "Intravenous Therapy," [http://en.wikipedia.org/wiki/Intravenous\\_therapy](http://en.wikipedia.org/wiki/Intravenous_therapy), Aug. 15, 2006, 6 pages.
- Wilkins E., et al., "Glucose Monitoring: State of the Art and Future Possibilities," *Med. Eng. Phys.*, vol. 18 (4), 1996, pp. 273-288.
- Wilkins E., et al., "Integrated Implantable Device for Long-Term Glucose Monitoring," *Biosensors & Bioelectronics*, vol. 10, 1995, pp. 485-494.
- Wilkins E.S., et al., "The Coated Wire Electrode Glucose Sensor," *Horm Metab Res Suppl.*, vol. 20, 1988, pp. 50-55.
- Wilson G.S., et al., "Enzyme-Based Biosensors for In Vivo Measurements," *Chem. Rev.*, vol. 100, 2000, pp. 2693-2704.
- Wilson G.S., et al., "Progress Toward the Development of an Implantable Sensor for Glucose," *Clinical Chemistry*, vol. 38 (9), 1992, pp. 1613-1617.
- Wolpert H., "Establishing a Continuous Glucose Monitoring Program," *Journal of Diabetes Science and Technology*, Mar. 2008, vol. 2 (2), pp. 307-310.
- Wolpert H.A., "Commentary: A Clinician's Perspective on Some of the Challenges in Closed Loop," *Diabetes Technology & Therapeutics*, vol. 5 (5), 2003, pp. 843-846.
- Wood W.D., et al., "Hermetic Sealing with Epoxy," *Pave Technology-Mechanical Engineering*, Mar. 1990, 3 pages.
- Woodward S.C., "How Fibroblasts and Giant Cells Encapsulate Implants: Considerations in Design of Glucose Sensors," *Diabetes Care*, vol. 5 (3) May-Jun. 1982, pp. 278-281.
- Worsley G.J. et al., "Measurement of Glucose in Blood with a Phenylboronic Acid Optical Sensor," *Journal of Diabetes Science and Technology*, vol. 2 (2), Mar. 2008, pp. 213-220.
- Wright M., et al., "Bioelectrochemical Dehalogenations Via Direct Electrochemistry of Poly(ethylene oxide)-Modified Myoglobin," *Electrochemistry Communications*, vol. 1, 1999, pp. 609-613.
- Wu H., et al., "In Situ Electrochemical Oxygen Generation with an Immunoisolation Device," *Annals New York Academy of Sciences*, vol. 875, 1999, pp. 105-125.
- Yamasaki Y., et al., "Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor," *Clinica Chimica Acta*. 93, 1989, pp. 93-98.
- Yamasaki Y., "The Development of a Needle-Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," *Medical Journal of Osaka University*, vol. 35 (1-2), Sep. 1984, pp. 25-34.
- Yang C., et al., "A Comparison of Physical Properties and Fuel Cell Performance of Nafion and Zirconium Phosphate/Nation Composite Membranes," *Journal of Membrane Science*, vol. 237, 2004, pp. 145-161.
- Yang Q., et al., "Development of Needle-Type Glucose Sensor with High Selectivity," *Science and Actuators B*, vol. 46, 1998, pp. 249-256.
- Yang S., et al., "A Glucose Biosensor Based On an Oxygen Electrode: In-Vitro Performances in a Model Buffer Solution and in Blood Plasma," *Biomedical Instrumentation & Technology*, vol. 30 (1), 1996, pp. 55-61.
- Yang S., et al., "Glucose Biosensors with Enzyme Entrapped in Polymer Coating," *Biomedical Instrument and Technology*, Mar./Apr. 1995, vol. 29 (2), pp. 125-133.
- Ye L., et al., "High Current Density Wired' Quinoprotein Glucose Dehydrogenase Electrode," *Analytical Chemistry*, vol. 65, 1993, pp. 238-241.
- Zamzow K.L., et al., "Development and Evaluation of a Wearable Blood Glucose Monitor," *ASAIO Transactions*, vol. 36 (3), 1990, pp. M588-M591.
- Zavalkoff S.R., et al., "Evaluation Of Conventional Blood Glucose Monitoring as An Indicator of Integrated Glucose Values Using a Continuous Subcutaneous Sensor," *Diabetes Care*, vol. 25(9), 2002, pp. 1603-1606.
- Zethelius B., et al., "Use Of Multiple Biomarkers to Improve the Prediction of Death From Cardiovascular Causes," *N. Engl. J. Med.*, vol. 358, May 2008, pp. 2107-2116.
- Zhang, et al., "Elimination of the Acetaminophen Interference in an Implantable Glucose Sensor," *Analytical Chemistry*, 1994, vol. 66 (7), pp. 1183-1188.
- Zhang Y., et al., "Electrochemical Oxidation Of H<sub>2</sub>O<sub>2</sub> On Pt and Pt + Ir Electrodes in Physiological Buffer and its Applicability to H<sub>2</sub>O<sub>2</sub>-Based Biosensors," *J. Electro Analytical Chemistry*, vol. 345, 1993, pp. 253-271.
- Zhang Y., et al., "In Vitro and In Vivo Evaluation of Oxygen Effects on a Glucose Oxidase Based Implantable Glucose Sensor," *Analytica Chimica Acta*, vol. 281, 1993, pp. 513-520.
- Zhu, et al., "Fabrication and Characterization of Glucose Sensors Based on a Microarray H<sub>2</sub>O<sub>2</sub> Electrode," *Biosensors & Bioelectronics*, 1994, vol. 9, pp. 295-300.
- Zhu, et al., "Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian blue Layer," *Sensors*, 2002, vol. 2, pp. 127-136.
- Ziaie, et al., "A Single-Channel Implantable Microstimulator for Functional Neuromuscular Stimulation," *IEEE Transactions on Biomedical Engineering*, 1997, vol. 44(10), pp. 909-920.
- U.S. Appl. No. 17/196,864, "Final Office Action", U.S. Appl. No. 17/196,864, filed Aug. 15, 2023, 23 pages.

\* cited by examiner



**FIG. 1**



**FIG. 2**







FIG. 3




**FIG. 4A**




**FIG. 4B**




**FIG. 5A**




**FIG. 5B**






**FIG. 5C**



**FIG. 6A**



**FIG. 6B**

**FIG. 7A****FIG. 7B****FIG. 7C**







FIG. 8

**FIG. 9**

**FIG. 10**

**FIG. 11**

1

**INTEGRATED DELIVERY DEVICE FOR  
CONTINUOUS GLUCOSE SENSOR****INCORPORATION BY REFERENCE TO  
RELATED APPLICATIONS**

Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. application Ser. No. 17/556,761, filed Dec. 20, 2021, which is a continuation of U.S. application Ser. No. 15/906,946, filed Feb. 27, 2018, which is a continuation of U.S. application Ser. No. 14/830,568, filed Aug. 19, 2015, now U.S. Pat. No. 9,937,293, which is a continuation of U.S. application Ser. No. 13/559,454 filed Jul. 26, 2012, now U.S. Pat. No. 9,155,843, which is a continuation of U.S. application Ser. No. 13/180,396 filed Jul. 11, 2011, now U.S. Pat. No. 8,460,231, which is a continuation of U.S. application Ser. No. 12/536,852 filed Aug. 6, 2009, now U.S. Pat. No. 7,976,492, which is a divisional of U.S. application Ser. No. 10/789,359 filed Feb. 26, 2004, now U.S. Pat. No. 7,591,801. Each of the aforementioned applications is incorporated by reference herein in its entirety, and each is hereby expressly made a part of this specification.

**FIELD OF THE INVENTION**

The present invention relates generally to systems and methods monitoring glucose in a host. More particularly, the present invention relates to an integrated medicament delivery device and continuous glucose sensor.

**BACKGROUND OF THE INVENTION**

Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which may cause an array of physiological derangements (for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) may be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.

Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically comprises uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic will normally only measure his or her glucose level two to four times per day. Unfortunately, these time intervals are so far spread apart that the diabetic will likely find out too late, sometimes incurring dangerous side effects, of a hyper- or hypoglycemic condition. In fact, it is not only unlikely that a diabetic will take a timely SMBG value, but the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods, inhibiting their ability to make educated insulin therapy decisions.

Home diabetes therapy requires personal discipline of the user, appropriate education from a doctor, proactive behavior under sometimes-adverse situations, patient calculations to determine appropriate therapy decisions, including types and amounts of administration of insulin and glucose into his or her system, and is subject to human error. Technologies are needed that ease the burdens faced by diabetic patients, simplify the processes involved in treating the

2

disease, and minimize user error which may cause unnecessarily dangerous situations in some circumstances.

**SUMMARY OF THE INVENTION**

5

In a first embodiment, a method for treating diabetes with an integrated glucose sensor and medicament delivery device is provided, including: receiving in a receiver a data stream from a glucose sensor, including one or more sensor data points; calculating medicament therapy responsive to the one or more sensor data points; validating the calculated therapy based on at least one of data input into the receiver and data obtained from an integrated single point glucose monitor; and outputting validated information reflective of the therapy recommendations.

10

In an aspect of the first embodiment, the therapy validation is configured to trigger a fail-safe module, if the validation fails, wherein the user must confirm a therapy decision prior to outputting therapy recommendations.

15

In an aspect of the first embodiment, the output step includes outputting the sensor therapy recommendations to a user interface.

20

In an aspect of the first embodiment, the output step includes displaying the sensor therapy recommendations on the user interface of at least one of a receiver and a medicament delivery device.

25

In an aspect of the first embodiment, the output step includes transmitting the therapy recommendations to a medicament delivery device.

30

In an aspect of the first embodiment, the output step includes delivering the recommended therapy via an automated delivery device.

35

In a second embodiment, a method for treating diabetes in a host with an integrated glucose sensor and medicament delivery device is provided, including: receiving in a receiver medicament delivery data responsive to medicament delivery from a medicament delivery device; receiving in a receiver a data stream from a glucose sensor, including one or more sensor data points for a time period before and after the medicament delivery; determining a host's metabolic response to the medicament delivery; receiving a subsequent data stream from the glucose sensor including one or more sensor data points; and calculating medicament therapy responsive to the host's metabolic response to the medicament delivery.

40

In an aspect of the second embodiment, the host's metabolic response is calculated using a pattern recognition algorithm.

45

In an aspect of the second embodiment, the step of determining a host's metabolic response to medicament delivery is repeated when the receiver receives additional medicament delivery data.

50

In an aspect of the second embodiment, the host's metabolic response iteratively determined for a time period exceeding one week.

55

In a third embodiment, a method for estimating glucose levels from an integrated glucose sensor and medicament delivery device is provided, including: receiving in a receiver a data stream from a glucose sensor, including one or more sensor data points; receiving in the receiver medicament delivery data responsive to medicament delivery from a medicament delivery device; evaluating medicament delivery data with glucose sensor data corresponding to delivery and release times of the medicament delivery data to determine individual metabolic patterns associated with

medicament delivery; and estimating glucose values responsive to individual metabolic patterns associated with the medicament delivery.

In an aspect of the third embodiment, the individual's metabolic patterns associated with medicament delivery are calculated using a pattern recognition algorithm.

In an aspect of the third embodiment, the step of determining the individual's metabolic patterns to medicament delivery is repeated when the receiver receives additional medicament delivery data.

In an aspect of the third embodiment, the individual's metabolic patterns are iteratively determined for a time period exceeding one week.

In a fourth embodiment, an integrated system for monitoring and treating diabetes is provided, including: a glucose sensor, wherein the glucose sensor substantially continuously measures glucose in a host for a period exceeding one week, and outputs a data stream, including one or more sensor data points; a receiver operably connected to the glucose sensor, wherein the receiver is configured to receive the data stream; and a medicament delivery device, wherein the delivery device is at least one of physically and operably connected to the receiver.

In an aspect of the fourth embodiment, the glucose sensor includes an implantable glucose sensor.

In an aspect of the fourth embodiment, the glucose sensor includes a long-term subcutaneously implantable glucose sensor.

In an aspect of the fourth embodiment, the medicament delivery device includes a syringe detachably connectable to the receiver.

In an aspect of the fourth embodiment, the medicament delivery device includes one or more transdermal patches detachably connectable to the receiver.

In an aspect of the fourth embodiment, the medicament delivery device includes an inhaler or spray delivery device detachably connectable to the receiver.

In an aspect of the fourth embodiment, the medicament delivery device includes a pen or jet-type injector.

In an aspect of the fourth embodiment, the medicament delivery device includes a transdermal pump.

In an aspect of the fourth embodiment, the medicament delivery device includes an implantable pump.

In an aspect of the fourth embodiment, the medicament delivery device includes a manual implantable pump.

In an aspect of the fourth embodiment, the medicament delivery device includes a cell transplantation device.

In an aspect of the fourth embodiment, the medicament delivery device is detachably connected to the receiver.

In an aspect of the fourth embodiment, the medicament delivery device is operably connected to the receiver by a wireless connection.

In an aspect of the fourth embodiment, the medicament delivery device is operably connected by a wired connection.

In an aspect of the fourth embodiment, further including a single point glucose monitor, wherein the single point glucose monitor is at least one of physically and operably connected to the receiver.

In an aspect of the fourth embodiment, the glucose sensor includes an enzyme membrane system for electrochemical detection of glucose the single point glucose monitor includes an enzyme membrane system for electrochemical detection of glucose.

In an aspect of the fourth embodiment, the receiver includes a microprocessor, and wherein the microprocessor includes programming for calculating and outputting medicament delivery instructions

5 In an aspect of the fourth embodiment, the microprocessor further includes a validation module that validates the medicament delivery instructions prior to outputting the instructions.

10 In an aspect of the fourth embodiment, the receiver is configured to receive medicament delivery data responsive to medicament delivery for a first time period from the medicament delivery device.

15 In an aspect of the fourth embodiment, the receiver includes a microprocessor, and wherein the microprocessor includes programming to determine a host's metabolic response to the medicament delivery by evaluating the sensor data points substantially corresponding to delivery and release of the medicament delivery for the first time period.

20 In an aspect of the fourth embodiment, the microprocessor calculates medicament therapy for a second time period responsive to sensor data and the host's metabolic response to the medicament delivery.

25 In an aspect of the fourth embodiment, the microprocessor includes programming to estimate glucose values responsive to glucose sensor data and host's metabolic response.

#### BRIEF DESCRIPTION OF THE DRAWINGS

30 FIG. 1 is a block diagram of an integrated system of the preferred embodiments, including a continuous glucose sensor, a receiver for processing and displaying sensor data, a medicament delivery device, and an optional single point glucose-monitoring device.

35 FIG. 2 is a perspective view of a continuous glucose sensor in one embodiment.

40 FIG. 3 is a block diagram of the electronics associated with a continuous glucose sensor in one embodiment.

FIGS. 4A and 4B are perspective views of an integrated system 10 in one embodiment, wherein a receiver is integrated with a medicament delivery device in the form of a manual syringe, and optionally includes a single point glucose monitor.

45 FIGS. 5A to 5C are perspective views of an integrated system in one embodiment, wherein a receiver is integrated with a medicament delivery device in the form of one or more transdermal patches housed within a holder, and optionally includes a single point glucose monitor.

50 FIGS. 6A and 6B are perspective views of an integrated system in one embodiment, wherein a receiver is integrated with a medicament delivery device in the form of a pen or jet-type injector, and optionally includes a single point glucose monitor.

55 FIGS. 7A to 7C are perspective views of an integrated system in one embodiment, wherein a sensor and delivery pump, which are implanted or transdermally inserted into the patient, are operably connected to an integrated receiver, and optionally include a single point glucose monitor.

60 FIG. 8 is a block diagram that illustrates integrated system electronics in one embodiment.

FIG. 9 is a flow chart that illustrates the process of validating therapy instructions prior to medicament delivery in one embodiment.

65 FIG. 10 is a flow chart that illustrates the process of providing adaptive metabolic control using an integrated sensor and medicament delivery device in one embodiment.

FIG. 11 is a flow chart that illustrates the process of glucose signal estimation using the integrated sensor and medicament delivery device in one embodiment.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.

##### Definitions

In order to facilitate an understanding of the disclosed invention, a number of terms are defined below.

The term "continuous glucose sensor," as used herein, is a broad term and are used in its ordinary sense, including, but not limited to, a device that continuously or continually measures glucose concentration, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer. It should be understood that continual or continuous glucose sensors can continually measure glucose concentration without requiring user initiation and/or interaction for each measurement, such as described with reference to U.S. Pat. No. 6,001,067, for example.

The phrase "continuous glucose sensing," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, the period in which monitoring of plasma glucose concentration is continuously or continually performed, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.

The term "biological sample," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, sample of a host body, for example, blood, interstitial fluid, spinal fluid, saliva, urine, tears, sweat, or the like.

The term "host," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, mammals such as humans.

The term "biointerface membrane," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a permeable or semi-permeable membrane that can include two or more domains and is typically constructed of materials of a few microns thickness or more, which can be placed over the sensing region to keep host cells (for example, macrophages) from gaining proximity to, and thereby damaging the sensing membrane or forming a barrier cell layer and interfering with the transport of glucose across the tissue-device interface.

The term "sensing membrane," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a permeable or semi-permeable membrane that can be comprised of two or more domains and is typically constructed of materials of a few microns thickness or more, which are permeable to oxygen and are optionally permeable to glucose. In one example, the sensing membrane comprises an immobilized glucose oxidase enzyme, which enables an electrochemical reaction to occur to measure a concentration of glucose.

The term "domain," as used herein is a broad term and is used in its ordinary sense, including, without limitation, regions of a membrane that can be layers, uniform or

non-uniform gradients (for example, anisotropic), functional aspects of a material, or provided as portions of the membrane.

As used herein, the term "copolymer," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, polymers having two or more different repeat units and includes copolymers, terpolymers, tetrapolymers, etc.

The term "sensing region," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular glucose. In one embodiment, the sensing region generally comprises a non-conductive body, a working electrode (anode), a reference electrode and a counter electrode (cathode) passing through and secured within the body forming an electrochemically reactive surface at one location on the body and an electronic connection at another location on the body, and a sensing membrane affixed to the body and covering the electrochemically reactive surface. The counter electrode typically has a greater electrochemically reactive surface area than the working electrode. During general operation of the sensor a biological sample (for example, blood or interstitial fluid) or a portion thereof contacts (for example, directly or after passage through one or more domains of the sensing membrane) an enzyme (for example, glucose oxidase); the reaction of the biological sample (or portion thereof) results in the formation of reaction products that allow a determination of the glucose level in the biological sample.

The term "electrochemically reactive surface," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place. In the case of the working electrode, the hydrogen peroxide produced by the enzyme catalyzed reaction of the glucose being detected reacts creating a measurable electronic current (for example, detection of glucose utilizing glucose oxidase produces  $H_2O_2$  as a by product,  $H_2O_2$  reacts with the surface of the working electrode producing two protons ( $2H^+$ ), two electrons ( $2e^-$ ) and one molecule of oxygen ( $O_2$ ) which produces the electronic current being detected). In the case of the counter electrode, a reducible species (for example,  $O_2$ ) is reduced at the electrode surface in order to balance the current being generated by the working electrode.

The term "electrochemical cell," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a device in which chemical energy is converted to electrical energy. Such a cell typically consists of two or more electrodes held apart from each other and in contact with an electrolyte solution. Connection of the electrodes to a source of direct electric current renders one of them negatively charged and the other positively charged. Positive ions in the electrolyte migrate to the negative electrode (cathode) and there combine with one or more electrons, losing part or all of their charge and becoming new ions having lower charge or neutral atoms or molecules; at the same time, negative ions migrate to the positive electrode (anode) and transfer one or more electrons to it, also becoming new ions or neutral particles. The overall effect of the two processes is the transfer of electrons from the negative ions to the positive ions, a chemical reaction.

The term "proximal" as used herein, is a broad term and is used in its ordinary sense, including, without limitation, near to a point of reference such as an origin or a point of attachment. For example, in some embodiments of a sensing membrane that covers an electrochemically reactive surface,

the electrolyte domain is located more proximal to the electrochemically reactive surface than the interference domain.

The term "distal" as used herein, is a broad term and is used in its ordinary sense, including, without limitation, spaced relatively far from a point of reference, such as an origin or a point of attachment. For example, in some embodiments of a sensing membrane that covers an electrochemically reactive surface, a resistance domain is located more distal to the electrochemically reactive surfaces than the enzyme domain.

The term "substantially" as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified.

The term "microprocessor," as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a computer system or processor designed to perform arithmetic and logic operations using logic circuitry that responds to and processes the basic instructions that drive a computer.

The term "ROM," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, read-only memory, which is a type of data storage device manufactured with fixed contents. ROM is broad enough to include EEPROM, for example, which is electrically erasable programmable read-only memory (ROM).

The term "RAM," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, a data storage device for which the order of access to different locations does not affect the speed of access. RAM is broad enough to include SRAM, for example, which is static random access memory that retains data bits in its memory as long as power is being supplied.

The term "A/D Converter," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, hardware and/or software that converts analog electrical signals into corresponding digital signals.

The term "RF transceiver," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, a radio frequency transmitter and/or receiver for transmitting and/or receiving signals.

The terms "raw data stream" and "data stream," as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, an analog or digital signal directly related to the analyte concentration measured by the analyte sensor. In one example, the raw data stream is digital data in "counts" converted by an A/D converter from an analog signal (for example, voltage or amps) representative of an analyte concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous analyte sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.

The term "counts," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from a working electrode.

The term "electronic circuitry," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, the components (for example, hardware and/or software) of a device configured to process data. In the case of an analyte sensor, the data includes biological information obtained by a sensor regarding the concentration of the analyte in a biological fluid. U.S. Pat. Nos. 4,757,022,

5,497,772 and 4,787,398, which are hereby incorporated by reference in their entirety, describe suitable electronic circuits that can be utilized with devices of certain embodiments.

5 The term "potentiostat," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an electrical system that controls the potential between the working and reference electrodes of a three-electrode cell at a preset value. The potentiostat forces whatever current is necessary to flow between the working and counter electrodes to keep the desired potential, as long as the needed cell voltage and current do not exceed the compliance limits of the potentiostat.

15 The terms "operably connected" and "operably linked," as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, one or more components being linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of glucose in a sample and convert that information into a signal; the signal can then be transmitted to an electronic circuit. In this case, the electrode is "operably linked" to the electronic circuit. These terms are broad enough to include wired and wireless connectivity.

20 The term "algorithmically smoothed," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, modification of a set of data to make it smoother and more continuous and remove or diminish 25 outlying points, for example, by performing a moving average of the raw data stream.

30 The term "algorithm," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, the computational processes (for example, programs) involved 35 in transforming information from one state to another, for example using computer processing.

The term "regression," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, finding a line in which a set of data has a minimal measurement (for example, deviation) from that line. Regression can 40 be linear, non-linear, first order, second order, and so forth. One example of regression is least squares regression.

45 The terms "recursive filter" and "auto-regressive algorithm," as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, an equation in which previous averages are part of the next filtered output. More particularly, the generation of a series of observations 50 whereby the value of each observation is partly dependent on the values of those that have immediately preceded it. One example is a regression structure in which lagged response values assume the role of the independent variables.

55 The terms "velocity" and "rate of change," as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, time rate of change; the amount of change divided by the time required for the change. In one embodiment, these terms refer to the rate of increase or decrease in an analyte for a certain time period.

60 The term "acceleration" as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, the rate of change of velocity with respect to time. This term is broad enough to include deceleration.

65 The term "clinical risk," as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an identified danger or potential risk to the health of a patient based on a measured or estimated analyte concentration, its rate of change, and/or its acceleration.

The term “clinically acceptable,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an analyte concentration, rate of change, and/or acceleration associated with that measured analyte that is considered to be safe for a patient.

The term “time period,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an amount of time including a single point in time and a path (for example, range of time) that extends from a first point in time to a second point in time.

The term “measured analyte values,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an analyte value or set of analyte values for a time period for which analyte data has been measured by an analyte sensor. The term is broad enough to include data from the analyte sensor before or after data processing in the sensor and/or receiver (for example, data smoothing, calibration, or the like).

The term “alarm,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, audible, visual, or tactile signal that are triggered in response to detection of clinical risk to a patient. In one embodiment, hyperglycemic and hypoglycemic alarms are triggered when present or future clinical danger is assessed based on continuous analyte data.

The term “computer,” as used herein, is broad term and is used in its ordinary sense, including, but not limited to, machine that can be programmed to manipulate data.

The term “modem,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an electronic device for converting between serial data from a computer and an audio signal suitable for transmission over a telecommunications connection to another modem.

#### Overview

FIG. 1 is a block diagram of an integrated system 10 of the preferred embodiments, including a continuous glucose sensor 12, a receiver 14 for processing and displaying sensor data, a medicament delivery device 16, and optionally a single point glucose-monitoring device 18. The integrated diabetes management system 10 of the preferred embodiments provides improved convenience and accuracy thus affording a diabetic patient 8 with improved convenience, functionality, and safety in the care of their disease.

FIG. 1 shows a continuous glucose sensor 12 that measures a concentration of glucose or a substance indicative of the concentration or presence of the glucose. In some embodiments, the glucose sensor 12 is an invasive, minimally invasive, or non-invasive device, for example a subcutaneous, transdermal, or intravascular device. In some embodiments, the sensor 12 may analyze a plurality of intermittent biological samples. The glucose sensor may use any method of glucose-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like. In alternative embodiments, the sensor 12 may be any sensor capable of determining the level of an analyte in the body, for example oxygen, lactase, insulin, hormones, cholesterol, medicaments, viruses, or the like. The glucose sensor 12 uses any known method to provide an output signal indicative of the concentration of the glucose. The output signal is typically a raw data stream that is used to provide a useful value of the measured glucose concentration to a patient or doctor, for example.

Accordingly, a receiver 14 is provided that receives and processes the raw data stream, including calibrating, validating, and displaying meaningful glucose values to a patient, such as described in more detail below. A medica-

ment delivery device 16 is further provided as a part of the integrated system 10. In some embodiments, the medicament delivery device 16 is a manual delivery device, for example a syringe, inhaler, or transdermal patch, which is manually integrated with the receiver 14. In some embodiments, the medicament delivery device 16 is a semi-automated delivery device, for example a pen or jet-type injector, an inhaler, a spray, or pump, which provides a semi-automated integration with the receiver 14. In some embodiments, the medicament delivery device 16 is an automated delivery device, for example a transcutaneous or implantable pump system, which provides an automated integration with the receiver 14. In some embodiments, an optional single point glucose monitor 18 is further provided as a part of the integrated system 10, for example a self-monitoring blood glucose meter (SMBG), non-invasive glucose meter, or the like.

Conventionally, each of these devices separately provides valuable information and or services to diabetic patients. Thus, a typical diabetic patient has numerous individual devices, which they track and consider separately. In some cases, the amount of information provided by these individual devices may require complex understanding of the nuances and implications of each device, for example types and amounts of insulin to deliver. Typically, each individual device is a silo of information that functions as well as the data provided therein, therefore when the devices are able to communicate with each other, enhanced functionality and safety may be realized. For example, when a continuous glucose monitor functions alone (for example, without data other than that which was gathered by the device), sudden changes in glucose level are tracked, but may not be fully understood, predicted, preempted, or otherwise considered in the processing of the sensor data; however, if the continuous glucose sensor were provided with information about time, amount, and type of insulin injections, calories consumed, time or day, meal time, or like, more meaningful, accurate and useful glucose estimation, prediction, and other such processing can be provided, such as described in more detail herein. By integrating these devices, the information from each component can be leveraged to increase the intelligence, benefit provided, convenience, safety, and functionality of the continuous glucose sensor and other integrated components. Therefore, it would be advantageous to provide a device that aids the diabetic patient in integrating these individual devices in the treatment of his/her disease.

#### Glucose Sensor

FIG. 2 is a perspective view of one embodiment of a continuous glucose sensor 12. In this embodiment, a body 20 and a sensing region 22 house the electrodes and sensor electronics (FIG. 3). The three electrodes within the sensing region are operably connected to the sensor electronics (FIG. 3) and are covered by a sensing membrane and a biointerface membrane (not shown), which are described in more detail below.

The body 20 is preferably formed from epoxy molded around the sensor electronics, however the body may be formed from a variety of materials, including metals, ceramics, plastics, or composites thereof. Co-pending U.S. patent application Ser. No. 10/646,333, entitled, “Optimized Sensor Geometry for an Implantable Glucose Sensor” discloses suitable configurations suitable for the body 20, and is incorporated by reference in its entirety.

In one embodiment, the sensing region 22 comprises three electrodes including a platinum working electrode, a platinum counter electrode, and a silver/silver chloride reference

electrode, for example. However a variety of electrode materials and configurations may be used with the implantable glucose sensor of the preferred embodiments. The top ends of the electrodes are in contact with an electrolyte phase (not shown), which is a free-flowing fluid phase disposed between the sensing membrane and the electrodes. In one embodiment, the counter electrode is provided to balance the current generated by the species being measured at the working electrode. In the case of a glucose oxidase based glucose sensor, the species being measured at the working electrode is H<sub>2</sub>O<sub>2</sub>. Glucose oxidase catalyzes the conversion of oxygen and glucose to hydrogen peroxide and gluconate according to the following reaction:



The change in H<sub>2</sub>O<sub>2</sub> can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H<sub>2</sub>O<sub>2</sub>. Oxidation of H<sub>2</sub>O<sub>2</sub> by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H<sub>2</sub>O<sub>2</sub>, or other reducible species at the counter electrode. The H<sub>2</sub>O<sub>2</sub> produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H<sup>+</sup>), two electrons (2e<sup>-</sup>), and one oxygen molecule (O<sub>2</sub>).

In one embodiment, a potentiostat (FIG. 3) is employed to monitor the electrochemical reaction at the electroactive surface(s). The potentiostat applies a constant potential to the working and reference electrodes to determine a current value. The current that is produced at the working electrode (and flows through the circuitry to the counter electrode) is substantially proportional to the amount of H<sub>2</sub>O<sub>2</sub> that diffuses to the working electrode. Accordingly, a raw signal can be produced that is representative of the concentration of glucose in the user's body, and therefore can be utilized to estimate a meaningful glucose value.

In some embodiments, the sensing membrane includes an enzyme, for example, glucose oxidase, and covers the electrolyte phase. In one embodiment, the sensing membrane generally includes a resistance domain most distal from the electrochemically reactive surfaces, an enzyme domain less distal from the electrochemically reactive surfaces than the resistance domain, and an electrolyte domain adjacent to the electrochemically reactive surfaces. However, it is understood that a sensing membrane modified for other devices, for example, by including fewer or additional domains, is within the scope of the preferred embodiments. Co-pending U.S. patent application Ser. No. 09/916,711, entitled, "SENSOR READ FOR USE WITH IMPLANTABLE DEVICES," which is incorporated herein by reference in its entirety, describes membranes that can be used in some embodiments of the sensing membrane. It is noted that in some embodiments, the sensing membrane may additionally include an interference domain that blocks some interfering species; such as described in the above-cited co-pending patent application. Co-pending U.S. patent application Ser. No. 10/695,636, entitled, "SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE" also describes membranes that may be used for the sensing membrane of the preferred embodiments, and is incorporated herein by reference in its entirety.

Preferably, the biointerface membrane supports tissue ingrowth, serves to interfere with the formation of a barrier cell layer, and protects the sensitive regions of the device from host inflammatory response. In one embodiment, the biointerface membrane generally includes a cell disruptive domain most distal from the electrochemically reactive

surfaces and a cell impermeable domain less distal from the electrochemically reactive surfaces than the cell disruptive domain. The cell disruptive domain is preferably designed to support tissue ingrowth, disrupt contractile forces typically found in a foreign body response, encourage vascularity within the membrane, and disrupt the formation of a barrier cell layer. The cell impermeable domain is preferably resistant to cellular attachment, impermeable to cells, and composed of a biostable material. Copending U.S. patent application Ser. No. 09/916,386, entitled, "MEMBRANE FOR USE WITH IMPLANTABLE DEVICES," U.S. patent application Ser. No. 10/647,065, entitled, "POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES," and U.S. Provisional Patent Application 60/544,722, filed Feb. 12, 2004 entitled, "BIOINTERFACE WITH INTEGRATED MACRO- AND MICRO-ARCHITECTURE," describe biointerface membranes that may be used in conjunction with the preferred embodiments, and are incorporated herein by reference in their entirety. It is noted that the preferred embodiments may be used with a short term (for example, 1 to 7 day sensor), in which case a biointerface membrane may not be required. It is noted that the biointerface membranes described herein provide a continuous glucose sensor that has a useable life of greater than about one week, greater than about one month, greater than about three months, or greater than about one year, herein after referred to as "long-term."

In some embodiments, the domains of the biointerface and sensing membranes are formed from materials such as silicone, polytetrafluoroethylene, polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, cellulosic polymers, polysulfones and block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers.

FIG. 3 is a block diagram that illustrates the electronics associated with a continuous glucose sensor 12 in one embodiment. In this embodiment, a potentiostat 24 is shown, which is operably connected to electrodes (FIG. 2) to obtain a current value, and includes a resistor (not shown) that translates the current into voltage. An A/D converter 26 digitizes the analog signal into "counts" for processing. Accordingly, the resulting raw data stream in counts is directly related to the current measured by the potentiostat 24.

A microprocessor 28 is the central control unit that houses ROM 30 and RAM 32, and controls the processing of the sensor electronics. It is noted that certain alternative embodiments can utilize a computer system other than a microprocessor to process data as described herein. In some alternative embodiments, an application-specific integrated circuit (ASIC) can be used for some or all the sensor's central processing as is appreciated by one skilled in the art. The ROM 30 provides semi-permanent storage of data, for example, storing data such as sensor identifier (ID) and programming to process data streams (for example, programming for data smoothing and/or replacement of signal artifacts such as described in copending U.S. Patent Application entitled, "SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM," filed Aug. 22, 2003). The RAM 32 can be used for the system's cache memory, for example for temporarily storing recent sensor data. In some

13

alternative embodiments, memory storage components comparable to ROM 30 and RAM 32 may be used instead of or in addition to the preferred hardware, such as dynamic RAM, static-RAM, non-static RAM, EEPROM, rewritable ROMs, flash memory, or the like.

A battery 34 is operably connected to the microprocessor 28 and provides the necessary power for the sensor 12. In one embodiment, the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used (for example, AAA, Nickel-cadmium, Zinc-carbon, Alkaline, Lithium, Nickel-metal hydride, Lithium-ion, Zinc-air, Zinc-mercury oxide, Silver-zinc, and/or hermetically-sealed). In some embodiments the battery is rechargeable. In some embodiments, a plurality of batteries can be used to power the system. In yet other embodiments, the receiver can be transcutaneously powered via an inductive coupling, for example. A Quartz Crystal 36 is operably connected to the microprocessor 28 and maintains system time for the computer system as a whole.

An RF Transceiver 38 is operably connected to the microprocessor 28 and transmits the sensor data from the sensor 12 to a receiver within a wireless transmission 40 via antenna 42. Although an RF transceiver is shown here, some other embodiments can include a wired rather than wireless connection to the receiver. A second quartz crystal 44 provides the system time for synchronizing the data transmissions from the RF transceiver. It is noted that the transceiver 38 can be substituted with a transmitter in other embodiments. In some alternative embodiments other mechanisms such as optical, infrared radiation (IR), ultrasonic, or the like may be used to transmit and/or receive data.

In one alternative embodiment, the continuous glucose sensor comprises a transcutaneous sensor such as described in U.S. Pat. No. 6,565,509 to Say et al. In another alternative embodiment, the continuous glucose sensor comprises a subcutaneous sensor such as described with reference to U.S. Pat. No. 6,579,690 to Bonnecaze et al. and U.S. Pat. No. 6,484,046 to Say et al. In another alternative embodiment, the continuous glucose sensor comprises a refillable subcutaneous sensor such as described with reference to U.S. Pat. No. 6,512,939 to Colvin et al. In another alternative embodiment, the continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,477,395 to Schulman et al. In another alternative embodiment, the continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,424,847 to Mastrototaro et al. All of the above patents are incorporated in their entirety herein by reference. In general, it should be understood that the disclosed embodiments are applicable to a variety of continuous glucose sensor configurations.

#### Receiver

The preferred embodiments provide an integrated system, which includes a receiver 14 that receives and processes the raw data stream from the continuous glucose sensor 12. The receiver may perform all or some of the following operations: a calibration, converting sensor data, updating the calibration, evaluating received reference and sensor data, evaluating the calibration for the analyte sensor, validating received reference and sensor data, displaying a meaningful glucose value to a user, calculating therapy recommendations, validating recommended therapy, adaptive programming for learning individual metabolic patterns, and prediction of glucose values, for example. Some complementary systems and methods associated with the receiver are described in more detail with reference to co-pending U.S.

14

patent application Ser. No. 10/633,367, entitled, "SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA," which is incorporated herein by reference in its entirety. FIGS. 9 to 11 describe some processes that may be programmed into the receiver. Additionally, the receiver 14 of the preferred embodiments works together with the other components of the system (for example, the medicament delivery device 16 and the single point glucose monitor 18) to provide enhanced functionality, convenience, and safety, such as described in more detail herein. FIGS. 4 to 7 are illustrations of a few exemplary integrated systems of the preferred embodiments, each of which include the receiver, such as described in more detail herein.

In some embodiments, the receiver 14 is a PDA- or pager-sized housing 46, for example, and comprises a user interface 48 that has a plurality of buttons 50 and a liquid crystal display (LCD) screen, which may include a backlight. In some embodiments, the receiver may take other forms, for example a computer, server, or other such device capable of receiving and processing the data such as described herein. In some embodiments the user interface may also include a keyboard, a speaker, and a vibrator such as described with reference to FIG. 8. The receiver 46 comprises systems (for example, electronics) necessary to receive, process, and display sensor data from the glucose sensor 12, such as described in more detail with reference to FIG. 8. The receiver 14 processes data from the continuous glucose sensor 12 and additionally processes data associated with at least one of the medicament delivery device 16, single point glucose meter 16, and user 8.

In some embodiments, the receiver 14 is integrally formed with at least one of the medicament delivery device 16, and single point glucose monitor 18. In some embodiments, the receiver 14, medicament delivery device 16 and/or single point glucose monitor 18 are detachably connected, so that one or more of the components can be individually detached and attached at the user's convenience. In some embodiments, the receiver 14, medicament delivery device 16, and/or single point glucose monitor 18 are separate from, detachably connectable to, or integral with each other; and one or more of the components are operably connected through a wired or wireless connection, allowing data transfer and thus integration between the components. In some embodiments, one or more of the components are operably linked as described above, while another one or more components (for example, the syringe or patch) are provided as a physical part of the system for convenience to the user and as a reminder to enter data for manual integration of the component with the system. Some exemplary embodiments are described with reference to FIGS. 4 to 7, however suffice it to say that each of the components of the integrated system may be manually, semi-automatically, or automatically integrated with each other, and each component may be in physical and/or data communication with another component, which may include wireless connection, wired connection (for example, via cables or electrical contacts), or the like.

#### Medicament Delivery Device

The preferred embodiments provide an integrated system 10, which includes a medicament delivery device 16 for administering a medicament to the patient 8. The integrated medicament delivery device can be designed for bolus injection, continuous injection, inhalation, transdermal absorption, other method for administering medicament, or any combinations thereof. The term medicament includes any substance used in therapy for a patient using the system 10, for example, insulin, glucagon, or derivatives thereof.

15

Published International Application WO 02/43566 describes glucose, glucagon, and vitamins A, C, or D that may be used with the preferred embodiments. U.S. Pat. Nos. 6,051,551 and 6,024,090 describe types of insulin suitable for inhalation that may be used with the preferred embodiments. U.S. Pat. Nos. 5,234,906, 6,319,893, and EP 760677 describe various derivatives of glucagon that may be used with the preferred embodiments. U.S. Pat. No. 6,653,332 describes a combination therapy that may be used with the preferred embodiments. U.S. Pat. No. 6,471,689 and WO 81/01794 describe insulin useful for delivery pumps that may be used with the preferred embodiments. U.S. Pat. No. 5,226,895 describes a method of providing more than one type of insulin that may be used with the preferred embodiments. All of the above references are incorporated herein by reference in their entirety and may be useful as the medicament(s) in the preferred embodiments.

#### Manual Integration

In some embodiments, the medicament delivery device 16 is a manual delivery device, for example a syringe, inhaler, transdermal patch, cell transplantation device, and/or manual pump for manual integration with the receiver. Manual integration includes medicament delivery devices wherein a user (for example, patient or doctor) manually selects the amount, type, and/or time of delivery. In some embodiments, the medicament delivery device 16 is any syringe suitable for injecting a medicament, as is appreciated by one skilled in the art. One example of a syringe suitable for the medicament delivery device of the preferred embodiments is described in U.S. Pat. No. 5,137,511, which is incorporated herein by reference in its entirety.

FIGS. 4A and 4B are perspective views of a integrated system 10 in one embodiment, wherein a receiver 14 is integrated with a medicament delivery device 16 in the form of a manual syringe 54, and optionally includes a single point glucose monitor 18, which will be described in more detail elsewhere herein. The receiver 14 receives, processes, and displays data from the continuous glucose monitor 12, such as described in more detail above, and may also receive, process, and display data manually entered by the user. In some embodiments, the receiver includes algorithms that use parameters provided by the continuous glucose sensor, such as glucose concentration, rate-of-change of the glucose concentration, and acceleration of the glucose concentration to more particularly determine the type, amount, and time of medicament administration. The medicament delivery device 16 is in the form of a syringe 54, which may comprise any known syringe configuration, such as described in more detail above. In some embodiments, the syringe 54 includes a housing, which is designed to hold a syringe as well as a plurality of types and amounts of medicament, for example fast-acting insulin, slow-acting insulin, and glucagon. In some embodiments, the syringe is detachably connectable to the receiver 14, and the receiver 14 provides and receives information to and from the patient associated with the time, type, and amount of medicament administered. In some embodiments, the syringe is stored in a holder that is integral with or detachably connected to the receiver 14. In some embodiments, the syringe 54 may be detachably connected directly to the receiver, provided in a kit with the receiver, or other configuration, which provides easy association between the syringe and the receiver.

Referring now to the integration between the syringe and the receiver, it is noted that the receiver can be programmed with information about the time, amount, and types of medicament that may be administered with the syringe, for example. In some embodiments during set-up of the system,

16

the patient and/or doctor manually enters information about the amounts and types of medicament available via the syringe of the integrated system. In some alternative embodiments, manufacturer-provided data can be downloaded to the receiver so that the patient and/or doctor can select appropriate information from menus on the screen, for example, to provide easy and accurate data entry. Thus, by knowing the available medicaments, the receiver may be programmed to customize the patient's therapy recommendations considering available types and amounts of medicaments in combination with concentration, rate-of-change, and/or acceleration of the patient's glucose. While not wishing to be bound by theory, it is believed that by storing available medicament therapies, the receiver is able to customize medicament calculations and recommend appropriate therapy based glucose on trend information and the preferred types and the amounts of medicament available to the patient.

Subsequently in some embodiments, once the patient has administered a medicament (including via the syringe and/or by other means), the amount, type, and/or time of medicament administration are input into the receiver by the patient. Similarly, the receiver may be programmed with standard medicaments and dosages for easy selection by the patient (for example, menus on the user interface). This information can be used by the receiver to increase the intelligence of the algorithms used in determining the glucose trends and patterns that may be useful in predicting and analyzing present, past, and future glucose trends, and in providing therapy recommendations, which will be described in more detail below. Additionally, by continuously monitoring the glucose concentration over time, the receiver provides valuable information about how a patient responds to a particular medicament, which information may be used by a doctor, patient, or by the algorithms within the receiver, to determine patterns and provide more personalized therapy recommendations. In other words, in some embodiments, the receiver includes programming that learns the patterns (for example, an individual's metabolic response to certain medicament deliveries and patient behavior) and to determine an optimum time, amount, and type of medicament to delivery in a variety of conditions (e.g., glucose concentration, rate-of-change, and acceleration). While not wishing to be bound by theory, it is believed that by continuously monitoring an individual's response to various medicaments, the patient's glucose levels can be more proactively treated, keeping the diabetic patient within safe glucose ranges substantially all the time.

In some embodiments, the receiver includes programming to predict glucose trends, such as described in U.S. provisional patent application 60/528,382, entitled, "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSORS", which is incorporated herein by reference in its entirety. In some embodiments, the predictive algorithms consider the amount, type, and time of medicament delivery in predicting glucose values. For example, a predictive algorithm that predicts a glucose value or trend for the upcoming 15 to 20 minutes uses a mathematical algorithm (for example, regression, smoothing, or the like) such as described in the above-cited provisional patent application 60/528,382 to project a glucose value. However outside influences, including medicament delivery may cause this projection to be inaccurate. Therefore, some embodiments provide programming in the receiver that uses the medicament delivery information received from the delivery device 14, in addition to other mathematical equations, to more accurately predict glucose values in the future.

In some alternative embodiments, the medicament delivery device 16 includes one or more transdermal patches 58 suitable for administering medicaments as is appreciated by one skilled in the art. WO 02/43566 describes one such transdermal patch, which may be used in the preferred embodiments. Although the above-cited reference and description associated with the FIGS. 5A to 5C describe a medicament (for example, glucagon) useful for treating hypoglycemia, it is understood that transdermal patches that release a medicament (for example, insulin) useful for treating hyperglycemia are also contemplated within the scope of the preferred embodiments.

FIGS. 5A to 5C are perspective views of an integrated system 10 in one embodiment, wherein a receiver 14 is integrated with a medicament delivery device 16 in the form of one or more transdermal patches 58 housed within a holder 56, and optionally includes a single point glucose monitor 18, which will be described in more detail elsewhere herein. The receiver 14 receives, processes, and displays data from the continuous glucose monitor 12, such as described in more detail above. The medicament delivery device 16 is in the form of one or more transdermal patches 58 held in a holder 56, which may comprise any known patch configuration.

The integration of the patches 58 with the receiver 14 includes similar functionality and provides similar advantages as described with reference to other manual integrations including manual medicament delivery devices (for example, syringe and inhaler). However, a unique advantage may be seen in the integration of a continuous glucose sensor with a glucagon-type patch. Namely, a continuous glucose sensor, such as described in the preferred embodiments, provides more than single point glucose readings. In fact, because the continuous glucose sensor 12 knows the concentration, rate-of-change, acceleration, the amount of insulin administered (in some embodiments), and/or individual patterns associated with a patient's glucose trends (learned over time as described in more detail elsewhere herein), the use of the glucagon patch can be iteratively optimized (inputting its usage into the receiver and monitoring the individual's metabolic response) to proactively preempt hypoglycemic events and maintain a more controlled range of glucose values. This may be particularly advantageous for nighttime hypoglycemia by enabling the diabetic patient (and his/her caretakers) to improve overall nighttime diabetic health. While not wishing to be bound by theory, the integration of the continuous glucose sensor and transdermal glucagon-type patch can provide diabetic patients with a long-term solution to reduce or avoid hypoglycemic events.

In some embodiments, the holder 58 is detachably connectable to the receiver 14 (for example on the side opposite the LCD), which enables convenient availability of the patch to the patient when the receiver indicates that a medicament (for example, glucose or glucagon) is recommended. It is further noted that although this holder is shown without another medicament delivery device 16 in the illustrations of FIGS. 5A to 5C, other medicaments (for example, insulin pen, insulin pump, such as described with reference to FIGS. 6 and 7) may be integrated into the system in combination with the medicament patch illustrated herein. While not wishing to be bound by theory, it is believed that by combining medicaments that aid the diabetic patient in different ways (for example, medicaments for treating hyper- and hypo-glycemic events, or, fast-acting and slow-acting medicaments), a simplified comprehensive solution for treating diabetes may be provided.

Manual Integration of delivery devices with the continuous glucose sensor 12 of the preferred embodiments may additionally be advantageous because the continuous device of the preferred embodiments is able to track glucose levels long-term (for example weeks to months) and adaptively improve therapy decisions based on the patients response over time.

In some alternative embodiments, the medicament delivery device 16 includes an inhaler or spray device suitable for administering a medicament into the circulatory system, as is appreciated by one skilled in the art. Some examples of inhalers suitable for use with the preferred embodiments include U.S. Pat. Nos. 6,167,880, 6,051,551, 6,024,090, which are incorporated herein by reference in their entirety. In some embodiments, the inhaler or spray device is considered a manual medicament delivery device, such as described with reference to FIGS. 4 and 5, wherein the inhaler or spray is manually administered by a patient, and wherein the patient manually enters data into the continuous receiver about the time, amount, and types of therapy. However, it is also possible that the inhaler or spray device used for administering the medicament may also comprise a microprocessor and operable connection to the receiver (for example, RF), such that data is sent and received between the receiver and inhaler or spray device, making it a semi-automated integration, which is described in more detail with reference to the integrated insulin pen below, for example.

In some embodiments, the inhaler or spray device is integrally housed within, detachably connected to, or otherwise physically associated with (for example, in a kit) to the receiver. The functionality and advantages for the integrated inhaler or spray device are similar to those described with reference to the syringe and/or patch integration, above. It is noted that the inhaler or spray device may be provided in combination with any other of the medicament delivery devices of the preferred embodiments, for example, a fast-acting insulin inhaler and a slow acting insulin pump may be advantageously integrated into the system of the preferred embodiments and utilized at the appropriate time as is appreciated by one skilled in the art. In some embodiments, wherein the inhaler or spray device includes a semi-automated integration with the receiver, the inhaler or spray device may by physically integrated with receiver such as described above and also operably connected to the receiver, for example via a wired (for example, via electrical contacts) or wireless (for example, via RF) connection.

In one alternative embodiment, a manual medicament delivery pump is implanted such as described in U.S. Pat. No. 6,283,944, which is incorporated herein by reference in its entirety. In this alternative embodiment, the patient-controlled implantable pump allows the patient to press on the device (through the skin) to administer a bolus injection of a medicament when needed. It is believed that providing glucagon or other medicament for treating hypoglycemia within this device will provide the ease and convenience that can be easily released by the patient and/or his or her caretaker when the continuous glucose sensor indicates severe hypoglycemia, for example. In some alternative embodiments, the manual implantable pump is filled with insulin, or other medicament for treating hyperglycemia. In either case, the manual pump and continuous glucose sensor will benefit from manual integrations described in more detail above.

In another alternative embodiment, a cell transplantation device, such as described in U.S. Pat. Nos. 6,015,572, 5,964,745, and 6,083,523, which are incorporated herein by

reference in their entirety, is manually integrated with the continuous sensor of the preferred embodiments. In this alternative embodiment, a patient would be implanted with beta islet cells, which provide insulin secretion responsive to glucose levels in the body. The receiver associated with the implantable glucose sensor can be programmed with information about the cell transplantation (for example, time, amount, type, etc). In this way, the long-term continuous glucose sensor may be used to monitor the body's response to the beta islet cells. This may be particularly advantageous when a patient has been using the continuous glucose sensor for some amount of time prior to the cell transplantation, and the change in the individual's metabolic patterns associated with the transplantation of the cells can be monitored and quantified. Because of the long-term continuous nature of the glucose sensor of the preferred embodiments, the long-term continuous effects of the cell transplantation can be consistently and reliably monitored. This integration may be advantageous to monitor any person's response to cell transplantation before and/or after the implantation of the cells, which may be helpful in providing data to justify the implantation of islet cells in the treatment of diabetes.

It is noted that any of the manual medicament delivery devices can be provided with an RF ID tag or other communication-type device, which allows semi-automated integration with that manual delivery device, such as described in more detail below.

#### Semi-Automated Integration

Semi-automated integration of medicament delivery devices **16** in the preferred embodiments includes any integration wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, or calculating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. In the preferred embodiments, semi-automated may also refer to a fully automated device (for example, one that does not require user interaction), wherein the fully automated device requires a validation or other user interaction, for example to validate or confirm medicament delivery amounts. In some embodiments, the semi-automated medicament delivery device is an inhaler or spray device, a pen or jet-type injector, or a transdermal or implantable pump.

FIGS. 6A and 6B are perspective views of an integrated system **10** in one embodiment, wherein a receiver **14** is integrated with a medicament delivery device **16** in the form of a pen or jet-type injector, hereinafter referred to as a pen **60**, and optionally includes a single point glucose monitor **18**, which will be described in more detail elsewhere herein. The receiver **14** receives, processes, and displays data from the continuous glucose monitor **12**, such as described in more detail above. The medicament delivery pen **60** of the preferred embodiments, includes any pen-type injector, such as is appreciated by one skilled in the art. A few examples of medicament pens that may be used with the preferred embodiments, include U.S. Pat. Nos. 5,226,895, 4,865,591, 6,192,891, and 5,536,249, all of which are incorporated herein by reference in their entirety.

FIG. 6A is a perspective view of an integrated system **10** in embodiment. The integrated system **10** is shown in an attached state, wherein the various elements are held by a mechanical means, as is appreciated by one skilled in the art. The components **14**, **16**, and **18**(optional) are also in operable connection with each other, which may include a wired or wireless connection. In some embodiments, the components include electrical contacts that operably connect the

components together when in the attached state. In some embodiments, the components are operably connected via wireless connection (for example, RF), and wherein the components may or may not be detachably connectable to each other. FIG. 6B show the components in an unattached state, which may be useful when the patient would like to carry minimal components and/or when the components are integrated via a wireless connection, for example.

Medicament delivery pen **60** includes at least a microprocessor and a wired or wireless connection to the receiver **14**, which are described in more detail with reference to FIG. 8. In some embodiments, the pen **60** includes programming that receives instructions sent from the receiver **14** regarding type and amount of medicament to administer. In some embodiments, wherein the pen includes more than one type of medicament, the receiver provides the necessary instructions to determine which type or types of medicament to administer, and may provide instructions necessary for mixing the one or more medicaments. In some embodiments, the receiver provides the glucose trend information (for example, concentration, rate-of-change, acceleration, or other user input information) and pen **60** includes programming necessary to determine appropriate medicament delivery.

Subsequently, the pen **60** includes programming to send information regarding the amount, type, and time of medicament delivery to the receiver **14** for processing. The receiver **14** can use this information received from the pen **60**, in combination with the continuous glucose data obtained from the sensor, to monitor and determine the patient's glucose patterns to measure their response to each medicament delivery. Knowing the patient's individual response to each type and amount of medicament delivery may be useful in adjusting or optimizing the patient's therapy. It is noted that individual metabolic profiles (for example, insulin sensitivity) are variable from patient to patient. While not wishing to be bound by theory, it is believed that once the receiver has learned (for example, monitored and determined) the individual's metabolic patterns, including glucose trends and associated medicament deliveries, the receiver can be programmed to adjust and optimize the therapy recommendations for the patient's individual physiology to maintain their glucose levels within a desired target range. In alternative embodiments, the pen **60** may be manually integrated with the receiver.

In some embodiments, the receiver includes algorithms that use parameters provided by the continuous glucose sensor, such as glucose concentration, rate-of-change of the glucose concentration, and acceleration of the glucose concentration to more particularly determine the type, amount, and time of medicament administration. In fact, all of the functionality of the above-described manual and semi-automated integrated systems, including therapy recommendations, adaptive programming for learning individual metabolic patterns, and prediction of glucose values, can be applied to the semi-automated integrated system **10**, such as described herein. However, the semi-automated integrated sensing and delivery system additionally provides convenience by automation (for example, data transfer through operable connection) and reduced opportunity for human error than may be experienced with the manual integration.

In some alternative embodiments, the semi-automated integration provides programming that requires at least one of the receiver **14**, single point glucose monitor **18**, and medicament delivery device **16** to be validated or confirmed by another of the components to provide a fail safe accuracy check; in these embodiments, the validation includes algo-

rithms programmed into any one or more of the components. In some alternative embodiments, the semi-automated integration provides programming that requires at least one of the receiver 14 and medicament delivery device 16 to be validated or confirmed by an a human (for example, confirm the amount and/or type of medicament). In these embodiments, validation provides a means by which the receiver can be used adjunctively, when the patient or doctor would like to have more control over the patient's therapy decisions, for example. See FIGS. 9 to 11 for processes that may be implemented herein.

Although the above description of semi-automated medicament delivery is mostly directed to an integrated delivery pen, the same or similar integration can be accomplished between a semi-automated inhaler or spray device, and/or a semi-automated transdermal or implantable pump device. Additionally, any combination of the above semi-automated medicament delivery devices may be combined with other manual and/or automated medicament delivery device within the scope of the preferred embodiments as is appreciated by one skilled in the art.

#### Automated Integration

Automated integration medicament delivery devices 16 in the preferred embodiments are any delivery devices wherein an operable connection between the integrated components provides for full control of the system without required user interaction. Transdermal and implantable pumps are examples of medicament delivery devices that may be used with the preferred embodiments of the integrated system 10 to provide automated control of the medicament delivery device 16 and continuous glucose sensor 12. Some examples of medicament pumps that may be used with the preferred embodiments include, U.S. Pat. No. 6,471,689, WO 81/01794, and EP 1281351, both of which are incorporated herein by reference in their entirety.

FIGS. 7A to 7C are perspective views of an integrated system in one embodiment, wherein a sensor and delivery pump, which are implanted or transdermally inserted into the patient, are operably connected to an integrated receiver, and optionally include a single point glucose monitor. FIG. 7A is a perspective view of a patient 8, in which is implanted or transdermally inserted a sensor 12 and a pump 70. FIGS. 7B and 7C are perspective views of the integrated receiver and optional single point glucose monitor in attached and unattached states. The pump 70 may be of any configuration known in the art, for example, such as cited above.

The receiver 14 receives, processes, and displays data associated with the continuous glucose monitor 12, data associated with the pump 70, and data manually entered by the patient 8. In some embodiments, the receiver includes algorithms that use parameters provided by the continuous glucose sensor, such as glucose concentration, rate-of-change of the glucose concentration, and acceleration of the glucose concentration to determine the type, amount, and time of medicament administration. In fact, all of the functionality of the above-described manual and semi-automated integrated systems, including therapy recommendations, confirmation or validation of medicament delivery, adaptive programming for learning individual metabolic patterns, and prediction of glucose values, can be applied to the fully automated integrated system 10, such as described herein with reference to FIGS. 7A to 7C. However, the fully automated sensing and delivery system can run with or without user interaction. Published Patent Application US 2003/0028089 provides some systems and methods for

providing control of insulin, which may be used with the preferred embodiments, and is incorporated herein by reference in its entirety.

In some embodiments of the automated integrated system 10, a fail-safe mode is provided, wherein the system is programmed with conditions whereby when anomalies or potentially clinically risky situations arise, for example when a reference glucose value (for example, from an SMBG) indicates a discrepancy from the continuous sensor 10 that could cause risk to the patient if incorrect therapy is administered. Another example of a situation that may benefit from a validation includes when a glucose values are showing a trend in a first direction that shows a possibility of "turn around," namely, the patient may be able to reverse 15 the trend with a particular behavior within a few minutes to an hour, for example. In such situations, the automated system may be programmed to revert to a semi-automated system requiring user validation or other user interaction to validate the therapy in view of the situation.

It is noted that in the illustrated embodiment, only one receiver 14 is shown, which houses the electronics for both the medicament delivery pump 70 and the continuous sensor 12. Although it is possible to house the electronics in two different receiver housings, providing one integrated housing 20 14 increases patient convenience and minimizes confusion or errors. In some embodiments, the sensor receiver electronics and pump electronics are separate, but integrated. In some alternative embodiments, the sensor and pump share the same electronics.

Additionally, the integrated receiver for the sensor and pump, can be further integrated with any combination with the above-described integrated medicament delivery devices, including syringe, patch, inhaler, and pen, as is appreciated by one skilled in the art.

#### Single Point Glucose Monitor

In the illustrated embodiments (FIGS. 4 to 7), the single point glucose monitor includes a meter for measuring glucose within a biological sample including a sensing region that has a sensing membrane impregnated with an enzyme, 40 similar to the sensing membrane described with reference to U.S. Pat. Nos. 4,994,167 and 4,757,022, which are incorporated herein in their entirety by reference. However, in alternative embodiments, the single point glucose monitor can use other measurement techniques such as optical, for example. It is noted that the meter is optional in that a separate meter can be used and the glucose data downloaded or input by a user into the receiver. However the illustrated embodiments show an integrated system that exploits the advantages associated with integration of the single point glucose monitor with the receiver 14 and delivery device 16.

FIGS. 4 to 7 are perspective views of integrated receivers including a single point glucose monitor. It is noted that the integrated single point glucose monitor may be integral with, detachably connected to, and/or operably connected 55 (wired or wireless) to the receiver 14 and medicament delivery device 16. The single point glucose monitor 18 integrates rapid and accurate measurement of the amount of glucose in a biological fluid and its associated processing with the calibration, validation, other processes associated 60 with the continuous receiver 14, such as described in more detail with reference to U.S. provisional patent application, 60/523,840, entitled "INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR," which is incorporated herein by reference in its entirety.

In the illustrated embodiments, the single point glucose monitor 18, such as described in the above-cited provisional patent application, 60/523,840, includes a body 62 that

houses a sensing region 64, which includes a sensing membrane located within a port. A shuttle mechanism 66 may be provided that preferably feeds a single-use disposable bio-protective film that can be placed over the sensing region 64 to provide protection from contamination. The sensing region includes electrodes, the top ends of which are in contact with an electrolyte phase (not shown), which is a free-flowing fluid phase disposed between the sensing membrane and the electrodes. The sensing region measures glucose in the biological sample in a manner such as described in more detail above, with reference the continuous glucose sensor and/or U.S. Pat. Nos. 4,994,167 and 4,757,022. The similarity of the measurement technologies used for the continuous glucose sensor and the single point glucose sensor provides an internal control that creates increased reliability by nature of consistency and decreased error potential that can otherwise be increased due to combining dissimilar measurement techniques. Additionally, the disclosed membrane system is known to provide longevity, repeatability, and cost effectiveness, for example as compared to single use strips, or the like. However, other single point glucose monitors may be used with the preferred embodiments.

In one alternative embodiment, the single point glucose monitor comprises an integrated lancing and measurement device such as described in U.S. Pat. No. 6,607,658 to Heller et al. In another alternative embodiment, the single point glucose monitor comprises a near infrared device such as described in U.S. Pat. No. 5,068,536 to Rosenthal et al. In another alternative embodiment, the single point glucose monitor comprises a reflectance reading apparatus such as described in U.S. Pat. No. 5,426,032 to Phillips et al. In another alternative embodiment, the single point glucose monitor comprises a spectroscopic transreflectance device such as described in U.S. Pat. No. 6,309,884 to Cooper et al. All of the above patents and patent applications are incorporated in their entirety herein by reference.

In some embodiments, the single point glucose meter further comprises a user interface that includes a display 72 and a button 74; however, some embodiments utilize the display 48 and buttons 50 of the receiver 14 rather than providing a separate user interface for the monitor 18. In some embodiments the single point glucose monitor measured glucose concentration, prompts, and/or messages can be displayed on the user interface 48 or 72 to guide the user through the calibration and sample measurement procedures, or the like. In addition, prompts can be displayed to inform the user about necessary maintenance procedures, such as "Replace Sensor" or "Replace Battery." The button 74 preferably initiates the operation and calibration sequences. The button can be used to refresh, calibrate, or otherwise interface with the single point glucose monitor 18 as is appreciated by one skilled in the art.

#### Integrated Electronics

FIG. 8 is a block diagram that illustrates integrated system electronics in one embodiment. One embodiment is described wherein the microprocessor within the receiver performs much of the processing, however it is understood that all or some of the programming and processing described herein can be accomplished within continuous glucose sensor, receiver, single point glucose monitor, and/or delivery device, or any combination thereof. Similarly, displays, alarms, and other user interface functions may be incorporated into any of the individual components of the integrated delivery device.

A quartz crystal 76 is operably connected to an RF transceiver 78 that together function to receive and synchro-

nize data streams via an antenna 80 (for example, transmission 40 from the RF transceiver 44 shown in FIG. 3). Once received, a microprocessor 82 processes the signals, such as described below.

The microprocessor 82 is the central control unit that provides the processing for the receiver, such as storing data, analyzing continuous glucose sensor data stream, analyzing single point glucose values, accuracy checking, checking clinical acceptability, calibrating sensor data, downloading data, recommending therapy instructions, calculating medicament delivery amount, type and time, learning individual metabolic patterns, and controlling the user interface by providing prompts, messages, warnings and alarms, or the like. The ROM 84 is operably connected to the microprocessor 82 and provides semi-permanent storage of data, storing data such as receiver ID and programming to process data streams (for example, programming for performing calibration and other algorithms described elsewhere herein). RAM 88 is used for the system's cache memory and is helpful in data processing. For example, the RAM 88 stores information from the continuous glucose sensor, delivery device, and/or single point glucose monitor for later recall by the user or a doctor; a user or doctor can transcribe the stored information at a later time to determine compliance with the medical regimen or evaluation of glucose response to medication administration (for example, this can be accomplished by downloading the information through the pc com port 90). In addition, the RAM 88 may also store updated program instructions and/or patient specific information. FIGS. 9 and 10 describe more detail about programming that is preferably processed by the microprocessor 82. In some alternative embodiments, memory storage components comparable to ROM and RAM can be used instead of or in addition to the preferred hardware, such as SRAM, EEPROM, dynamic RAM, non-static RAM, rewritable ROMs, flash memory, or the like.

In some embodiments, the microprocessor 82 monitors the continuous glucose sensor data stream 40 to determine a preferable time for capturing glucose concentration values using the single point glucose monitor electronics 116 for calibration of the continuous sensor data stream. For example, when sensor glucose data (for example, observed from the data stream) changes too rapidly, a single point glucose monitor reading may not be sufficiently reliable for calibration during unstable glucose changes in the host; in contrast, when sensor glucose data are relatively stable (for example, relatively low rate of change), a single point glucose monitor reading can be taken for a reliable calibration. In some additional embodiments, the microprocessor can prompt the user via the user interface to obtain a single point glucose value for calibration at predetermined intervals. In some additional embodiments, the user interface can prompt the user to obtain a single point glucose monitor value for calibration based upon certain events, such as meals, exercise, large excursions in glucose levels, faulty or interrupted data readings, or the like. In some embodiments, certain acceptability parameters can be set for reference values received from the single point glucose monitor. For example, in one embodiment, the receiver only accepts reference glucose data between about 40 and about 400 mg/dL.

In some embodiments, the microprocessor 82 monitors the continuous glucose sensor data stream to determine a preferable time for medicament delivery, including type, amount, and time. In some embodiments, the microprocessor is programmed to detect impending clinical risk and may request data input, a reference glucose value from the single

point glucose monitor, or the like, in order to confirm a therapy recommendation. In some embodiments, the microprocessor is programmed to process continuous glucose data and medicament therapies to adaptive adjust to an individual's metabolic patterns. In some embodiments, the microprocessor is programmed to project glucose trends based on data from the integrated system (for example, medicament delivery information, user input, or the like). In some embodiments, the microprocessor is programmed to calibrate the continuous glucose sensor based on the integrated single point glucose monitor. Numerous other programming may be incorporated into the microprocessor, as is appreciated by one skilled in the art, as is described in cited patents and patent applications here, and as is described with reference to flowcharts of FIGS. 9 to 11.

It is noted that one advantage of integrated system of the preferred embodiments can be seen in the time stamp of the sensor glucose data, medicament delivery data, and reference glucose data. Namely, typical implementations of the continuous glucose sensor 12, wherein the medicament delivery 16 and/or single point glucose monitor 18 is not integral with the receiver 14, the reference glucose data or medicament delivery data can be obtained at a time that is different from the time that the data is input into the receiver 14. Thus, the user may not accurately input the "time stamp" of the delivery or (for example, the time or obtaining reference glucose value or administering the medicament) at the time of reference data input into the receiver. Therefore, the accuracy of the calibration of the continuous sensor, prediction of glucose values, therapy recommendations, and other processing is subject to human error (for example, due to inconsistencies in entering the actual time of the single point glucose test). In contrast, the preferred embodiments of the integrated system advantageously do no suffer from this potential inaccuracy when the time stamp is automatically and accurately obtained at the time of the event. Additionally, the processes of obtaining reference data and administering the medicament may be simplified and made convenient using the integrated receiver because of fewer loose parts (for example, cable, test strips, etc.) and less required manual data entry.

A battery 92 is operably connected to the microprocessor 82 and provides power for the receiver. In one embodiment, the battery is a standard AAA alkaline battery, however any appropriately sized and powered battery can be used. In some embodiments, a plurality of batteries can be used to power the system. In some embodiments, a power port (not shown) is provided permit recharging of rechargeable batteries. A quartz crystal 94 is operably connected to the microprocessor 168 and maintains system time for the computer system as a whole.

A PC communication (com) port 90 may be provided to enable communication with systems, for example, a serial communications port, allows for communicating with another computer system (for example, PC, PDA, server, or the like). In one exemplary embodiment, the receiver is able to download historical data to a physician's PC for retrospective analysis by the physician. The PC communication port 90 can also be used to interface with other medical devices, for example pacemakers, implanted analyte sensor patches, infusion devices, telemetry devices, or the like.

A user interface 96 comprises a keyboard 98, speaker 100, vibrator 102, backlight 104, liquid crystal display (LCD) 106, and/or one or more buttons 108. The components that comprise the user interface 96 provide controls to interact with the user. The keyboard 98 can allow, for example, input of user information about himself/herself, such as mealtime,

exercise, insulin administration, and reference glucose values. The speaker 100 can provide, for example, audible signals or alerts for conditions such as present and/or predicted hyper- and hypoglycemic conditions. The vibrator 102 can provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above. The backlight 104 can be provided, for example, to aid the user in reading the LCD in low light conditions. The LCD 106 can be provided, for example, to provide the user with visual data output. In some embodiments, the LCD is a touch-activated screen. The buttons 108 can provide for toggle, menu selection, option selection, mode selection, and reset, for example. In some alternative embodiments, a microphone can be provided to allow for voice-activated control.

The user interface 96, which is operably connected to the microprocessor 82 serves to provide data input and output for both the continuous glucose sensor, delivery mechanism, and/or for the single point glucose monitor.

In some embodiments, prompts or messages can be displayed on the user interface to guide the user through the initial calibration and sample measurement procedures for the single point glucose monitor. Additionally, prompts can be displayed to inform the user about necessary maintenance procedures, such as "Replace Sensing Membrane" or "Replace Battery." Even more, the glucose concentration value measured from the single point glucose monitor can be individually displayed.

In some embodiments, prompts or messages can be displayed on the user interface to convey information to the user, such as malfunction, outlier values, missed data transmissions, or the like, for the continuous glucose sensor. Additionally, prompts can be displayed to guide the user through calibration of the continuous glucose sensor. Even more, calibrated sensor glucose data can be displayed, which is described in more detail with reference co-pending U.S. patent application Ser. No. 10/633,367 and U.S. provisional patent application 60/528,382, both of which are incorporated herein by reference in their entirety.

In some embodiments, prompts or messages about the medicament delivery device can be displayed on the user interface to inform or confirm to the user type, amount, and time of medicament delivery. In some embodiments, the user interface provides historical data and analytes pattern information about the medicament delivery, and the patient's metabolic response to that delivery, which may be useful to a patient or doctor in determining the level of effect of various medicaments.

Electronics 110 associated with the delivery device 16 (namely, the semi-automated and automated delivery devices) are operably connected to the microprocessor 82 and include a microprocessor 112 for processing data associated with the delivery device 16 and include at least a wired or wireless connection (for example, RF transceiver) 114 for transmission of data between the microprocessor 82 of the receiver 14 and the microprocessor 112 of the delivery device 16. Other electronics associated with any of the delivery devices cited herein, or other known delivery devices, may be implemented with the delivery device electronics 110 described herein, as is appreciated by one skilled in the art.

In some embodiments, the microprocessor 112 comprises programming for processing the delivery information in combination with the continuous sensor information. In some alternative embodiments, the microprocessor 82 comprises programming for processing the delivery information in combination with the continuous sensor information. In

some embodiments, both microprocessors 82 and 112 mutually processor information related to each component.

In some embodiments, the medicament delivery device 16 further includes a user interface (not shown), which may include a display and/or buttons, for example. U.S. Pat. Nos. 6,192,891, 5,536,249, and 6,471,689 describe some examples of incorporation of a user interface into a medicament delivery device, as is appreciated by one skilled in the art.

Electronics 116 associated with the single point glucose monitor 18 are operably connected to the microprocessor 120 and include a potentiostat 118 in one embodiment that measures a current flow produced at the working electrode when a biological sample is placed on the sensing membrane, such as described above. The current is then converted into an analog signal by a current to voltage converter, which can be inverted, level-shifted, and sent to an A/D converter. The microprocessor can set the analog gain via its a control port (not shown). The A/D converter is preferably activated at one-second intervals. The microprocessor looks at the converter output with any number of pattern recognition algorithms known to those skilled in the art until a glucose peak is identified. A timer is then preferably activated for about 30 seconds at the end of which time the difference between the first and last electrode current values is calculated. This difference is then divided by the value stored in the memory during instrument calibration and is then multiplied by the calibration glucose concentration. The glucose value in milligram per deciliter, millimoles per liter, or the like, is then stored in the microprocessor, displayed on the user interface, used to calibrate of the glucose sensor data stream, downloaded, etc.

#### Programming and Processing (Draw Flow Diagrams)

FIG. 9 is a flow chart that illustrates the process 130 of validating therapy instructions prior to medicament delivery in one embodiment. In some embodiments, the therapy recommendations include a suggestion on the user interface of time, amount, and type of medicament to delivery. In some embodiments, therapy instructions includes calculating a time, amount, and/or type of medicament delivery to administer, and optionally transmitting those instructions to the delivery device. In some embodiments, therapy instructions include that portion of a closed loop system wherein the determination and delivery of medicament is accomplished, as is appreciated by one skilled in the art.

Although computing and processing of data is increasingly complex and reliable, there are circumstances by which the therapy recommendations necessitate human intervention. Some examples include when a user is about to alter his/her metabolic state, for example due to behavior such as exercise, meal, pending manual medicament delivery, or the like. In such examples, the therapy recommendations determined by the programming may not have considered present or upcoming behavior, which may change the recommended therapy. Numerous such circumstances can be contrived, suffice it to say that a validation may be advantageous in order to ensure that therapy recommendations are appropriately administered.

At block 132, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which may be in wired or wireless communication with the sensor. The sensor data point(s) may be raw or smoothed, such as described in co-pending U.S. patent application Ser. No. 10/648,849, entitled "SYSTEMS AND METHODS FOR

REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM," which is incorporated herein by reference in its entirety.

At block 134, a medicament calculation module, which is a part of a processor module, calculates a recommended medicament therapy based on the received sensor data. A variety of algorithms may be used to calculate a recommended therapy as is appreciated by one skilled in the art.

At block 136, a validation module, which is a part of the processor module, optionally validates the recommended therapy. The validation may include a request from the user, or from another component of the integrated system 10, for additional data to ensure safe and accurate medicament recommendation or delivery. In some embodiments, the validation requests and/or considers additional input, such as time of day, meals, sleep, calories, exercise, sickness, or the like. In some embodiments, the validation module is configured to request this information from the user. In some embodiments, the validation module is responsive to a user inputting such information.

In some embodiments, when the integrated system 10 is in fully automated mode, the validation module is triggered when a potential risk is evaluated. For example, when a clinically risky discrepancy is evaluated, when the acceleration of the glucose value is changing or is low (indicative of a significant change in glucose trend), when it is near a normal meal, exercise or sleep time, when a medicament delivery is expected based on an individual's dosing patterns, and/or a variety of other such situations, wherein outside influences (meal time, exercise, regular medicament delivery, or the like) may deem consideration in the therapy instructions. These conditions for triggering the validation module may be pre-programmed and/or may be learned over time, for example, as the processor module monitors and patterns an individual's behavior patterns.

In some embodiments, when the integrated system 10 is in semi-automated mode, the system may be programmed to request additional information from the user regarding outside influences unknown to the integrated system prior to validation. For example, exercise, food or medicament intake, rest, or the like may input into the receiver for incorporation into a parameter of the programming (algorithms) that processing the therapy recommendations.

At block 138, the receiver confirms and sends (for example, displays, transmits and/or delivers) the therapy recommendations. In manual integrations, the receiver may simply confirm and display the recommended therapy, for example. In semi-automated integrations, the receiver may confirm, transmit, and optionally delivery instructions to the delivery device regarding the recommended therapy, for example. In automated integrations the receiver may confirm and ensure the delivery of the recommended therapy, for example. It is noted that these examples are not meant to be limiting and there are a variety of methods by which the receiver may confirm, display, transmit, and/or deliver the recommended therapy within the scope of the preferred embodiments.

FIG. 10 is a flow chart 140 that illustrates the process of providing adaptive metabolic control using an integrated system in one embodiment. In this embodiment, the integrated system is programmed to learn the patterns of the individual's metabolism, including metabolic response to medicament delivery.

At block 142, a medicament data receiving module, which may be programmed within the receiver 14 and/or medicament delivery device 16, receives medicament delivery data, including time, amount, and/or type. In some embodiments,

the user is prompted to input medicament delivery information into the user interface. In some embodiments, the medicament delivery device 16 sends the medicament delivery data to the medicament data-receiving module.

At block 144, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which may be in wired or wireless communication with the sensor.

At block 146, the processor module, which may be programmed into the receiver 14 and/or the delivery device 16 is programmed to monitor the sensor data from the sensor data module 142 and medicament delivery from the medicament delivery module 144 to determine an individual's metabolic profile, including their response to various times, amounts, and/or types of medicaments. The processor module uses any pattern recognition-type algorithm as is appreciated by one skilled in the art to quantify the individual's metabolic profile.

At block 148, a medicament calculation module, which is a part of a processor module, calculates the recommended medicament based on the sensor glucose data, medicament delivery data, and/or individual's metabolic profile. In some embodiments, the recommended therapy is validated such as described with reference to FIG. 9 above. In some embodiments, the recommended therapy is manually, semi-automatically, or automatically delivered to the patient.

At block 150, the process of monitoring and evaluation a patient's metabolic profile is repeated with new medicament delivery data, wherein the processor monitors the sensor data with the associated medicament delivery data to determine the individual's metabolic response in order to adaptively adjust, if necessary, to newly determined metabolic profile or patterns. This process may be continuous throughout the life of the integrated system, may be initiated based on conditions met by the continuous glucose sensor, may be triggered by a patient or doctor, or may be provided during a start-up or learning phase.

While not wishing to be bound by theory, it is believed that by adaptively adjusting the medicament delivery based on an individual's metabolic profile, including response to medicaments, improved long-term patient care and overall health can be achieved.

FIG. 11 is a flow chart 152 that illustrates the process of glucose signal estimation using the integrated sensor and medicament delivery device in one embodiment. It is noted that glucose estimation and/or prediction are described in co-pending patent application Ser. No. 10/633,367 and provisional patent application 60/528,382, both of which have been incorporated herein by reference in their entirety. However, the preferred embodiments described herein, further incorporated additional data of medicament delivery in estimating or predicting glucose trends.

At block 154, a sensor data receiving module, also referred to as the sensor data module, receives sensor data (e.g., a data stream), including one or more time-spaced sensor data points, from a sensor via the receiver, which may be in wired or wireless communication with the sensor.

At block 156, the medicament data receiving module, which may be programmed within the receiver 14 and/or medicament delivery device 16, receives medicament delivery data, including time, amount, and/or type.

At block 158, the processor module evaluates medicament delivery data with substantially time corresponding glucose sensor data to determine individual metabolic patterns associated with medicament delivery. "Substantially

time corresponding data" refers to that time period during which the medicament is delivered and its period of release in the host.

At block 160, the processor module estimates glucose values responsive to individual metabolic patterns associated with the medicament delivery. Namely, the individual metabolic patterns associated with the medicament delivery are incorporated into the algorithms that estimate present and future glucose values, which are believed to increase accuracy of long-term glucose estimation.

## EXAMPLES

In one exemplary implementation of the preferred embodiments, the continuous glucose sensor (and its receiver) comprises programming to track a patient during hypoglycemic or near-hypoglycemic conditions. In this implementation, the processor includes programming that sends instructions to administer a hypoglycemic treating medicament, such as glucagon, via an implantable pump or the like, when the glucose level and rate of change surpass a predetermined threshold (for example, 80 mg/dL and 2 mg/dL/min). In this situation, the sensor waits a predetermined amount of time (for example, 40 minutes), while monitoring the glucose level, rate of change of glucose, and/or acceleration/deceleration of glucose in the patient, wherein if the rate of change and/or acceleration shows a changing trend away from hypoglycemia (for example, decreased deceleration of glucose levels to non-hypoglycemia, then the patient need not be alarmed. In this way, the automated glucagon delivery device can proactively preempt hypoglycemic conditions without alerting or awaking the patient.

In another exemplary implementation of the preferred embodiments, a continuous glucose sensor is integrated with a continuous medicament delivery device (for example, an insulin pump) and a bolus medicament delivery device (for example, an insulin pen). In this embodiment, the integration takes exploits the benefits of automated and semi-automated device, for example, providing an automated integration with an infusion pump, while provide semi-automated integration with an insulin pen as necessary.

In yet another exemplary implementation of the preferred embodiments, a medicament delivery device is provided that includes reservoirs of both fast acting insulin and slow acting insulin. The medicament delivery device is integrated with the receiver as described elsewhere herein, however in this implementation, the receiver determines an amount of fast acting insulin and an amount of slow acting insulin, wherein the medicament delivery device is configured to mix slow- and fast-acting insulin in the amounts provided. In this way, the receiver and medicament delivery device can work together in a feedback loop to iteratively optimize amounts of slow and fast acting insulin for a variety of situations (for example, based on glucose level, rate of change, acceleration, and behavioral factors such as diet, exercise, time of day, etc.) adapted to the individual patient's metabolic profile.

In yet another exemplary implementation of the preferred embodiments, an integrated hypo- and hyper-glycemic treating system is provided. In this implementation, a manual-, semi-automated, or automated integration of an insulin delivery device is combined with a manual-, semi-automated, or automated integration of a glucose or glucagon delivery device. These devices are integrated with the receiver for the continuous glucose sensor in any manner described elsewhere herein. While not wishing to be bound

by theory, it is believed that the combination of a continuous glucose sensor, integrated insulin device, and integrated glucose or glucagon device provides a simplified, comprehensive, user friendly, convenient, long-term and continuous method of monitoring, treating, and optimizing comprehensive care for diabetes.

Methods and devices that can be suitable for use in conjunction with aspects of the preferred embodiments are disclosed in copending applications including U.S. application Ser. No. 10/695,636 filed Oct. 28, 2003 and entitled, "SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE"; U.S. patent application Ser. No. 10/648,849 entitled, "SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM," filed Aug. 22, 2003; U.S. patent application Ser. No. 10/646,333 entitled, "OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR," filed Aug. 22, 2003; U.S. patent application Ser. No. 10/647,065 entitled, "POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES," filed Aug. 22, 2003; U.S. patent application Ser. Nos. 10/633,367, 10/632,537, 10/633,404, and 10/633,329, each entitled, "SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA," filed Aug. 1, 2003; U.S. patent application Ser. No. 09/916,386 filed Jul. 27, 2001 and entitled "MEMBRANE FOR USE WITH IMPLANTABLE DEVICES"; U.S. patent application Ser. No. 09/916,711 filed Jul. 27, 2001 and entitled "SENSING REGION FOR USE WITH IMPLANTABLE DEVICE"; U.S. patent application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled "DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS"; U.S. patent application Ser. No. 10/153,356 filed May 22, 2002 and entitled "TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS"; U.S. application Ser. No. 09/489,588 filed Jan. 21, 2000 and entitled "DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS"; U.S. patent application Ser. No. 09/636,369 filed Aug. 11, 2000 and entitled "SYSTEMS AND METHODS FOR REMOTE MONITORING AND MODULATION OF MEDICAL DEVICES"; and U.S. patent application Ser. No. 09/916,858 filed Jul. 27, 2001 and entitled "DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS," as well as issued patents including U.S. Pat. No. 6,001,067 issued Dec. 14, 1999 and entitled "DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS"; U.S. Pat. No. 4,994,167 issued Feb. 19, 1991 and entitled "BIOLOGICAL FLUID MEASURING DEVICE"; and U.S. Pat. No. 4,757,022 filed Jul. 12, 1988 and entitled "BIOLOGICAL FLUID MEASURING DEVICE." All of the above patents and patent applications are incorporated in their entirety herein by reference.

The above description provides several methods and materials of the invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this application or practice of the invention provided herein. Consequently, it is not intended that this invention be limited to the specific embodiments provided herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims. All patents, applications, and other references cited herein are hereby incorporated by reference in their entirety.

What is claimed is:

1. A method of operating a medicament delivery device capable of administering a medicament to a patient, the method comprising:
  - 5 obtaining, by a receiver associated with the medicament delivery device, measured analyte values indicative of an analyte concentration of the patient provided by an analyte sensor;
  - 10 identifying, by the receiver, occurrence of a learned pattern of the patient based on the measured analyte values of the analyte concentration over time;
  - 15 providing, by the receiver, a user interface indicating the identified pattern; and
  - 20 in response to receiving a user validation that is required under conditions that are learned based on the identified pattern, adjusting, by the receiver, operation of the medicament delivery device to administer the medicament to the patient based on the identified pattern.
2. The method of claim 1, further comprising:
  - 25 determining, by the receiver, a personalized therapy recommendation for a bolus injection, the personalized therapy recommendation determined based at least in part on a meal; and
  - 30 operating, by the receiver, the medicament delivery device to administer the bolus injection of the medicament to the patient.
3. The method of claim 1, wherein adjusting the operation of the medicament delivery device is based on a meal.
4. The method of claim 1, wherein adjusting the operation of the medicament delivery device is based on exercise.
5. The method of claim 1, wherein the occurrence of the learned pattern is identified based on historical measured analyte values having the learned pattern.
- 35 6. The method of claim 1, wherein the operation of the medicament delivery device is carried out, at least in part, within a closed loop.
7. The method of claim 1, wherein determination of the medicament administered is carried out within a closed loop.
- 40 8. The method of claim 1, wherein administering the medicament by the medicament delivery device is carried out within a closed loop.
9. The method of claim 1, wherein the receiver includes programming that learns patterns.
- 45 10. The method of claim 1, wherein the learned pattern is learned using pattern recognition.
11. A system comprising:
  - a medicament delivery device to administer medicament to a patient;
  - 50 an analyte sensor to provide measurements of analyte values indicative of an analyte concentration of the patient;
  - a data storage component to store measured analyte values indicative of the analyte concentration of the patient over time;
  - a receiver operably connected to the medicament delivery device, the analyte sensor, and the data storage component to:
  - 55 identify, by the receiver, occurrence of a learned pattern of the patient based on the measured analyte values of the analyte concentration over time; and
  - in response to receiving a user validation that is required under conditions that are learned based on the identified pattern, adjust operation of the medicament delivery device to administer the medicament to the patient based on the identified pattern.

**33**

**12.** The system of claim **11**, wherein the receiver is further configured to provide a user interface indicating the identified pattern.

**13.** The system of claim **11**, wherein the receiver is further configured to:

determine a personalized therapy recommendation for a bolus injection, the personalized therapy recommendation determined based at least in part on a meal; and operate the medicament delivery device to administer the bolus injection of the medicament to the patient.

**14.** The system of claim **11**, wherein the operation of the medicament delivery device is adjusted based on a meal.

**15.** The system of claim **11**, wherein the operation of the medicament delivery device is adjusted based on exercise.

**16.** The system of claim **11**, wherein the occurrence of the learned pattern is identified based on historical measured analyte values having the learned pattern.

**17.** The system of claim **11**, wherein the operation of the medicament delivery device is carried out, at least in part, within a closed loop of the system.

**18.** The system of claim **11**, wherein determination of the medicament administered is carried out within a closed loop of the system.

**19.** One or more computer-readable storage media storing instructions that are executable by one or more processors to perform operations including:

**34**

obtaining, by a receiver associated with a medicament delivery device, measured analyte values indicative of an analyte concentration of a patient provided by an analyte sensor;

5 identifying, by the receiver, occurrence of a learned pattern of the patient based on the measured analyte values of the analyte concentration over time; providing, by the receiver, a user interface indicating the identified pattern; and

in response to receiving a user validation that is required under conditions that are learned based on the identified pattern, adjusting, by the receiver, operation of the medicament delivery device to administer a medicament to the patient based on the identified pattern.

**20.** The one or more computer-readable storage media of claim **19**, wherein the operations further include:

determining, by the receiver, a personalized therapy recommendation for a bolus injection, the personalized therapy recommendation determined based at least in part on a meal; and

operating, by the receiver, the medicament delivery device to administer the bolus injection of the medicament to the patient.

\* \* \* \* \*